Mise en page 1 - ISTH 2009
Mise en page 1 - ISTH 2009
Mise en page 1 - ISTH 2009
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
* Pres<strong>en</strong>ting Author<br />
Coagulation factors and inhibitors<br />
Tissue factor, TFPI, Factor VII<br />
P-T-001<br />
P-T-002<br />
P-T-003<br />
P-T-004<br />
P-T-006<br />
P-T-007<br />
P-T-008<br />
P-T-009<br />
P-T-010<br />
P-T-011<br />
P-T-012<br />
P-T-013<br />
THE HAEMOSTASIS REGISTRY – AUSTRALIAN AND NEW ZEALAND EXPERIENCE<br />
WITH RFVIIA<br />
L. E. Phillips (AU), J. Isbister, S. Dunkley*, J. McNeil, P. Cameron<br />
COAGULATION FACTOR VII LEVELS ARE MODULATED BY THE BIOLOGICAL CLOCK<br />
M. Pinotti* (IT), C. Bertolucci, I. Colognesi, E. Frigato, V. Pasquali, P. R<strong>en</strong>zi, A. Foa,<br />
F. Bernardi<br />
BLOOD COAGULATION REACTIONS ON NANOSCALE MEMBRANE SURFACES<br />
V. S. Pureza* (US), A. W. Shaw, S. G. Sligar, J. H. Morrissey<br />
VIRAL MYOCARDITIS IS A HYPERCOAGULATIVE STATE. INCREASED TISSUE<br />
FACTOR EXPRESSION AND PLASMA THROMBOGENICITY<br />
U. Rauch (DE), S. Antoniak*, U. Boltz<strong>en</strong>, A. Kallwellis-Opara, P. Bobbert, A. Riad,<br />
W. Poller, M. Pauschinger, H. Schultheiss<br />
TISSUE FACTOR DEPENDENT INITIATION OF PLATELET AND FIBRIN THROMBUS<br />
FORMATION<br />
A. Zampolli* (US), W. Ruf, Z. M. Ruggeri<br />
USE OF RECOMBINANT FACTOR VIIA IN CARDIOSURGERY PATIENTS, INCLUDING<br />
NEONATES AND INFANTS UNDER 1 YEAR OF AGE<br />
N. N. Samsonova* (RU), L. A. Bokeria, G. Lobacheva, K. Diasamidze, L. G. Klimovich,<br />
E. Kozar, M. Plushch<br />
HEME INDUCES TISSUE FACTOR EXPRESSION IN HUMAN LUNG MICROVASCULAR<br />
ENDOTHELIAL CELLS: RELATIONSHIP TO CLINICAL HEMOLYTIC STATES<br />
Y. B. N. Setty* (US), S. Gay<strong>en</strong>-Betal, J. Zhang, S. Kulkarni, M. Stuart<br />
BLOOD FLOW SUPPRESSES FEEDBACK ACTIVATION OF EXTRINSIC TENASE BY<br />
FACTOR XA AND PREVENTS CLOTTING<br />
A. M. Shibeko* (RU), O. E. Avilov, M. A. Panteleev, E. S. Lobanova, F. I. Ataullakhanov<br />
ELEVATED LEVELS OF FACTOR VIIA-ANTITHROMBIN COMPLEXES IN PATIENTS WITH<br />
PREVIOUS MYOCARDIAL INFARCTION<br />
A. Silveira* (SE), D. Scanavini, S. Boquist, C. Ericsson, J. H. Morrissey, A. Hamst<strong>en</strong><br />
EXPRESSION OF THE TFPI V264M MUTANT IN VASCULAR CELL CULTURES<br />
INVOLVES STABILITY OF MRNA<br />
G. Skretting* (NO), T. Li<strong>en</strong>, T. O. Anders<strong>en</strong>, P. M. Sandset, N. Ivers<strong>en</strong><br />
EFFECT OF GLYCOPEGYLATION ON THE PHARMACOKINETIC PROPERTIES OF<br />
FVIIA<br />
B. B. Sor<strong>en</strong>s<strong>en</strong>* (DK), D. Karpf, A. V. Groth, B. V. Bysted, M. B. Hermit, M. Tranholm,<br />
S. E. Bjørn, K. Kinealy, D. Zopf, R. J. Bayer, M. S. Kalo, H. R. St<strong>en</strong>nicke<br />
DETERMINATION OF TISSUE FACTOR ORIGIN USING SIRNA KNOCKDOWN<br />
APPROACH IN HUMAN PERIPHERAL BLOOD WHITE CELLS<br />
M. Sovershaev* (NO), E. Egorina, H. Devold, J. Ols<strong>en</strong>, B. Østerud<br />
236
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-014<br />
P-T-015<br />
P-T-016<br />
P-T-017<br />
P-T-018<br />
P-T-019<br />
P-T-020<br />
P-T-021<br />
CLEARANCE OF FACTOR VIIA (FVIIA) IN THE MOUSE IS NOT AFFECTED BY ALPHA<br />
2-MACROGLOBULIN GENE DELETION OR ACTIVE-SITE BLOCKAGE OF FVIIA<br />
A. Steinoe* (DK), D. M. Karpf, E. H. N. Ols<strong>en</strong>, M. Tranholm, L. C. Peters<strong>en</strong>,<br />
H. R. St<strong>en</strong>nicke, M. Ezban, B. B. Sor<strong>en</strong>s<strong>en</strong><br />
RECOMBINANT ACTIVATED HUMAN FACTOR VII (FVIIA) BINDS TO THE ENDOTHELIAL<br />
PROTEIN C RECEPTOR (EPCR) ON HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS<br />
(HUVEC)<br />
A. Steinoe* (DK), B. B. Sor<strong>en</strong>s<strong>en</strong>, H. R. St<strong>en</strong>nicke<br />
DEVELOPMENT OF LONG-ACTING FVIIA DERIVATIVES BY GLYCOPEGYLATION<br />
H. R. St<strong>en</strong>nicke (DK), R. J. Bayer, M. S. Kalo, H. Ostergaard*, P. K. Holm, K. Kinealy,<br />
B. B. Sør<strong>en</strong>s<strong>en</strong>, S. E. Bjørn, D. Zopf<br />
A CODING SNP AT THE GPI-ATTACHMENT SITE IN THE TFPI-BETA-SPECIFIC EXON IS<br />
ASSOCIATED WITH TFPI LEVELS<br />
H. L. Vos* (NL), A. Van Hylckama Vlieg, F. R. Ros<strong>en</strong>daal, P. M. Sandset<br />
CHANGES OF TISSUE FACTOR PATHWAY IN PATIENTS WITH ACUTE MYOCARDIAL<br />
INFARCTION<br />
R. Wang* (CN), B. W<strong>en</strong>, Y. Ma, P. P<strong>en</strong>, H. Li, D. Zhong, L. Li<br />
SIGNAL TRANSDUCTION PATHWAYS OF INTERLEUKIN-6 INDUCING TISSUE FACTOR<br />
EXPRESSION IN VASCULAR ENDOTHELIAL CELLS<br />
Z. W<strong>en</strong>* (CN), B. Li, X. He, Y. Sun, H. Zhang, X. Tang, J. Hu, H. Wang, S. He<br />
CONSTRUCTION AND IDENTIFICATION OF LENTIVIRUS - MEDIATED RNAI VECTORS<br />
CONTAINING HUMAN TISSUE FACTOR<br />
S. L. Xiong* (CN), J. Bao, L. Zh<strong>en</strong>g, F. Y. Z<strong>en</strong>g, Y. R. Qiu, Q. Wang<br />
MECHANISMS OF THROMBUS FORMATION DIFFER BETWEEN ATHEROSCLEROTIC<br />
AND NORMAL ARTERIES IN HYPERCHOLESTEROLEMIC RABBITS<br />
A. Yamashita* (JP), S. Matsuda, M. Takahashi, T. Sumi, K. Nishihira, T. Imamura,<br />
K. Kitamura, Y. Asada<br />
Tuesday Posters<br />
Factor VIII, Factor V<br />
P-T-022<br />
P-T-023<br />
P-T-024<br />
P-T-025<br />
SITE-SPECIFIC PEGYLATION OF RFVIII RESULTS IN PROLONGED IN VIVO EFFICACY<br />
J. E. Murphy* (US), C. Pan, T. Barnett, B. Mei, J. Strauss, H. Tjandra, L. Tang,<br />
P. Esmon, J. Newgr<strong>en</strong>, K. Landskroner, M. Parmathi, J. Severs, J. Teare, H. Jiang,<br />
B. Dev<strong>en</strong>s, G. Pierce, K. Konstantinov, M. Fournel<br />
ASSOCIATION OF BLOOD PRESSURE AND FACTOR VIII IN LEIDEN THROMBOPHILIA<br />
STUDY (LETS) AND CARDIOVASCULAR HEALTH STUDY (CHS)<br />
A. Y. Noss<strong>en</strong>t* (NL), N. L. Smith, J. C. J. Eik<strong>en</strong>boom, R. M. Bertina, F. R. Ros<strong>en</strong>daal,<br />
B. M. Psaty<br />
FVIII CONCENTRATES OF RECOMBINANT ORIGIN SHOW A HIGHER THROMBIN<br />
SENSITIVITY THAN PLASMA-DERIVED FVIII CONCENTRATES BUT NEARLY<br />
IDENTICAL APC-MEDIATED INACTIVATION KINETICS<br />
B. Poetzsch* (DE), J. Mueller, I. Dücker, J. Old<strong>en</strong>burg<br />
IMMUNOGLOBULIN ISOTYPES AND FUNCTIONAL ANTI-FVIII ANTIBODIES IN<br />
RESPONSE TO FVIII TREATMENT IN TWO STRAINS OF HEMOPHILIA A MICE<br />
M. Qadura* (CA), M. Othman, A. Labelle, E. Burnett, C. Hough, D. Lillicrap, P. Thompson<br />
P-T-026<br />
BIOLOGICAL ACTIVITY OF PEGYLATED FACTOR VIII<br />
L. Regan* (US), X. Jiang, P. Ramsey, J. Severs, S. Sompalli, N. Samuels, J. Teare,<br />
A. Tollner, L. Tang<br />
237
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-027<br />
P-T-028<br />
P-T-029<br />
P-T-030<br />
P-T-031<br />
P-T-032<br />
P-T-033<br />
P-T-034<br />
P-T-035<br />
P-T-036<br />
P-T-037<br />
P-T-038<br />
P-T-039<br />
A NOVEL RECOMBINANT B-DOMAIN-DELETED FACTOR VIII EXPRESSED IN A HUMAN<br />
CELL LINE<br />
H. Sandberg* (SE), I. Agerkvist, E. Lindner, K. Martinelle, S. Winge<br />
DISCOVERY OF COMPOUNDS THAT INHIBIT FACTOR VA-MEMBRANE INTERACTION<br />
BY IN SILICO SCREENING<br />
K. Segers* (NL), O. Sperandio, M. Sack, R. Fischer, M. M. Miteva, J. Rosing,<br />
G. A. F. Nicolaes, B. O. Villoutreix<br />
THE ROLE OF THROMBIN EXOSITES I AND II IN THE ACTIVATION OF HUMAN<br />
COAGULATION FACTOR V<br />
K. Segers* (NL), B. Dahlbäck, P. E. Bock, G. Tans, J. Rosing, G. A. F. Nicolaes<br />
FACTOR V DEFICIENCY DUE TO A NOVEL HOMOZYGOUS MUTATION:FV N468S, BUT<br />
NO BLEEDING TENDENCY<br />
K. Shinozawa* (JP), K. Amano, O. Takamiya, N. Shiozaki, T. Ando, I. Seita, K. Ogata,<br />
T. Suzuki, H. Inaba, K. Fukutake<br />
COMBINED FACTOR V AND FACTOR VIII DEFICIENCY: MUTATION ANALYSIS AND<br />
ETHNICAL BACKGROUND OF FIVE PATIENTS<br />
K. Sittinger* (DE), C. Geis<strong>en</strong>, M. Watzka, V. Ivaskevicius, C. Heller, G. Kappert,<br />
H. J. Laws, B. Zieger, E. Seifried, J. Old<strong>en</strong>burg, J. G. Kadar<br />
EFFICACY AND SAFETY OF FVIII WITH PEGYLATED LIPOSOMES IN HAEMOPHILIA A<br />
J. Spira* (SE), O. P. Pluyshch, T. A. Andreeva, R. N. Khametova<br />
3D STRUCTURES OF MEMBRANE-BOUND FACTOR VIII<br />
S. Stoilova-McPhie* (UK), C. D. J. Parm<strong>en</strong>ter, G. Kemball-Cook<br />
A CRYO-ELECTRON MICROSCOPY STUDY OF RECOMBINANT FVIII BINDING TO PS<br />
LIPOSOMES<br />
C. D. J. Parm<strong>en</strong>ter (UK), M. C. Cane, G. Kemball-Cook, S. Stoilova-McPhie*<br />
MUTATIONS AT THE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN<br />
(LRP) BINDING SITE OF THE FVIII A2 DOMAIN DID NOT REDUCE LRP BINDING OR<br />
INCREASE HALF-LIFE OF NON-ACTIVATED FVIII<br />
L. Tang* (US), J. E. Murphy, T. Barnett, B. Mei, M. Pamarthi, J. Strauss, J. Tjandra,<br />
Y. Ch<strong>en</strong>, O. Dryga, G. Medvedeff, J. Nixon, D. Chamberlain, J. Newgr<strong>en</strong>, M. Fournel<br />
PEGYLATION PROTECTS FACTOR VIII FROM THE INHIBITION OF ANTIBODY<br />
INHIBITORS<br />
L. Tang* (US), C. Pan, H. Atwal, J. Nixon, T. Barnett, J. E. Murphy, B. Mei, M. Fournel<br />
FACTOR V MUTATIONS, SER234LEU AND ARG413CYS, ARE ASSOCIATED WITH<br />
FACTOR V DEFICIENCY AND A BLEEDING TENDENCY<br />
X. Wang* (CN), P. Jin, Q. Ding, H. Wang<br />
ABSENCE OF INHIBITOR FORMATION IN PREVIOUSLY TREATED HAEMOPHILIA<br />
A PATIENTS TREATED WITH A DOUBLE VIRUS INACTIVATED, PLASMA DERIVED<br />
FACTOR VIII/VWF CONCENTRATE IN PROSPECTIVE CLINICAL STUDIES<br />
J. Windyga* (PL), A. Klukowska, M. Jans<strong>en</strong>, J. Feddern<br />
ALLELIC FREQUENCY AND MINOR VARIATIONS OF THE FACTOR V R2 HAPLOTYPE<br />
IN JAPANESE POPULATION<br />
T. Yamazaki* (JP), H. Okada, Y. Toyoda, S. Kunishima, M. Hamaguchi, H. Saito,<br />
T. Kojima<br />
238
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-040<br />
RESIDUES 311-325 ON THE HEAVY CHAIN OF FVA REPRESENT AN ACTIVATED<br />
PROTEIN C BINDING REGION<br />
S. Yegneswaran* (US), Y. Kojima, M. J. Heeb, A. J. Gale, J. H. Griffin<br />
Factor XIII and tissue transglutaminase<br />
P-T-041<br />
P-T-042<br />
P-T-043<br />
P-T-044<br />
P-T-045<br />
CEREBRAL THROMBOSIS ASSOCIATED WITH HETEROZYGOUS FV LEIDEN<br />
MUTATION AND HIGH LIPOPROTEIN A LEVEL IN A GIRL WITH FACTOR XIII<br />
DEFICIENCY<br />
M. Akbalik (TR), F. Duru, T. Fisgin, H. Tasdemir, L. Incesu, D. Albayrak*, H. Ozyurek<br />
EVALUATION OF A NEW, AUTOMATED QUANTITATIVE FACTOR XIII ASSAY<br />
K. Alhomsi (US), R. O. Salem, K. A. Morin*, E. M. Van Cott<br />
A NOVEL MUTATION IN EXON 10 OF FACTOR XIII SUBUNIT B<br />
L. R. Alvarado* (US), D. J. Nug<strong>en</strong>t, A. E. Lovejoy, P. Nakagawa, L. B. Hsieh,<br />
J. Chediak, S. A. Williams<br />
FACTOR XIII PHARMACOKINETICS<br />
L. R. Alvarado* (US), P. Nakagawa, L. B. Hsieh, D. J. Nug<strong>en</strong>t<br />
FXIII VARIANTS WITH ALTERED THROMBIN ACTIVATION RATES<br />
M. D. Anders<strong>en</strong>* (DK), M. Kjalke, S. Bang, I. Lautrup-Lars<strong>en</strong>, P. Becker, A. S. Anders<strong>en</strong>,<br />
I. V. Diers, R. Røjkjær, O. H. Ols<strong>en</strong>, H. R. St<strong>en</strong>nicke<br />
P-T-046<br />
P-T-047<br />
P-T-048<br />
TRANSIENT ACTIVATION OF BLOOD COAGULATION FACTOR XIII BY<br />
POLYMORPHONUCLEAR GRANULOCYTE ELASTASE<br />
Z. Bagoly* (HU), F. Fazakas, G. Haramura, E. Tóth, L. Muszbek<br />
GENERATION AND EXPRESSION OF RECOMBINANT FACTOR XIII-B MUTANTS<br />
I. Balogh* (HU), E. Dzsudzsak, E. Ajzner, A. Fekete, A. Csapo, J. Kappelmayer<br />
SECRETION OF COAGULATION FACTOR XIIIA FROM HAEMATOPOIETIC CELLS<br />
P. A. Cordell* (UK), P. J. Grant, R. J. Pease<br />
Tuesday Posters<br />
P-T-049<br />
P-T-050<br />
P-T-051<br />
P-T-052<br />
P-T-053<br />
A NOVEL DELETION MUTATION (C.1254 DEL33BP OR C.1251DEL33BP) IN THE F13A<br />
GENE CAUSING SEVERE FACTOR XIII DEFICIENCY<br />
Q. Ding* (CN), X. Wang, J. Wu, H. Ch<strong>en</strong>, H. Wang<br />
DETERMINATION OF PLASMA COAGULATION FACTOR XIII WITH THE NOVEL<br />
FLUOROGENIC ISOPEPTIDASE ASSAY<br />
K. Oertel (DE), A. Hunfeld, E. Specker, C. Reiff, R. Seitz, R. Pasternack, J. Dodt*<br />
FACTOR XIIIA-V34L AND FACTOR XIIIB-H95R GENE VARIANTS AND SURVIVAL AFTER<br />
MYOCARDIAL INFARCTION<br />
D. Gemmati* (IT), F. Federici, G. Campo, M. L. Serino, M. Valgimigli, G. Guardigli,<br />
P. Ferraresi, F. Bernardi, R. Ferrari, G. L. Scapoli, L. Catozzi<br />
EFFECT OF RECOMBINANT FACTOR XIII-A ON ENDOTHELIAL BARRIER FUNCTION<br />
M. Gruda* (US), S. Turman, E. H. N. Ols<strong>en</strong><br />
PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST<br />
THE B SUBUNIT OF FACTOR XIII THAT INHIBIT THE FORMATION OF<br />
HETEROTETRAMERIC COMPLEX OF A AND B SUBUNITS<br />
É. Katona* (HU), A. Csapó, I. Szabó, G. Haramura, L. Muszbek<br />
239
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Factor VII activating protease<br />
P-T-054<br />
P-T-055<br />
P-T-056<br />
P-T-057<br />
P-T-058<br />
INVESTIGATION OF HUMAN RECOMBINANT FVIIA METABOLISM IN A PERFUSED RAT<br />
LIVER MODEL<br />
R. Appa* (DK), M. S. Christ<strong>en</strong>s<strong>en</strong><br />
STRUCTURE-FUNCTION ANALYSIS OF THE BINDING PROPERTIES AND ENZYMATIC<br />
ACTIVITY OF FACTOR VII ACTIVATING PROTEASE (FSAP) USING RECOMBINANT<br />
MUTANT PROTEINS<br />
L. Muhl* (DE), T. Weimer, K. T. Preissner, S. M. Kanse<br />
THE CHANGE AND MUTUAL RELATIONS BETWEEN PROTEIN Z AND PARTIAL<br />
INFLAMMATORY FACTORS IN CEREBRAL INFARCTION<br />
X. Pan* (CN)<br />
THE FACTOR VII ACTIVATING PROTEASE (FSAP) POLYMORPHISM (G534E) IS<br />
ASSOCIATED WITH A DECREASED RISK FOR RESTENOSIS AFTER PERCUTANEOUS<br />
CORONARY INTERVENTION<br />
D. Pons* (NL), S. M. Kanse, M. P. M. De Maat, P. A. F. M. Doev<strong>en</strong>dans,<br />
R. J. De Winter, R. A. Tio, J. W. Jukema<br />
FVII ACTIVITY AND R353Q POLYMORPHISM IN ASIAN INDIAN FAMILIES WITH<br />
CORONARY ARTERY DISEASE<br />
J. Shanker* (IN), P. Ganapathy, V. S. Rao, B. K. Natesha, M. Mukherjee, V. V. Kakkar<br />
Markers of coagulation activation<br />
P-T-059<br />
P-T-060<br />
P-T-061<br />
P-T-062<br />
P-T-063<br />
P-T-064<br />
HEMOSTASIS DISORDERS MARKERS IN INTRACRACRANIAL MENONGIOMAS (IM)<br />
PATIENTS<br />
M. A. Aloeva* (GE), E. O. Vorobyova, G. E. Magalashvili<br />
D-DIMER IN PATIENTS WITH ACUTE LEUKEMIA AFTER TRANSPLANTATION OF<br />
HEMATOPOIETIC STEM CELLS<br />
V. A. Atamonov (RU), T. V. Vavilova*, L. M. Fregatova, L. S. Zubarovskaya,<br />
E. V. Sem<strong>en</strong>ova, S. N. Bondar<strong>en</strong>co<br />
QUALITATIVE DETECTION OF PROTHROMBIN FRAGMENT 1+2 IN SPOT URINE<br />
FOLLOWING MAJOR ORTHOPAEDIC SURGERY<br />
L. C. Borris* (DK), M. Breindahl, M. Lass<strong>en</strong>, C. Ryge, F. Misselwitz<br />
ENDOGENOUS THROMBIN POTENTIAL (ETP) IN PLASMA FROM PATIENTS WITH AMI<br />
DURING ANTITHROMBOTIC TREATMENT<br />
E. Brodin* (NO), I. Seljeflot, H. Arnes<strong>en</strong>, H. Appelbom, J. B. Hans<strong>en</strong><br />
HEMOSTATIC MARKERS AS PROGNOSTIC FACTORS IN ATRIAL FIBRILLATION.<br />
PRELIMINARY RESULTS OF A PROSPECTIVE STUDY<br />
V. Caruso* (AR), F. Alberto, S. S. Mesch<strong>en</strong>gieser, K. Vizcaychipi, S. Grosso,<br />
A. Sánchez-Luceros, P. Casais, M. F. H<strong>en</strong>dler, M. A. Lazzari<br />
HEMOSTATIC PROFILE IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE<br />
DISEASE (PAOD): ASSOCIATION TO ANKLE-BRACHIAL INDEX (ABI)<br />
A. P. L. Mota (BR), M. E. R. C. Santos, G. F. G. Lages, M. G. Carvalho*,<br />
F. C. L. Silva<br />
240
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-065<br />
P-T-066<br />
P-T-067<br />
P-T-068<br />
P-T-069<br />
LACK OF EFFECT ON MARKERS OF THROMBIN GENERATION AND FIBRINOLYSIS BY<br />
PARTIAL FACTOR IXA INHIBITION FOLLOWING HIP FRACTURE SURGERY<br />
O. E. Dahl* (UK), B. I. Eriksson, M. R. Lass<strong>en</strong>, D. P. Ward, R. Rothlein, G. Davis,<br />
A. G. G. Turpie<br />
CLINICAL EVALUATION OF A NEW QUANTITATIVE HIGHLY SENSITIVE D-DIMER<br />
ASSAY FOR EXCLUSION OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM<br />
P. de Moerloose* (CH), G. Palareti, C. Aguilar, C. Legnani, G. Reber, D. Peetz<br />
COAGULATION FACTORS AND THE PROTEIN C SYSTEM AS DETERMINANTS OF<br />
THROMBIN GENERATION<br />
A. W. J. H. Dielis* (NL), E. Castoldi, H. M. H. Spronk, R. Van Oerle, K. Hamulyák,<br />
J. Rosing, H. t<strong>en</strong> Cate<br />
D-DIMER LEVELS IN RELATION TO FACTOR V 1691 GENOTYPE AND ORAL<br />
ANTICOAGULATION. A CASE-CONTROL-STUDY OF 46 HOMOZYGOUS AND<br />
HETEROZYGOUS FACTOR V LEIDEN PATIENTS<br />
U. Harbrecht* (DE), C. Gnida, J. Old<strong>en</strong>burg<br />
D-DIMER LEVELS IN RELATION TO FACTOR V 1691 GENOTYPE AND ORAL<br />
ANTICOAGULATION. A CASE-CONTROL-STUDY OF 46 HOMOZYGOUS AND<br />
HETEROZYGOUS FACTOR V LEIDEN PATIENTS<br />
U. Harbrecht* (DE), C. Gnida, J. Old<strong>en</strong>burg<br />
P-T-070<br />
P-T-071<br />
P-T-072<br />
THROMBIN GENERATION AMONG SUDANESE ESSENTIAL HYPERTENSION PATIENTS<br />
F. M. Hassan* (SD), M. M. Hamid<br />
FIBRIN D-DIMERS IS ASSOCIATED WITH PREVALENT CARDIOVASCULAR EVENTS IN<br />
THE MOLI-SANI STUDY<br />
L. Iacoviello* (IT), A. Di Castelnuovo, A. De Curtis, S. Costanzo, A. Arcari, F. C<strong>en</strong>tritto,<br />
F. De Lucia, I. Di Stefano, R. Di Giuseppe, S. Magnacca, A. Pampuch, E. Plescia, L. Rago,<br />
C. Silvestri, B. Vohnout, F. Zito, G. De Gaetano, M. B. Donati, M. Persichillo<br />
QUANTITATION OF D-DIMER BY LOCI TECHNOLOGY<br />
A. Kappel* (DE), H. Althaus, M. Ehm<br />
Tuesday Posters<br />
Protein C, Protein S, thrombomodulin<br />
P-T-073<br />
P-T-074<br />
P-T-075<br />
P-T-076<br />
ILPCA, A RECOMBINANT PC ACTIVATOR SUCCESSFULLY USED TO FORMULATE AN<br />
AUTOMATED PC CHROMOGENIC ASSAY IN LIQUID FORMAT<br />
D. Sanchez-Martinez* (US), D. Diaz, M. Smirnov, M. Triscott<br />
FOUR NOVEL CAUSATIVE MUTATIONS IDENTIFIED IN THE PROS1 GENE OF<br />
JAPANESE DEEP VEIN THROMBOSIS PATIENTS WITH PROTEIN S DEFICIENCY<br />
N. Sanda* (JP), Y. Fujimori, T. Kashiwagi, T. Yamada, K. Okumura, A. Takagi, T. Murate,<br />
T. Iwasaki, A. Katsumi, K. Yamamoto, T. Matsushita, T. Naoe, H. Saito, T. Kojima<br />
COMPARISON OF ENDOTHELIAL CELL PROTEIN C RECEPTOR (EPCR) MRNA FORMS<br />
IN MONOCYTES AND HUVEC<br />
B. Saposnik* (FR), P. Gaussem, A. Lokajczyk, B. Vedie, J. Emmerich, M. Aiach,<br />
S. Gandrille<br />
RECOMBINATION IN ENDOTHELIAL CELL PROTEIN C RECEPTOR GENE PROCR.<br />
INFERENCE FOR THROMBOPHILIC PATIENTS SCREENING<br />
B. Saposnik* (FR), A. Lokajczyk, M. Aiach, S. Gandrille<br />
241
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-077<br />
P-T-078<br />
P-T-079<br />
P-T-080<br />
P-T-081<br />
P-T-082<br />
P-T-083<br />
P-T-084<br />
P-T-085<br />
P-T-086<br />
THE RGDS SEQUENCE OF THE ANTICOAGULANT PROTEIN C (PC) CONTRIBUTES TO<br />
ITS ENDOTHELIAL CELL RECEPTOR (EPCR) BINDING<br />
B. Saposnik* (FR), V. Vermillard, C. Bachelot-Loza, D. Borgel, M. Aiach, S. Gandrille<br />
ENDOGENOUS PROTEIN C INHIBITS PULMONARY COAGULATION BUT FACILITATES<br />
BACTERIAL DISSEMINATION IN THE EARLY PHASE OF PNEUMOCOCCAL<br />
PNEUMONIA IN MICE<br />
M. Schout<strong>en</strong>* (NL), C. van ‘t Veer, M. M. Levi, C. T. Esmon, T. van der Poll<br />
PROTEIN S DEFICIENCY IN HIV INFECTED PEDIATRIC PATIENTS ON<br />
ANTIRETROVIRAL THERAPY<br />
K. Shetty* (IN)<br />
ANTI-PROTEIN S ANTIBODIES IN CHILDREN WITH PURPURA FULMINANS AND IN<br />
HEALTHY CHILDREN FOLLOWING VARICELLA AS WELL AS IN CHILDREN WITH<br />
THROMBOSIS<br />
U. Tedgard* (SE), O. Rask, R. Ljung, A. Hillarp<br />
PROS1 ANALYSIS IN 87 PEDIGREES WITH HEREDITARY PROTEIN S DEFICIENCY<br />
DEMONSTRATES STRIKING GENOTYPE-PHENOTYPE ASSOCIATIONS<br />
M. K. T<strong>en</strong> Kate* (NL), M. Platteel, R. Mulder, G. Van Der Steege, J. Van Der Meer,<br />
G. A. F. Nicolaes<br />
VALIDATION OF THE PROTEIN C/S RATIO TO IDENTIFY CARRIERS OF A PROTEIN S<br />
GENE MUTATION<br />
M. K. t<strong>en</strong> Kate* (NL), R. Mulder, M. Platteel, G. van der Steege, J. van der Meer,<br />
A. B. Mulder<br />
PHYTOESTROGENS DOWN-REGULATE PROTEIN S EXPRESSION IN HEPG2 CELLS<br />
H. Tsuda* (JP), K. Tadokoro, Y. Hiroto, M. Kishikawa, E. Nakazono<br />
ACTIVATED PROTEIN C INCREASES TISSUE FACTOR EXPRESSION ON HUMAN<br />
UMBILICAL ENDOTHELIAL CELL BY EPCR-DEPENDENT BUT PAR-1-INDEPENDENT<br />
MANNER<br />
M. Uchiba* (JP), Y. Yonemura, K. Okajima, Y. Ando, H. Mitsuya, J. Wojta, C. Kaun,<br />
B. R. Binder<br />
THE SCREEN OF INHERITED ANTICOAGULANT PROTEINS DEFICIENCY AMONG<br />
NORMAL CHINESE<br />
X. Wei* (CN), Q. Ding, X. Wang, H. Wang<br />
GENETIC ANALYSIS OF HEREDITARY PROTEIN S DEFICIENCY IN TWO CHINESE<br />
PEDIGREES<br />
F. Yang* (CN), P. Jin, X. Wang, H. Wang<br />
Laboratory methods and experim<strong>en</strong>tal models<br />
P-T-087<br />
P-T-088<br />
POSSIBLE MECHANISMS OF THE DEVELOPMENT OF DIC SYNDROME<br />
B. I. Kuznik* (RU), E. V. Alfonsova, Y. A. Vitkovsky, N. N. Tsybikov<br />
CURRENT PRACTICE IN THROMBOSIS AND HAEMOSTASIS: A SINGLE-CENTER<br />
RETROSPECTIVE STUDY<br />
C. M. Lambert* (BE), C. R. Hermans<br />
242
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-089<br />
A COMPARATIVE EVALUATION OF THE CS-2000I COAGULATION ANALYSER USING<br />
CLOTTING, AMIDOLYTIC AND IMMUNO-TURBIDOMETRIC ASSAYS<br />
A. S. Lawrie* (UK), K. Kobayashi, K. Tajima, N. Matsuo, S. Hoshiko, Y. Hamaguchi,<br />
R. Liesner, S. J. Machin, I. J. Mackie<br />
P-T-090<br />
P-T-091<br />
P-T-092<br />
P-T-093<br />
QUALITY MONITORING OF FRESH-FROZEN PLASMA (FFP) AND THE EFFECT OF<br />
WHOLE BLOOD STORAGE AT 4 o C OVERNIGHT<br />
A. S. Lawrie* (UK), R. A. Cardigan, S. J. Machin, I. J. Mackie<br />
THE PLASMA SAMPLE DILUTION IMPROVES THE CORRELATION BETWEEN<br />
REAGENTS FOR PT-METHODS<br />
T. L. Lindahl (SE), A. Osman, K. M. Gustafsson*<br />
COMPARISON OF TWO ANTI-XA ASSAYS USING A SINGLE CALIBRATION CURVE FOR<br />
MONITORING HEPARIN ANTICOAGULATION<br />
D. L. McGlasson* (US), G. A. Fritsma<br />
EXTERNAL QUALITY CONTROL FOR THE COAGUCHEK INR MEASUREMENT<br />
IMPORTANT TO CONTROL TEST STRIP QUALITY: EVIDENCE FOR LIMITED<br />
PROPORTIONAL DIFFERENCES<br />
P. Meijer* (NL), C. Kluft, L. Poller, F. van der Meer, M. Keown, S. Ibrahim,<br />
T. van d<strong>en</strong> Besselaar, A. Tripodi, J. Jespers<strong>en</strong><br />
P-T-094<br />
P-T-095<br />
P-T-096<br />
INTER-LABORATORY VARIATION AND THE EFFECT OF THE TYPE OF FLUORIMETER<br />
ON THE RESULTS OF THE TECHNOTHROMBIN® THROMBIN GENERATION ASSAY<br />
P. Meijer* (NL), C. Kluft<br />
ACL TOP PERFORMANCE IN ROUTINE COAGULATION TESTING<br />
M. Milos* (HR), D. Co<strong>en</strong> Herak, L. Kuric, I. Horvat, R. Zadro<br />
THROMBELASTOGRAPHY MAY NOT ALWAYS DETECT CLINICALLY RELEVANT<br />
FACTOR XIII DEFICIENCY<br />
G. Moessmer* (DE)<br />
Tuesday Posters<br />
P-T-097<br />
P-T-098<br />
P-T-099<br />
P-T-100<br />
P-T-101<br />
A COMPARATIVE STUDY OF LOW MOLECULAR WEIGHT HEPARIN (LMWH)<br />
MONITORING BY ANTI-XA LEVELS, OVERALL HAEMOSTASIS POTENTIAL (OHP) AND<br />
CALIBRATED AUTOMATED THROMBOGRAM (CAT) ASSAYS<br />
L. Tay (AU), M. Aboud, C. M. Ward, M. C. Morel-Kopp*<br />
INFLUENCE OF ADDING 4% BSA IN THE BETHESDA ASSAY FOR FACTOR VIII<br />
INHIBITOR QUANTIFICATION<br />
A. Moret* (ES), V. Cortina, S. Haya, M. A. Perales, A. R. Cid, J. A. Aznar<br />
FIRST EXPERIENCE WITH THROGA (THROMBIN GENERATION ASSAY) IN<br />
IDENTIFICATION OF HYPER- AND HYPOCOAGULABILITY<br />
G. Nowak* (DE), A. Wies<strong>en</strong>burg<br />
MONITORING UNFRACTIONATED HEPARIN IN A PATIENT WITH RENAL AND HEPATIC<br />
INSUFFICIENCY YIELDS DISCORDANT RESULTS COMPARING ANTI-XA ASSAY AND<br />
PARTIAL THROMBOPLASTIN TIME. A CASE REPORT<br />
R. F. Padmore* (CA), M. Calvert<br />
ACCURACY AND COST EVALUATION OF A PORTABLE INR MONITOR<br />
O. Paoletti (IT), A. Alatri, G. Morstabilini, A. Fugazza, S. Testa*<br />
243
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-102<br />
P-T-103<br />
P-T-104<br />
P-T-105<br />
P-T-106<br />
P-T-107<br />
P-T-108<br />
P-T-109<br />
P-T-110<br />
P-T-111<br />
P-T-112<br />
EVALUATION OF A NEW INR PORTABLE MONITOR<br />
O. Paoletti (IT), A. Alatri, G. Morstabilini, M. Mazzolari, S. Testa*<br />
PROTHROMBIN TIME: COMPARISON BETWEEN DIFFERENT REAGENTS<br />
O. Paoletti (IT), A. Alatri, G. Morstabilini, S. Testa*<br />
PT INR: COMPARISON BETWEEN TWO DIFFERENT POINT OF CARE SYSTEMS<br />
O. Paoletti (IT), A. Alatri, G. Morstabilini, S. Testa*<br />
HAEMOSTATS BONDED WITHIN INTERMOLECULAR COMPLEXES AND THEIR EFFECT<br />
ON PLATELET COUNT DECREASE IN ANTICOAGULATED BLOOD<br />
M. Pecka* (CZ)<br />
THROMBELASTOGRAPHY STUDY OF HEMOSTATIC AGENTS<br />
H. T. P<strong>en</strong>g (CA), M. D. Blostein*, D. Gamble, H. Huang, P. N. Shek<br />
EVALUATION OF THE COAGUCHEK® XS PLUS SYSTEM IN A SWISS COMMUNITY<br />
SETTING<br />
A. Deom (CH), G. Reber*, D. Tsakiris, F. Hannes, W. J. Plesch<br />
INR RESULTS OF THE COAGUCHEK XS PLUS SYSTEM ARE EQUIVALENT TO THOSE<br />
OF THE COAGUCHEK XS SYSTEM<br />
W. J. Plesch* (DE), T. Wolf, B. Dikkeschei<br />
PERFORMANCE OF THE COAGUCHEK XS PLUS SYSTEM USING LIQUID QUALITY<br />
CONTROL SAMPLES<br />
W. J. Plesch* (DE), T. Wolf, B. Dikkeschei<br />
OPTIMIZATION OF COAGULATION FACTOR ASSAYS FOR IMPROVED ACCURACY<br />
OVER AN EXTENDED LINEAR RANGE<br />
J. Polgar* (US), J. Havelick, Q. Li, N. Laur<strong>en</strong>t, U. Mahesh, D. Matte, Z. Gruman,<br />
P. Haley, E. Do<strong>en</strong>ges, C. M. Holland, I. Csapo, C. Crowley, M. Doyle, M. Triscott<br />
INFLUENCE OF THE SOURCE OF PHOSPHOLIPIDS FOR APTT-BASED FIX ASSAYS<br />
AND POTENTIAL CONSEQUENCES FOR THE DIAGNOSIS OF MILD/MODERATE<br />
HAEMOPHILIA B<br />
C. Pouplard (FR), A. Lequerrec*, M. Trossaert, B. Delahousse, C. Guerois,<br />
B. Giraudeau, Y. Gruel<br />
APPLICABILITY OF A THROMBIN GENERATION TEST IN LABORATORY SCREENING<br />
A. E. Pusateri (US), L. Grimm, V. King*<br />
244
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Haemorrhagic disorders<br />
Haemophilia A and B<br />
P-T-113<br />
P-T-114<br />
P-T-115<br />
P-T-116<br />
COMBINED POLYMORPHISM MARKERS FOR CARRIER AND PRENATAL DIAGNOSIS<br />
OF HAEMOPHILIA IN CHINA<br />
Y. Lu* (CN), X. Wang, Q. Ding, H. Wang<br />
RECOMBINATION IN ONE HAEMOPHILIA A FAMILY<br />
Y. Lu* (CN), X. Wang, Q. Ding, H. Wang<br />
EARLY VIRAL KINETICS PORTENDS THE LONG-TERM OUTCOME OF COMBINED<br />
THERAPY WITH PEGYLATED INTERFERON (PEG-IFN) PLUS RIBAVIRIN IN<br />
HEMOPHILIACS WITH HCV/HIV COINFECTION<br />
M. E. Mancuso* (IT), M. G. Rumi, E. Santagostino, R. Soffredini, A. Coppola, A. Rocino,<br />
S. Linari, M. Colombo, P. M. Mannucci<br />
PORT IS NOT A SAFE AND SUITABLE VENOUS ACCESS FOR IMMUNE TOLERANCE<br />
TREATMENT (ITT) IN HEMOPHILIC CHILDREN<br />
M. E. Mancuso* (IT), E. Santagostino, S. M. Siboni, P. M. Mannucci<br />
P-T-117<br />
P-T-118<br />
P-T-119<br />
IMMUNE TOLERANCE INDUCTION TO FVIII IN HEMOPHILIA A MICE USING<br />
SUBCUTANEOUSLY IMPLANTED FVIII GENE-MODIFIED ENDOTHELIAL PROGENITOR<br />
CELLS<br />
H. Matsui* (CA), A. Labelle, C. Hegadorn, P. Thompson, E. Burnett, C. Hough, D. Lillicrap<br />
U.S. INHIBITOR PILOT PROJECT: STUDY DESIGN AND METHODS VALIDATION<br />
J. M. Soucie* (US), C. H. Miller, M. Creary, W. C. Hooper, T. C. Abshire, D. B. Brettler,<br />
P. Bock<strong>en</strong>stedt, J. Dipaola, G. Massey, A. Neff, A. Shapiro, M. Tarantino, B. M. Wicklund,<br />
D. Dimichele, U. D. C. Working Group<br />
NON-CATHETER SUPERIOR CAVA VEIN THROMBOSIS IN A PATIENT WITH<br />
HEMOPHILIA B AND HIGH TITRE INHIBITOR<br />
M. E. Mingot* (ES), A. Heiniger<br />
Tuesday Posters<br />
P-T-120<br />
P-T-121<br />
P-T-122<br />
P-T-123<br />
P-T-124<br />
HANDHELD COMPUTERS: AN EFFECTIVE SYSTEM TO RECORD HOME-THERAPY<br />
DATA OF PATIENTS WITH HAEMOPHILIA<br />
R. Nunez* (ES), N. F. Perez, R. Perez Garrido, M. Brasser, A. Kimmet<br />
LONG-TERM PHARMACOVIGILANCE UPDATE WITH A RECOMBINANT FVIII<br />
CONCENTRATE FOR THE TREATMENT OF HEMOPHILIA A<br />
J. Old<strong>en</strong>burg* (DE), P. Petrini, A. Faradji, A. Tagliaferri, I. Pabinger, S. Knaub,<br />
C. Zacharias, H. L<strong>en</strong>k For Int. Helixate® Nexg<strong>en</strong> Phv Group<br />
EXERCISE IMPROVES THE GLOBAL HEMOSTATIC EFFICACY IN SEVERE<br />
HEMOPHILIA A DOGS, AS DETERMINED BY THROMBELASTOGRAPHY<br />
M. Othman* (CA), S. Webster, Y. Chirinian, D. Lillicrap<br />
MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF FVIII MUTATIONS IN A<br />
FEMALE WITH SEVERE HEMOPHILIA A<br />
A. Dos Santos (BR), S. A. L. Montalvão, C. Furlan Freguia, E. V. De Paula,<br />
J. M. Annichino-Bizzacchi, R. M. Camire, M. C. Ozelo*<br />
MILD HAEMOPHILIA A (P. A1824T) ASSOCIATED WITH HEREDITARY COAGULATION<br />
FACTOR XII DEFICIENCY AND HETEROZYGOUS PROTHROMBIN 20210G/A MUTATION<br />
R. Perez (ES), R. Nunez*, R. Garcia-Lozano, O. Fernandez<br />
245
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-125<br />
P-T-126<br />
P-T-127<br />
P-T-128<br />
P-T-129<br />
THE UK NATIONAL EXTERNAL QUALITY ASSESSMENT SCHEME (UK NEQAS) FOR<br />
MOLECULAR GENETIC TESTING IN HAEMOPHILIA<br />
D. J. Perry* (UK), A. Goodeve, M. Hill, I. J<strong>en</strong>nings, S. Kitch<strong>en</strong>, I. Walker<br />
OVERWEIGHT IN DUTCH HAEMOPHILIA PATIENTS<br />
M. Peters* (NL), F. F. G. Hofstede, P. P. W. Kamphuis<strong>en</strong>, K. K. Fijnvandraat, I. I. Plug<br />
SELF-RATED HEALTH PREDICTS MORTALITY IN PATIENTS WITH HEMOPHILIA<br />
I. Plug* (NL), F. R. Ros<strong>en</strong>daal, J. G. van der Bom<br />
IDENTIFICATION OF FACTOR VIII GENE MUTATIONS IN 120 HAEMOPHILIA A<br />
PATIENTS: DETECTION OF 26 NOVEL MUTATIONS AND CORRELATION WITH FVIII<br />
INHIBITOR DEVELOPMENT<br />
Y. Repesse* (FR), D. Ferandiz, M. Slaoui, P. Gautier, A. Le Querrec, J. Lavergne,<br />
A. Borel Derlon<br />
ABNORMAL PATTERN FOR FVIII GENE INTRON 1 INVERSION IN ONE BRAZILIAN<br />
FAMILY<br />
S. M. Rez<strong>en</strong>de (BR), S. F. Pio*, G. Correa, D. Zouain<br />
P-T-130 FAILURE OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA B PATIENTS WITH C,<br />
T 6460 NONSENSE MUTATION<br />
N. I. Rodriguez* (US), W. Hoots, D. L. Brown, M. Womack, M. Cantini, M. A. Escobar<br />
P-T-131<br />
P-T-132<br />
P-T-133<br />
P-T-134<br />
P-T-135<br />
P-T-136<br />
P-T-137<br />
REGULATION OF DEVELOPMENT AND FUNCTION ENDOTHELIAL CELLS BY<br />
XENOGENIC IMMUNOGLOBULINS<br />
V. I. Rugal* (RU), O. A. Rukavitsin<br />
ACUTE CORONARY STENT THROMBOSIS IN A PATIENT WITH SEVERE HAEMOPHILIA<br />
ON DUAL ANTIPLATELET THERAPY<br />
L. Rus<strong>en</strong>* (RO), C. Lambert, C. Hermans<br />
ENDOTHELIAL DYSFUNCTION IN HEMOPHILIA PATIENTS<br />
M. T. Sartori* (IT), F. Bilora, E. Zanon, C. Varvarikis, G. Saggiorato, E. Campagnolo,<br />
G. Cella<br />
DOUBLE MUTATION, A 2-BP DELETION AND VAL 211ILE, IN THE BLOOD<br />
COAGULATION FACTOR IX GENE IN A PATIENT WITH SEVERE HEMOPHILIA B<br />
I. Seita* (JP), K. Shinozawa, H. Kato, A. Koh, A. Tsujikawa, T. Suzuki, K. Amano,<br />
H. Inaba, K. Fukutake<br />
CONTRIBUTION OF NATURAL ANTICOAGULANT AND FIBRINOLYTIC FACTORS IN<br />
MODULATING THE CLINICAL SEVERITY OF HEMOPHILIA PATIENTS<br />
S. Shetty* (IN), S. Vora, B. Kulkarni, L. Mota, M. Vijapurkar, L. Quadros, K. Ghosh<br />
SUCCESSFUL TREATMENT OF HIGH TITRE FACTOR VIII (FVIII) INHIBITOR IN TWO<br />
PATIENTS WITH MILD AND MODERATE HAEMOPHILIA A WITH RITUXIMAB ALONE<br />
M. Sigaud* (FR), S. Voisin, A. Lefrancois, M. Fouassier, C. Ternisi<strong>en</strong>, M. Hamidou,<br />
M. Trossaert<br />
NATURAL CLEARANCE OF HEPATITIS C VIRUS INFECTION AND HUMAN LEUKOCYTE<br />
ANTIGEN CLASS II ALLELES IN CHILDREN WITH HAEMOPHILIA<br />
R. Simanis* (LV), J. Eglite, L. Viksna, S. Lejniece, A. Sochnevs, Z. Kovalova<br />
246
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Haemophilia therapy<br />
P-T-138<br />
P-T-139<br />
P-T-140<br />
P-T-141<br />
P-T-142<br />
INHIBITOR DEVELOPMENT IN PATIENTS WITH HEMOPHILIA A TREATED WITH<br />
SUCROSE-FORMULATED RECOMBINANT FACTOR VIII<br />
M. Maas-Enriquez* (DE), E. Gorina, N. Bajwa, G. Lemm<br />
HOME CLINICAL ASSISTANCE: SICILIAN SURVEY ON THE HCA SUPPORT FOR THE<br />
MANAGEMENT OF THE PROPHYLAXIS IN PAEDIATRIC HAEMOPHILIAC PATIENTS<br />
G. Mancuso* (IT), F. Gagliano, G. Bruno, M. Rizzo, M. Mansueto<br />
PHYSICAL EXAMINATION IN PATIENTS WITH SEVERE HEMOPHILIA UNDER<br />
PROPHYLACTIC TREATMENT - EFFICACY OF AN EARLY LONG-TERM PROPHYLAXIS?<br />
S. Masurat* (DE), A. Weid<strong>en</strong>hammer, K. Christ<strong>en</strong>s<strong>en</strong>, T. Spranger, A. Takla, G. Auerswald<br />
HAEMOPHILIA TREATMENT IN SERBIA FROM 2000 TO 2006 – HOW TO REACH ONE<br />
UNIT PER CAPITA IN LOW ECONOMIC CAPACITY COUNTRY<br />
D. Mikovic* (RS), G. Jankovic, L. Rakic, M. Kovac, A. Maslac<br />
IMPACT OF FVIII PRODUCT CHANGE IN SEVERE HAEMOPHILIA A PATIENTS<br />
PREVIOUSLY TREATED WITH PLASMA-DERIVED FVIII<br />
M. E. Mingot* (ES), D. Bardan, A. Martín, A. Heiniger<br />
P-T-143<br />
P-T-144<br />
P-T-145<br />
FINAL RESULTS OF A FEASIBILITY STUDY ON AN ELECTRONIC MONITORING<br />
SYSTEM IN HEMOPHILIA CARE<br />
W. Mondorf* (DE), H. Pollmann<br />
RESTORING INITIAL THROMBIN GENERATION DOES NOT NORMALIZE CUTANEOUS<br />
WOUND HEALING IN HEMOPHILIA B<br />
A. G. McDonald (US), J. Brock, U. Hedner, M. Ezban, H. R. Roberts, D. M. Monroe,<br />
M. Hoffman*<br />
THE CLINICAL RESULTS OF P32 RADIOSYNOVECTOMY IN HEMOPHILIC PATIENTS<br />
WITH CHRONIC SYNOVITIS<br />
S. J. Mortazavi* (IR), S. Asadollahi, M. Farzan, S. Shahriaran, M. Aghili, S. Izadyar,<br />
M. Lak<br />
Tuesday Posters<br />
P-T-146<br />
P-T-147<br />
P-T-148<br />
P-T-149<br />
P-T-150<br />
EVALUATION OF THE SAFETY AND PHARMACOKINETICS OF A RAPID-ACTING<br />
RECOMBINANT FVII ANALOGUE, NN1731, IN HEALTHY MALE SUBJECTS<br />
J. Møss* (DK), B. Scharling, M. Ezban, T. Møller Sør<strong>en</strong>s<strong>en</strong><br />
POSTMARKETING SURVEILLANCE STUDY OF SUCROSE-FORMULATED<br />
RECOMBINANT FACTOR VIII FOR SEVERE HEMOPHILIA A: FINAL RESULTS<br />
R. Musso* (IT), E. Santagostino, A. Faradji, M. Maas-Enriquez<br />
PHARMACOKINETICS OF A MIXTURE OF FVIIA AND FX IN RATS<br />
Y. Nakatomi* (JP), H. Matsui, M. Tsuji, A. Shiranita, T. Nakamura, T. Nakashima,<br />
S. Gokudan, H. Miyazaki, S. Oonishi, E. Kusumoto, K. Tomokiyo, Y. Ogata, T. Shigaki<br />
IMMUNE-TOLERANCE IN HAEMOPHILIA A USING PLASMA-DERIVED FACTOR VIII<br />
CONCENTRATE FANHDI<br />
J. Needham* (UK), A. Roy, Y. Stebbings, H. Lewis, G. Mathias<br />
EFFICACY AND SAFETY OF A SOLVENT-DETERGENT TREATED AND 15-NM FILTERED<br />
HUMAN COAGULATION FACTOR IX ADMINISTERED BY CONTINUOUS INFUSION IN<br />
HAEMOPHILIA B PATIENTS UNDERGOING SURGICAL PROCEDURES<br />
C. Négrier* (FR), S. Claeyss<strong>en</strong>s, P. Gautier, M. Bertrand, C. Beaufort, N. Knuchel,<br />
F. Bridey, V. Chamouard, R. Fleury<br />
247
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-151<br />
P-T-152<br />
P-T-153<br />
P-T-154<br />
P-T-155<br />
P-T-156<br />
PRION PROTEIN REMOVAL DURING MANUFACTURING OF HIGH-PURITY VWF/FVIII<br />
CONCENTRATES<br />
A. Neisser-Svae* (AT), G. Gruber, M. Stadler, L. Biesert, T. Schmidt, J. Roemisch,<br />
T. Svae<br />
EFFECTS OF THE FACTOR V G1691A MUTATION AND THE FACTOR II G20210A<br />
VARIANT ON THE CLINICAL EXPRESSION OF SEVERE HEMOPHILIA A (< 1%) IN<br />
CHILDREN<br />
U. Nowak-Gottl (DE), K. Kurnik*, C. Escuriola Ettingshaus<strong>en</strong>, R. Schobess, N. Bogdanova<br />
NEEDLE INDUCED HAEMARTHROSIS: A MURINE MODEL OF HEMOPHILIC SYNOVITIS<br />
K. Ovlis<strong>en</strong>* (DK), A. T. Krist<strong>en</strong>s<strong>en</strong>, M. Tranholm<br />
SERIOUS BLEEDS IN HAEMOPHILIAC A CHILDREN AND CONTINUOUS INFUSION (CI)<br />
B. Pautard* (FR), T. Tinot, V. Li Thiao Te, B. Horlé, C. Vinciguerra, B. Roussel<br />
THE STABILITY OF A PLASMA-DERIVED FACTOR VIII PRODUCT DURING SIMULATED<br />
CONTINUOUS INFUSION<br />
H. Pham* (AU), J. Tzouroutis, T. Martinelli<br />
THE EFFECT OF ACTIVATED FACTOR IX ON THE FACTOR IX COAGULANT AND<br />
NAPTT ACTIVITY OF A HIGH-PURITY FACTOR IX CONCENTRATE<br />
W. M. Pickering* (UK), E. Gray<br />
Recombinant activated Factor VII or APCC<br />
P-T-157<br />
P-T-158<br />
P-T-159<br />
P-T-160<br />
P-T-161<br />
P-T-162<br />
P-T-163<br />
ASSESSMENT OF THROMBOTIC ADVERSE EVENTS (TAES) WITH ACTIVATED<br />
PROTHROMBIN COMPLEX CONCENTRATES (APCCS): 17 YEAR EXPERIENCE<br />
B. M. Ew<strong>en</strong>stein* (US), B. S. Yoon, G. Spotts, D. Lee<br />
ANAMNESIS IN PATIENTS WITH HEMOPHILIA AND INHIBITORS WHO RECEIVE<br />
ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES FOR PROPHYLAXIS<br />
N. P. Ewing* (US), L. Pull<strong>en</strong>s, C. De Guzman<br />
RECOMBINANT COAGULATION FACTOR VIIA IN THERAPY OF MASSIVE POST-<br />
PARTUM BLEEDING AT PATIENT WITH IDIOPATHIC THROMBOCYTOPENIA (ITP)<br />
T. A. Fedorova* (RU), E. A. Chernukha, T. K. Puchko, O. V. Rogachevskiy<br />
LONGTERM PROPHYLACTIC TREATMENT WITH RECOMBINANT FACTOR VIIA<br />
(NOVOSEVEN) IN SEVERE CONGENITAL FACTOR VII DEFICIENT PATIENTS<br />
R. B. Zotz* (DE), R. E. Scharf, A. Gerhardt<br />
THE ANALYSIS OF TREATMENT BY RFVIIA IN CARDIO SURGICAL BLEEDING<br />
M. Hulikova* (SK)<br />
RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE<br />
THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA<br />
(NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED<br />
WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS<br />
A. Iorio* (IT), E. Marchesini, A. Falcou, V. Caso, M. Pastorello, V. Tiscione, P. Ballarino,<br />
F. Altomonte, G. Baldi, G. Agnelli, D. Toni<br />
CAN THROMBIN GENERATION (TG) BE USED TO MONITOR RFVIIA TREATMENT:<br />
IN VIVO “MINI- PK” STUDY IN HEMOPHILIA A PATIENTS<br />
G. K<strong>en</strong>et (IL), T. Livnat*, U. Martinowitz, I. Tamarin, B. Ravid, A. Zivelin<br />
248
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-164<br />
P-T-165<br />
P-T-166<br />
P-T-167<br />
P-T-168<br />
P-T-169<br />
INTRA-SUBJECT VARIABILITY OF THROMBOELASTOGRAPHIC PARAMETERS<br />
FOLLOWING RFVIIA IN VIVO ADMINISTRATION IN HAEMOPHILIA PATIENTS:<br />
A MULTI-CENTRE, RANDOMIZED TRIAL<br />
G. K<strong>en</strong>et* (IL), C. B. St<strong>en</strong>mo, A. Blemings, W. Wegert, J. Goudemand, M. Krause,<br />
W. Schramm, J. Ingerslev, U. Martinovitz<br />
STUDY OF RECOMBINANT FACTOR VIIA ACTION MECHANISM: A MATHEMATICAL<br />
MODEL<br />
M. A. Khanin* (RU), K. V. Tyurin, A. Platonov<br />
EFFECT OF RFVIIA ON BLEEDING IN HES HEMODILUTED RABBITS<br />
B. Lauritz<strong>en</strong>* (DK)<br />
RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN THE TREATMENT OF CRITICAL<br />
HAEMORRHAGE. A SINGLE CENTRE EXPERIENCE<br />
M. Lopez Fernandez (ES), M. Amor Otero*, C. Andón Saavedra, J. Batlle Fonrodona<br />
SECONDARY PROPHYLAXIS WITH RECOMBINANT ACTIVATED FACTOR VII (RFVIIA)<br />
IN A SEVERE HAEMOPHILIA A PATIENT WITH ANTI-FACTOR VIII INHIBITORS<br />
A. Marquès-Verdier* (FR), C. Chaleteix, B. Soulié, J. O. Bay<br />
PRIMARY PROPHYLAXIS WITH RECOMBINANT FACTOR VIIA IN A PATIENT WITH<br />
HAEMOPHILIA A AND INHIBITOR<br />
M. Q. Molina* (ES), V. J. Yuste, M. A. Román, I. F. Bello, J. R. Garrido, F. H. Navarro,<br />
M. M. Salces<br />
P-T-170<br />
P-T-171<br />
P-T-172<br />
PROPHYLAXIS WITH RECOMBINANT FVIIA<br />
M. Q. Molina* (ES), I. F. Bello, V. J. Yuste, M. A. Román, M. M. Salces, J. R. Garrido,<br />
F. H. Navarro<br />
ILIOPSOAS ABSCESS IN A 4-YEAR-OLD BOY WITH SEVERE HAEMOPHILIA<br />
S. J. Mortazavi* (IR)<br />
THE USE OF FEIBA DURING SURGERIES IN HAEMOPHILIA PATIENTS WITH<br />
INHIBITORS TO FACTOR VIII AND IX<br />
C. Negrier* (FR), K. W. Hoots, H. Gajek, R. Berg, R. Fleury, D. Steph<strong>en</strong>s, E. Skvortsova<br />
Tuesday Posters<br />
Von Willebrand disease<br />
P-T-173<br />
P-T-174<br />
P-T-175<br />
P-T-176<br />
INVESTIGATION OF ACQUIRED VON WILLEBRAND'S SYNDROME IN PATIENTS WITH<br />
HYPOTHYROIDISM<br />
N. M. Antonijevic* (RS), D. Mikovic, M. Kovac, S. Popovic, V. Sreckovic, A. Beletic,<br />
B. Jakovljevic, J. Perunicic, M. Petakov, S. Savic, Z. Vasiljevic, B. Trbojevic<br />
STRUCTURAL AND THERMODYNAMIC EFFECTS OF TYPE 2M AND TYPE 2B VWD<br />
MUTATIONS IN THE A1 DOMAIN OF VWF<br />
M. Auton* (US), J. Moake, M. A. Cruz<br />
CLINICAL AND BIOLOGICAL ASPECTS OF VON WILLEBRAND DISEASE IN ALGERIA<br />
L. Badereddine* (DZ), L. Baghli, B. B<strong>en</strong>hadda<br />
SAFETY AND EFFICACY OF VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE<br />
FOR PROPHYLAXIS DURING ELECTIVE SURGERY IN SUBJECTS WITH VON<br />
WILLEBRAND DISEASE<br />
J. Bernstein* (US), J. C. Gill, C. A. Leissinger, J. Dipaola, M. V. Ragni, R. Shopnick,<br />
L. A. Val<strong>en</strong>tino, C. Friedman, S. Knaub<br />
249
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-177<br />
P-T-178<br />
P-T-179<br />
P-T-180<br />
P-T-181<br />
P-T-182<br />
P-T-183<br />
P-T-184<br />
P-T-185<br />
P-T-186<br />
P-T-187<br />
250<br />
A BAYESIAN APPROACH TO THE DIAGNOSIS OF TYPE 1 VON WILLEBRAND DISEASE<br />
A. Tosetto* (IT), G. Castaman, F. Rodeghiero<br />
BLEEDING SCORE IS INCREASED IN AFFECTED RELATIVES WITH TYPE 1 VON<br />
WILLEBRAND DISEASE AND ABNORMAL MULTIMERIC PATTERN IDENTIFIED IN THE<br />
EU MCMDM-1 VWD STUDY<br />
G. Castaman* (IT), A. Tosetto, F. Rodeghiero, A. Goodeve, A. B. Federici, J. Batlle,<br />
D. Meyer, C. Mazurier, J. Goudemand, J. Eik<strong>en</strong>boom, E. Fressinaud, R. Schnepp<strong>en</strong>heim,<br />
U. Budde, J. Ingerslev, Z. Vorlova, D. Habart, L. Holmberg, S. Lethag<strong>en</strong>, J. Pasi, F. Hill, I. Peake<br />
HETEROGENEITY OF PHENOTYPES IN PATIENTS WITH VON WILLEBRAND DISEASE<br />
ASSOCIATED WITH NULL MUTATIONS: AN OBSERVATION IN FAMILIES WITH THREE<br />
NOVEL MUTATIONS<br />
G. Castaman* (IT), S. H. Giacomelli, R. Ghiotto, K. Bertoncello, M. Bernardi, D. Madeo,<br />
A. Tosetto, F. Rodeghiero<br />
PREVALENCE OF VON WILLEBRAND’S DISEASE IN PREMENOPAUSAL WOMEN WITH<br />
IRON DEFICIENCY ANEMIA AND MENORRHAGIA<br />
Y. Ch<strong>en</strong>* (TW), S. Ch<strong>en</strong>g, T. Chao, W. Tsai, S. Huang, S. Hu, J. Chiang<br />
SENSITIVITY OF THE PLATELET FUNCTION ANALYZER (PFA-100) AS A SCREENING<br />
TEST FOR LABORATORY DIAGNOSIS OF VON WILLEBRAND DISEASE<br />
D. Co<strong>en</strong> Herak* (HR), M. Milos, R. Zadro<br />
ALTERED BINDING OF PURIFIED TYPE 2M VICENZA VON WILLEBRAND FACTOR TO<br />
PLATELET RECEPTOR ALPHAIIBBETA3 AND GPIB-V-IX COMPLEX<br />
L. De Marco* (IT), G. Castaman, M. R. Cozzi, M. Mazzucato, A. Steffan, M. Battiston,<br />
F. Rodeghiero<br />
A MUTATION IN EXON 27 OF THE VWF GENE CAUSING TYPE 2M AND TYPE 3 VON<br />
WILLEBRAND DISEASE IN THREE PATIENTS IN A FAMILY FROM THE WEST OF<br />
SCOTLAND<br />
M. S. Enayat* (UK), A. M. Guilliatt, A. Alvi, C. R. Tait, F. G. H. Hill<br />
2B OR NOT 2B? DISPARATE DISCRIMINATION OF FUNCTIONAL VWF DISCORDANCE<br />
USING DIFFERENT ASSAYS OR METHODOLOGIES FOR VWF LEADS TO SUCCESS OR<br />
FAILURE IN THE EARLY IDENTIFICATION OF TYPE 2B VWD<br />
E. J. Favaloro* (AU), R. Bonar, A. Street, K. Marsd<strong>en</strong><br />
EFFICACY AND SAFETY OF HIGHLY PURIFIED VWF/FVIII CONCENTRATES IN THE<br />
TREATMENT OF INHERITED VON WILLEBRAND DISEASE: RESULTS FROM THE<br />
RETROSPECTIVE ITALIAN STUDY ON 103 CASES<br />
A. B. Federici* (IT), M. G. Mazzucconi, G. Barillari, R. Musso, E. Zanon, G. Castaman,<br />
R. Targhetta, G. Mancuso, G. Muleo, A. Coppola, M. D'Incà, G. Gamba, M. Latella,<br />
P. C. Schinco, L. Valdrè, P. M. Mannucci<br />
FINAL ANALYSIS OF A PROSPECTIVE-MULTICENTRE STUDY TO EVALUATE<br />
EFFICACY AND SAFETY OF A TRIPLE-SECURED VON WILLEBRAND FACTOR (VWF)<br />
A. B. Federici* (IT), A. Borel-Derlon, V. Roussel-Robert, J. Goudemand, C. A. Lee,<br />
I. Scharrer, C. Rothschild, E. Berntorp, Z. Tellier, F. Bridey, P. M. Mannucci & Fr<strong>en</strong>ch<br />
VWF SD-35-DH Study Group<br />
THE VON WILLEBRAND FACTOR (VWF) AND FACTOR VIII ACTIVITIES VERSUS VWF<br />
ANTIGEN RATIOS IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 1: RESULTS<br />
FROM THE EUROPEAN MULTICENTER MCMDM-1VWD STUDY<br />
A. B. Federici* (IT), A. Tosertto, J. C. Eik<strong>en</strong>boom, A. Goodeve, U. Budde, R. Bader,<br />
M. T. Canciani, G. Castaman, J. Battle, D. Meyer, C. Mazurier, J. Goudemand,<br />
R. Schnepp<strong>en</strong>heim, J. Ingerslev, Z. Vorlova, D. Habart, L. Holmberg, S. Lethag<strong>en</strong>,<br />
J. Pasi, F. Hill, F. Rodeghiero, I. R. Peake
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-188<br />
P-T-189<br />
P-T-190<br />
P-T-191<br />
P-T-192<br />
TYPE 2B VON WILLEBRAND’S DISEASE. REPORT FROM A SINGLE CENTER IN<br />
ARGENTINA<br />
J. P. Frontroth* (AR), M. D. Hepner, G. Pieroni, G. B. Sciuccati, A. Feliú Torres,<br />
M. M. Bonduel<br />
RATE OF DE NOVO VWF MUTATIONS IN PATIENTS HISTORICALLY DIAGNOSED WITH<br />
TYPE 1 VWD IN THE EUROPEAN STUDY, MOLECULAR AND CLINICAL MARKERS FOR<br />
THE DIAGNOSIS AND MANAGEMENT OF TYPE 1 VWD (MCMDM-1VWD)<br />
A. Goodeve* (UK), G. Castaman, F. Rodeghiero, A. B. Federici, J. Batlle, D. Meyer,<br />
C. Mazurier, J. Goudemand, J. Eik<strong>en</strong>boom, R. Schnepp<strong>en</strong>heim, U. Budde, J. Ingerslev,<br />
D. Habart, Z. Vorlova, L. Holmberg, S. Lethag<strong>en</strong>, J. Pasi, F. Hill, M. Hashemi Soteh,<br />
L. Baronciani, C. Halld<strong>en</strong>, A. Guilliatt, W. Lester, I. Peake<br />
LABORATORY DIAGNOSIS AND MONITORING OF DDAVP TREATMENT OF<br />
VON WILLEBRAND DISEASE BY FLOW CYTOMETRY<br />
P. Gresele (IT), S. Giannini*, M. Leone, A. Mezzasoma<br />
VICENZA MUTATION R1205H IDENTIFIED IN TWO TYPE 1 VON WILLEBRAND DISEASE<br />
FAMILIES FROM ISRAEL<br />
M. B. Hashemi Soteh* (IR), A. Inbal, I. Peake, J. Anson, A. Goodeve<br />
VON WILLEBRAND DISEASE TYPES 2A MUTATION (C.4789C>T, P.R1597W) IN THREE<br />
IRANIAN PATIENTS<br />
M. B. Hashemi Soteh* (IR), G. Rastegar Lari, F. Ala, M. Jazebi<br />
Von Willebrand factor<br />
P-T-193<br />
P-T-194<br />
EFFICACY OF A FVIII/VWF CONCENTRATE AS REPLACEMENT THERAPY IN<br />
PREVENTING EXCESSIVE BLEEDING IN SUBJECTS WITH CONGENITAL VON<br />
WILLEBRAND DISEASE (VWD) WHO UNDERWENT SURGICAL OR INVASIVE<br />
PROCEDURES<br />
L. M. Aledort* (US), G. Rivard, C. M. Kessler<br />
PRIMARY HEMOSTATIC EFFICACY OF RVWF IN A NOVEL MODEL OF VASCULAR<br />
INJURY IN MICE WITH SEVERE VWF DEFICIENCY<br />
B. Baumgartner* (AT), P. L. Turecek, B. Eder, E. M. Muchitsch, H. Gritsch, E. Fesl,<br />
H. P. Schwarz<br />
Tuesday Posters<br />
P-T-195<br />
P-T-196<br />
P-T-197<br />
P-T-198<br />
ADAMTS13 AND VWF IN PEDIATRIC PATIENTS WITH SEVERE MENINGOCOCCAL<br />
SEPSIS<br />
T. N. Bongers* (NL), M. Emonts, M. P. M. De Maat, R. De Groot, J. A. Hazelzet,<br />
F. W. G. Leebeek<br />
ADAMTS13 LEVELS ARE ASSOCIATED WITH THE RISK OF ARTERIAL THROMBOSIS<br />
IN YOUNG SUBJECTS<br />
T. N. Bongers* (NL), E. L. E. De Bruijne, D. W. J. Dippel, J. W. Deckers,<br />
D. Poldermans, M. P. M. De Maat, F. W. G. Leebeek<br />
CHARACTERIZATION OF THE INTERACTION BETWEEN VON WILLEBRAND FACTOR<br />
AND OSTEOPROTEGERIN<br />
O. D. Christophe* (FR), S. Shahbazi, C. Fribourg, P. J. L<strong>en</strong>ting, V. Terraube, D. V. Cécile<br />
SHEAR-INDUCED DISULFIDE BOND FORMATION REGULATES ADHESION ACTIVITY<br />
OF VON WILLEBRAND FACTOR<br />
J. Dong* (US), H. Choi, Z. Tao, C. Ball, L. Nolasco, H. Pownall, J. Moake<br />
251
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-199<br />
P-T-200<br />
P-T-201<br />
P-T-202<br />
P-T-203<br />
P-T-204<br />
P-T-205<br />
P-T-206<br />
P-T-207<br />
P-T-208<br />
P-T-209<br />
P-T-210<br />
P-T-211<br />
VON WILLEBRAND FACTOR (VWF)-BINDING TO COLLAGEN III UNDER<br />
PHYSIOLOGICAL FLOW CONDITIONS AND VWF-MEDIATED PLATELET BINDING<br />
B. Fuchs* (DE), C. Fisseau, C. Kannicht<br />
HOW ABO BLOOD GROUPS AFFECT VON WILLEBRAND FACTOR LEVELS IN<br />
NORMAL SUBJECTS<br />
L. Gallinaro* (IT), M. Cattini, A. Bertomoro, E. Pontara, F. Sartorello, C. Soldera,<br />
R. Padrini, A. Pagnan, A. Casonato<br />
HOW ABO BLOOD GROUPS AFFECT VON WILLEBRAND FACTOR LEVELS IN<br />
NORMAL SUBJECTS<br />
L. Gallinaro* (IT), M. Cattini, A. Bertomoro, E. Pontara, F. Sartorello, C. Soldera,<br />
R. Padrini, A. Pagnan, A. Casonato<br />
COLLAGEN AFFINITY TO VON WILLEBRAND FACTOR CONTAINED IN A<br />
THERAPEUTIC FVIII/VWF CONCENTRATE EVALUATED BY SURFACE PLASMON<br />
RESONANCE<br />
S. Grancha* (ES), J. I. Jorquera<br />
STABILITY OF HIGH PURITY THERAPEUTIC FVIII/VWF CONCENTRATE AFTER<br />
RECONSTITUTION<br />
S. Grancha* (ES), J. I. Jorquera<br />
AUTOMATED QUANTIFICATION OF VON WILLEBRAND FACTOR ACTIVITY WITH<br />
HEMOSIL ON THE CA 7000 COAGULOMETER: A VALIDATION STUDY<br />
F. Guerrero* (FR), I. Bruny, P. Sie<br />
THE EFFECT OF ABO BLOOD GROUP ON VON WILLEBRAND FACTOR PROPEPTIDE<br />
LEVELS IN NORMAL INDIVIDUALS<br />
S. L. Haberichter* (US), P.erson, R. G. Hoffman, J. C. Gill, R. R. Montgomery<br />
THE <strong>ISTH</strong> SSC VON WILLEBRAND FACTOR (VWF) ONLINE DATABASE<br />
D. J. Hampshire* (UK), P. D. James, D. Lillicrap, I. R. Peake, A. C. Goodeve<br />
VWF FUNCTIONS, ADAMTS-13 ACTIVITY AND ANTIGEN LEVELS IN PATIENTS WITH<br />
LIVER CIRRHOSIS<br />
I. Tornai (HU), M. Papp, M. L. Udvardy, J. Harsfalvi*<br />
IDENTIFICATION AND EXPRESSION OF R763G MUTATION ABOLISHING THE<br />
CLEAVAGE OF VON WILLEBRAND FACTOR PROPEPTIDE, AT THE HETEROZYGOUS<br />
AND HOMOZYGOUS STATE<br />
L. Hilbert* (FR), P. Nurd<strong>en</strong>, M. Guicheteau, C. Caron, C. Mazurier<br />
PHARMACOKINETIC PROFILES AND PHARMACOKINETIC AND PHARMACODYNAMIC<br />
RELATIONSHIP OF A VWF INHIBITORY APTAMER IN THE CYNOMOLGUS MONKEY<br />
R. M. Hutabarat* (US), T. McCauley, A. Makim, S. Lewis, P. Merlino, M. Gilbert,<br />
P. Bouchard<br />
A NEW SIMPLE AND RELIABLE METHOD FOR INVESTIGATING THE AFFINITY<br />
BETWEEN COLLAGEN AND VON WILLEBRAND FACTOR IN PLASMA SAMPLES<br />
M. Karlman* (SE), B. Wiman<br />
A NEW SIMPLE AND RELIABLE METHOD FOR INVESTIGATING THE AFFINITY<br />
BETWEEN FACTOR VIII AND VON WILLEBRAND FACTOR IN PLASMA SAMPLES<br />
M. Karlman* (SE), A. Karlsson, B. Wiman<br />
252
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-212<br />
P-T-213<br />
P-T-214<br />
COMPARISON OF THE ASSERACHROM VON WILLEBRAND FACTOR ANTIGEN ASSAY<br />
AND THE LIATEST VWF ASSAY AUTOMATED ON THE AMAX 200 COAGULATION<br />
ANALYZER IN HUMAN AND CANINE PLASMA SAMPLES<br />
M. Lauzon* (CA), F. Angeloni, N. McEw<strong>en</strong>, J. McGrath, M. Johnston<br />
CHARACTERIZATION OF COMMERCIALLY AVAILABLE VWF-CONTAINING FVIII<br />
CONCENTRATES BY VWF MULTIMER ANALYSIS<br />
H. J. Metzner* (DE), U. Budde, M. Albers, S. Schulte<br />
IDENTIFICATION OF AMINO ACID RESIDUES RESPONSIBLE FOR VON WILLEBRAND<br />
FACTOR BINDING TO SULFATIDES BY CHARGED TO ALANINE SCANNING<br />
MUTAGENESIS<br />
T. Nakayama* (JP), T. Matsushita, J. Sadler, A. Katsumi, T. Kojima, T. Naoe, H. Saito<br />
Inherited and acquired platelet disorders<br />
P-T-215<br />
HIGH PREVALENCE OF IRON DEFICIENCY AMONG PATIENTS REFERRED FOR<br />
EVALUATION OF A BLEEDING DISORDER<br />
M. Pai* (CA), Y. Liu, S. Whittaker, E. Arnold, J. Seecharan, K. Moffat, K. Webert,<br />
N. Heddle, C. P. M. Hayward<br />
P-T-216<br />
P-T-217<br />
P-T-218<br />
BERNARD-SOULIER PLATELETS EXPOSE MORE PROCOAGULANT<br />
PHOSPHATIDYLSERINE (PS), WITH PAR1 AND PAR4 MEDIATING THE SYNERGISTIC<br />
EFFECT OF THROMBIN ON COLLAGEN-STIMULATED PS EXPRESSION<br />
M. L. Rand* (CA), H. Wang, K. W. A. Bang, J. Teitel, V. S. Blanchette, J. Freedman,<br />
A. T. Nurd<strong>en</strong><br />
DIAGNOSTIC EFFICACY OF SYSTEMATIC INVESTIGATION OF NON-VON WILLEBRAND<br />
BLEEDERS: RESULTS OF A PROSPECTIVE STUDY<br />
D. Rapson* (CA), M. Bowman, D. Lillicrap, P. James<br />
NINE NOVEL MUTATIONS IDENTIFIED IN GLYCOPROTEINS (GP) IB AND IX GENES<br />
AMONG 13 UNRELATED PATIENTS WITH BERNARD SOULIER SYNDROME IN INDIA<br />
R. Rebecca Jacob* (IN), J. Giridhara Rao, A. Viswabandya, S. Baidya, S. C. Nair,<br />
B. George, V. Mathews, M. Chandy, A. Srivastava<br />
Tuesday Posters<br />
P-T-219<br />
P-T-220<br />
P-T-221<br />
P-T-222<br />
NOVEL MOLECULAR DEFECT IN THE PLATELET ADP RECEPTOR P2Y12 OF A<br />
PATIENT WITH HAEMORRHAGIC DIATHESIS<br />
J. A. Remijn* (NL), M. J. W. Ijsseldijk, E. C. Dompeling, H. Engel, L. D. Dikkeschei,<br />
P. G. De Groot, R. J. Slingerland<br />
DETECTION OF NONMUSCLE MYOSIN-IIA, INCLUSIONS IN NEUTROPHILS, D-VARIANT<br />
OF FIBULIN-1 AND MUTATIONS WITHIN MYH9 GENE IN PATIENTS WITH MYH9-<br />
RALATED DISORDERS<br />
S. Rittich* (CZ), D. Mikul<strong>en</strong>kova, P. Salaj, I. Hrachovinova<br />
THROMBOCYTOPENIA: ANALYSIS OF 317 PATIENTS<br />
C. Rothschild* (BR), E. Cabral, M. P. Garanito<br />
EVALUATION OF OUR CASES WITH GLANZMANN THROMBASTHENIA<br />
Z. Salcioglu* (TR), G. Aydogan, F. Akici, Z. Baslar, H. H. S. Sayilan S<strong>en</strong>, N. Aktay Ayaz,<br />
H. Aldemir, O. Yanilmaz<br />
P-T-223<br />
IDENTIFICATION OF 8 NOVEL MUTATIONS IN THE NON-MUSCLE MYOSIN HEAVY<br />
CHAIN 9 (MYH9 ) GENE IN 11 UNRELATED PATIENTS WITH<br />
MACROTHROMBOCYTOPENIA<br />
B. Saposnik* (FR), S. Binard, S. Elbaz, A. Nurd<strong>en</strong>, P. Nurd<strong>en</strong>, O. F<strong>en</strong>neteau,<br />
M. F. Hurtaud-Roux, M. C. Alessi, C. Boinot, R. Favier, S. Bellucci, N. Schlegel<br />
253
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-224<br />
P-T-225<br />
P-T-226<br />
P-T-227<br />
P-T-228<br />
P-T-229<br />
P-T-230<br />
CUTANEOUS DELAYED-TYPE IV-HYPERSENSITIVITY REACTION (DTH) TO HEPARIN<br />
AND HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II (HIT) – IS THERE AN<br />
ASSOCIATION?<br />
M. Schindewolf* (DE), E. Lindhoff-Last, R. J. Ludwig, W. H. Boehncke, H. Kroll<br />
SEVERE NEONATAL ALLOIMMUNE THROMBOCYTOPENIA CAUSED BY LOW-AVIDITY<br />
ANTI-HPA-1A ALLOANTIBODIES<br />
I. Socher* (DE), C. Andrei-Selmer, G. Bein, H. Kroll, S. Santoso<br />
A VERY RARE CONGENITAL BLEEDIND DISORDER-BERNARD SOULIER SYNDROME,<br />
FOUND IN A FAMILY IN MACEDONIA<br />
S. G. Stankovic* (MK), M. Ivanovski, A. Stojanovic<br />
DIAGNOSIS AND THERAPY OF CHILDREN WITH INHERITED DEFECTS OF PLATELET<br />
FUNCTION IN GERMAN SPEAKING COUNTRIES: QUALITY PROJECT THROMKID<br />
W. Streif* (AT), M. Olivieri, S. Weickardt, H. Rott, U. Nowak- Göttl, C. Wermes,<br />
C. Escuriola, H. Laws, U. Harbrecht, R. Schnepp<strong>en</strong>heim, W. Eberl, R. Knöfler, W. Streif<br />
THE ROLE OF FC-GAMMA RECEPTOR GENE POLYMORPHISMS IN THE CLINICAL<br />
OUTCOME OF NEWLY DIAGNOSED ITP IN CHILDREN<br />
M. D. Tarantino* (US), G. Streater, L. Pumfrey, D. Nug<strong>en</strong>t, S. Williams<br />
POLYCYTHAEMIA VERA, ANTIPHOSPHOLPID ANTIBODIES AND ACQUIRED PLATELET<br />
FUNCTION ABNORMALITIES<br />
J. Toth* (HU), J. Harsfalvi, J. Kappelmayer, T. Szanto, M. Szarvas, L. Rejto, P. Soltesz,<br />
M. Udvardy, L. Muszbek<br />
A HETEROZYGOUS MUTATION OF GPIIB IN PATIENT WITH GLANZMANN<br />
THROMBASTHENIA<br />
Z. Yu* (CN), J. Su, X. Bai, Z. Wang, C. Ruan<br />
Acquired coagulation disorders incl. DIC<br />
P-T-231<br />
P-T-232<br />
P-T-233<br />
P-T-234<br />
P-T-235<br />
P-T-236<br />
254<br />
SUCCESSFUL INHIBITOR-ELIMINATION W ITH RITUXIMAB IN ONE PATIENT WITH<br />
A CARRIER STATE FOR HEMOPHILIA A AND 4 PATIENTS WITH ACQUIRED<br />
HEMOPHILIA A<br />
A. Huth-Kühne* (DE), J. Findeklee, M. Bajanova, P. Lages, R. Zimmermann<br />
CLINICAL EFFICACY OF ANTI-VENOM TREATMENT IN PAPUAN NEW GUINEA<br />
SNAKE-BITE PATIENTS<br />
R. Summerhayes* (AU), V. Ignjatovic, D. Williams, K. Winkel, P. Monagle,<br />
B. Solch<strong>en</strong>berger<br />
SUCCESSFUL IMMUNE TOLERANCE INDUCTION TREATMENT OF THERAPY-<br />
RESISTENT ACQUIRED HAEMOPHILIA WITH HIGH INHIBITOR TITER: A CASE REPORT<br />
P. Ilonczai* (HU), A. Schlammadinger, Z. Oláh, K. Rázsó, Z. Bereczky, Z. Boda<br />
POISONING WITH SUPERWARFARIN<br />
L. A. Jones* (AR), A. Sánchez-Luceros, S. S. Mesch<strong>en</strong>gieser, P. Casais, S. Grosso,<br />
A. N. Blanco, M. Shearer, M. A. Lazzari<br />
ACQUIRED VON WILLEBRAND DISEASE IN A PATIENT WITH SYSTEMIC LUPUE<br />
ERYTHEMATOSUS<br />
F. A. Karim* (MY), Y. Ayob<br />
INCREASED THROMBIN GENERATION CAPACITY IN SEPTIC PATIENTS WITH DIC<br />
K. Kawasugi* (JP), C. Simazu, M. Noguchi, H. Tashiro, M. Gotoh, N. Shirafuji,<br />
J. Matsuda, Y. Miyazawa
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-237<br />
P-T-238<br />
P-T-239<br />
P-T-240<br />
P-T-241<br />
P-T-242<br />
COAGULATION STUDIES IN PATIENTS PRESENTING WITH HYPOTHERMIA<br />
M. Donald (UK), W. Morrison, M. Savory, R. Kerr*<br />
PLASMA LEVEL OF STROMAL DERIVED FACTOR-1 (SDF-1) IS INCREASED IN<br />
DISSEMINATED INTRAVASCULAR COAGULATION PATIENTS WHO HAVE A POOR<br />
OUTCOME: IN VITRO EFFECT OF SDF-1 ON COAGULOPATHY<br />
H. Kim* (KR), J. Kim, J. Chung, K. Han, S. Park, H. Cho<br />
INFLUENCE OF ANTIEPILEPTIC DRUGS ON THE COAGULATION<br />
M. Krause* (DE), C. Pud<strong>en</strong>s, C. Kirchmaier, R. Großmann, R. Gerlach<br />
RESPONSE TO RITUXIMAB AND EPITOPE MAPPING OF INHIBITORY ANTIBODIES IN<br />
ACQUIRED HAEMOPHILIA<br />
M. Krause* (DE), C. Ko<strong>en</strong>igs, C. Kessel, C. Kirchmaier, W. Kreuz<br />
DDAVP VERSUS VWF-CONTAINING FACTOR CONCENTRATE IN A PATIENT WITH<br />
ACQUIRED VON WILLEBRAND SYNDROME (AVWS) ASSOCIATED WITH ESSENTIAL<br />
THROMBOCYTHEMIA (ET)<br />
R. Kruse-Jarres* (US)<br />
COAGULATION PARAMETERS OF THE <strong>ISTH</strong> OVERT DIC SCORE: FIRST, THEIR<br />
DISTRIBUTION<br />
A. Leyte* (NL), S. Hog<strong>en</strong>boom, B. G. Cramer, J. P. J. Wester, R. J. Bosman, H. M.<br />
Oudemans-Van Straat<strong>en</strong>, H. I. Van Der Spoel, W. E. Terpstra, M. Treskes, D. F. Zandstra<br />
P-T-243<br />
P-T-244<br />
P-T-245<br />
PEPTIDE MECHANISMS REGULATION OF HEMOSTASIS IN PURULENT SURGICAL<br />
INFECTION<br />
I. D. Likhanov* (RU), M. N. Tsibikov<br />
ELEVATED PLASMIN-ALPHA2-ANTIPLASMIN LEVELS IN SYSTEMIC AMYLOIDOSIS<br />
INDICATE ACTIVATION OF THE FIBRINOLYTIC SYSTEM<br />
C. Maas* (NL), B. Bouma, M. F. B. G. Gebbink, B. P. C. Haz<strong>en</strong>berg, H. Lokhorst<br />
FACTOR V IS AN INDEPENDENT PREDICTOR OF MORTALITY IN PATIENTS WITH<br />
CIRRHOSIS: USEFUL TOOL IN PATIENTS WAITING FOR LIVER TRANSPLANTATION<br />
M. E. Martinuzzo* (AR), G. S. Cerrato, R. R. Forastiero, A. Ruf, L. Chavez, F. Cairo,<br />
V. Descalzi, G. Podestá, F. Villamil, S. Perez Lloret, F. Gruz, C. Fuxman<br />
Tuesday Posters<br />
P-T-246<br />
P-T-247<br />
P-T-248<br />
P-T-249<br />
P-T-250<br />
FIBRIN MONOMER BY A QUANTITATIVE ASSAY IN PATIENTS WITH DISSEMINATED<br />
INTRAVASCULAR COAGULATION<br />
F. T. Mathonnet* (FR), M. Tetegan, B. De Jonghe, M. Uzan, C. Fischer, Y. Giudicelli,<br />
J. Coltat, H. Outin<br />
ACQUIRED HEMOPHILIA IN AN HIV PATIENT<br />
M. E. Mingot* (ES), I. Ballesteros, I. Perez De Pedro, M. Castaño, M. Causse,<br />
A. Heiniger<br />
EVALUATION FOR HYPERCOAGULOPATHY IN THALASSEMIA MAJOR PATIENTS IN<br />
ISFAHAN<br />
A. Moafi* (IR), M. Sabri, M. Abedini<br />
ROLE OF HEMATOLOGIC AND SCREENING HEMOSTATIC PROFILE ON ADMISSION, IN<br />
PREDICTION OF DEVELOPMENT OF COMPLICATIONS IN HOSPITALIZED PATIENTS<br />
WITH DENGUE FEVER<br />
M. Murari* (IN), U. Dewan<br />
EARLY DIAGNOSIS OF SEPTIC DISSEMINATED INTRAVASCULAR COAGULOPATHY<br />
D. Oh* (KR), M. M. J. Jang, S. S. J. Lee, S. S. Y. Chong, M. M. S. Kang<br />
255
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Platelets<br />
Platelets biochemistry and signal transduction<br />
P-T-251<br />
P-T-252<br />
P-T-253<br />
P-T-254<br />
P-T-255<br />
P-T-256<br />
P-T-257<br />
P-T-258<br />
P-T-259<br />
P-T-260<br />
P-T-261<br />
P-T-262<br />
A ROLE FOR DENSE GRANULE SECRETION IN POTENTIATION OF STORE-OPERATED<br />
CALCIUM ENTRY IN HUMAN PLATELETS<br />
A. G. S. Harper* (UK), M. J. Mason, S. O. Sage<br />
A ROLE FOR THE NA+/CA2+ EXCHANGER IN STORE-OPERATED CALCIUM ENTRY IN<br />
HUMAN PLATELETS<br />
A. G. S. Harper* (UK), S. O. Sage<br />
TRANSACTIVATION OF THE INSULIN RECEPTOR MEDIATES PAR-1 RECEPTOR<br />
SIGNALLING TO P85 PI3 KINASE/PKB IN HUMAN PLATELETS<br />
I. Hers* (UK)<br />
PHOSPHOPROTEIN PROFILING OF COLLAGEN PEPTIDE ACTIVATED PLATELETS:<br />
A FOCUS ON SERINE AND THREONINE PHOSPHORYLATION EVENTS<br />
J. M. Howes* (UK), K. S. Lilley, R. W. Farndale<br />
A GADS-INDEPENDENT PATHWAY OF PLCGAMMA2 REGULATION DOWNSTREAM OF<br />
THE COLLAGEN RECEPTOR, GPVI<br />
C. E. Hughes* (UK), C. Pedaries, J. M. Auger, J. McGlade, A. C. Pearce, S. P. Watson<br />
REGULATION OF PHOSPHODIESTERASE 3A IN HUMAN PLATELETS IS MEDIATED BY<br />
PROTEIN KINASE C<br />
R. W. Hunter* (UK), J. E. Harthill, C. MacKintosh, I. Hers<br />
LIPID RAFT-DEPENDENT ACTIVATION OF NOVEL 33-KDA SER/THR KINASE IN<br />
THROMBIN-STIMULATED PLATELETS<br />
M. Ido* (JP), K. Nakanishi, S. Tanaka, M. Bonno, H. Yamamoto, Y. Komada,<br />
E. C. Gabazza, T. Hayashi, K. Suzuki<br />
A ROLE FOR GEMS IN PLATELET GLYCOPROTEIN IB-MEDIATED PLATELET<br />
ACTIVATION<br />
W. Jin* (JP), O. Inoue, K. Inoue, N. Tamura, K. Satoh, M. C. Berndt, M. Handa, S. Goto,<br />
Y. Ozaki<br />
THE CRITICAL ROLE OF MYOSIN IIA IN PLATELET INTERNAL CONTRACTION<br />
G. J. Johnson* (US), L. A. Leis, M. D. Krumwiede, J. G. White<br />
SYNERGISM BETWEEN GI ACTIVATION AND CA2+ MOBILIZATION IN PLATELET<br />
THROMBOXANE A2 FORMATION<br />
M. Kaneko* (JP), N. Kanno, K. Satoh, Y. Ozaki, Y. Yatomi<br />
THE RAPID PROCOAGULANT MEMBRANE SCRAMBLING INDUCED BY CALCIUM<br />
IONOPHORES IN PLATELETS AND LYMPHOCYTES IS DIFFERENT FROM THAT<br />
INDUCED BY THAPSIGARGIN IN PLATELETS: DEMONSTRATION WITH<br />
CYCLOSPORIN A<br />
D. M. Kerbiriou-Nabias* (FR), A. Arachiche, I. Garcin, L. Combettes, D. Geldwerth,<br />
J. M. Freyssinet, T. Letellier, J. Dachary-Prig<strong>en</strong>t<br />
CONTRIBUTION OF INDIVIDUAL PURINOCEPTOR SUBTYPES TO PLATELET<br />
ACTIVATION BY VON WILLEBRAND FACTOR UNDER STATIC CONDITIONS<br />
J. C. Kermode* (US), Q. Zh<strong>en</strong>g<br />
256
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-263<br />
P-T-264<br />
P-T-265<br />
P-T-266<br />
P-T-267<br />
P-T-268<br />
REGULATION OF INSULIN-LIKE GROWTH FACTOR 1 IN PLATELET ACTIVATION<br />
S. Kim* (US), S. P. Kunapuli<br />
REDUNDANT AND NON-REDUNDANT ROLES FOR CLASSICAL PKC ISOFORMS IN<br />
THE REGULATION OF PLATELET FUNCTION<br />
O. Konopatskaya* (UK), J. D. Molk<strong>en</strong>tin, A. W. Poole<br />
LDL-INDUCED PLATELET ACTIVATION INVOLVES SPECIFIC DOMAINS IN APOB100<br />
S. J. A. Korporaal* (NL), L. Buitrago Murcia, A. Koekman, J. N. Akkerman<br />
ACTIVATION OF PLATELETS BY A VON WILLEBRAND FACTOR-BINDING PEPTIDE<br />
SEQUENCE PRESENT IN COLLAGEN III<br />
B. D. Maddox* (UK), R. W. Farndale<br />
THE OMEGA-3 FATTY ACID DOCOSAHEXAENOATE (DHA) REDUCES<br />
CYCLOOXYGENASE(COX)-2 INDUCTION BY INHIBITING NADP(H) OXIDASE AND<br />
PKCe: POSSIBLE INVOLVEMENT OF 15-LIPOXIGENASE(LO)-1<br />
M. Massaro (IT), E. Scoditti, M. Carluccio, C. Storelli, A. Distante, R. De Caterina*<br />
PAR4 INDUCES FULL PLATELET SPREADING ON A FIBRINOGEN MATRIX:<br />
INVOLVEMENT OF ERK2 AND P38 AND CA2+ MOBILIZATION<br />
A. Mazharian* (FR), S. Roger, E. Berrou, F. Adam, A. Kauskot, P. Nurd<strong>en</strong>,<br />
M. Jandrot-Perrus, M. Bryckaert<br />
P-T-269<br />
PLATELET ITIM PROTEINS INHIBIT BASAL SIGNALLING BY YXXL-CONTAINING<br />
PLATELET ACTIVATION RECEPTORS<br />
J. Mori* (UK), A. C. Pearce, J. C. Spalton, M. G. Tomlinson, Y. A. S<strong>en</strong>is, S. P. Watson<br />
Integrins and adhesive proteins<br />
P-T-270<br />
INVOLVEMENT OF THE MAP KINASE JNK1 IN THROMBUS FORMATION<br />
F. Adam* (FR), A. Kauskot, A. Mazharian, N. Ajz<strong>en</strong>berg, E. Berrou, A. Bonnefoy,<br />
M. F. Hoylaerts, M. Bryckaert<br />
Tuesday Posters<br />
P-T-271<br />
P-T-272<br />
P-T-273<br />
CHARACTERISATION OF PREDICTED OESTROGEN RESPONSE ELEMENTS IN THE<br />
ITGA2 GENE PROMOTER<br />
F. M. Al-Zahrani* (UK), M. E. Daly, P. R. Winship<br />
INTEGRIN-LINKED KINASE (ILK) IN PLATELET ALPHAIIB-BETA3 SIGNALING AND<br />
ARTERIAL THROMBOSIS<br />
E. G. Arias-Salgado* (ES), R. B. Rodriguez, N. Butta, S. Garcia-Munoz, R. Parrilla,<br />
M. S. Ayuso<br />
ANTITHROMBOTIC EFFECT OF RECOMBINANT DISINTEGRIN IN A MOUSE<br />
THROMBOSIS MODEL<br />
K. Chung (KR), K. Kwack*, Y. Sohn, D. Kim, S. Lee<br />
P-T-274 A B3 ASP217 VAL SUBSTITUTION IN A PATIENT WITH VARIANT GLANZMANN<br />
THROMBATHENIA SEVERELY AFFECTS INTEGRIN AIIBB3 FUNCTIONS<br />
G. D'Andrea* (IT), R. Bafunno, V. Longo, G. Vecchione, E. Grandone, M. Margaglione<br />
P-T-275<br />
A TAILOR-MADE PEPTIDE-AFFINITY COLUMN TO IDENTIFY NOVEL BINDING<br />
PARTNERS FOR A CYTOPLASMIC MOTIF OF THE PLATELET INTEGRIN ALPHA IIB<br />
M. Raab (IE), H. Daxecker*, M. Devocelle, A. Treumann, N. Moran<br />
257
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-276<br />
P-T-277<br />
P-T-278<br />
P-T-279<br />
P-T-280<br />
P-T-281<br />
P-T-282<br />
P-T-283<br />
P-T-284<br />
P-T-285<br />
P-T-286<br />
807C/T POLYMORPHISM IN THE PLATELET GLYCOPROTEIN IA GENE IN PATIENTS<br />
WITH RETINAL VEIN OCCLUSION<br />
T. Gadelha* (BR), A. Biancardi, F. Marilda, G. C. Souza, M. H. C. F. Oliveira,<br />
B. T. Correa<br />
INCREASED PLATELET AGGREGATION AFTER DDAVP ADMINISTRATION MAY BE<br />
EXPLAINED BY DECREASED EXPRESSION OF THE TETRASPANIN CD9<br />
A. P. Gadisseur (BE), I. Vrelust*, I. Vang<strong>en</strong>echt<strong>en</strong>, F. Vertess<strong>en</strong>, M. Van Der Plank<strong>en</strong><br />
CALDAG-GEFI-DEFICIENCY CAUSES IMPAIRED BETA1, BETA2, AND BETA3 INTEGRIN<br />
ACTIVATION IN NEUTROPHILS AND PLATELETS: A MODEL FOR LEUKOCYTE<br />
ADHESION DEFICIENCY-III (LAD-III)<br />
T. Goerge* (US), W. Bergmeier, H. Wang, J. R. Critt<strong>en</strong>d<strong>en</strong>, A. C. W. Baldwin,<br />
S. M. Cifuni, D. E. Housman, A. M. Graybiel, D. D. Wagner<br />
PLATELET GLYCOPROTEINS: PREDICTORS OR PROGRESSION MARKERS IN<br />
CARDIOVASCULAR DISEASE?<br />
D. A. Gurney* (UK), G. W. Moore, S. Rangarajan<br />
A ROLE FOR ß3 95–105 IN FIBRINOGEN BINDING AND PLATELET AGGREGATION<br />
T. A. Haas* (CA)<br />
A NATURAL MUTATION AND SPECIFIC ARTIFICIAL DELETIONS IN THE BETA3<br />
CYTOPLASMIC TAIL PREVENT ANTIBODY-MEDIATED ACTIVATION OF INTEGRIN<br />
ALPHAIIB-BETA3<br />
H. Hauschner* (IL), N. Ros<strong>en</strong>berg, U. Seligsohn<br />
IS BETA3-ARG261 RESPONSIBLE FOR THE EXCLUSIVE BINDING OF ALPHAIIB TO<br />
BETA3?<br />
H. Hauschner* (IL), N. Ros<strong>en</strong>berg, M. Landau, U. Seligsohn<br />
FCGAMMARII MEDIATES PLATELET AGGREGATION CAUSED BY DISINTEGRINS AND<br />
GPIIB/IIIA MONOCLONAL ANTIBODY, AP2<br />
P. L. Ho (TW), C. H. Chang, T. F. Huang*<br />
NOVEL INTERACTING PROTEINS WITH PLATELET a2β1 CYTOPLASMIC TAILS:<br />
RHOGDIβ AND SLAP-2<br />
B. F. Iserbyt* (BE), S. Katsutani, S. Stael<strong>en</strong>s, G. R. Van De Walle, N. Vandeputte, I. Pareyn,<br />
H. Deckmyn<br />
IMPAIRED 'OUTSIDE-IN' INTEGRIN ALPHAIIBBETA3 SIGNALING AND THROMBUS<br />
STABILITY IN CD151 AND TSSC6-DEFICIENT MICE<br />
D. E. Jackson* (AU), L. M. Lau, M. W. Goschnick, J. L. Wee, Y. S. Liu, M. P. Hogarth,<br />
L. M. Robb, M. J. Hickey, M. D. Wright, L. K. Ashman<br />
VON WILLEBRAND FACTOR-GLYCOPROTEIN IB AND INTEGRIN ALPHA2BETA1-<br />
COLLAGEN INTERACTIONS MAKE COMPLEMENTARY, COLLAGEN-TYPE–SPECIFIC<br />
CONTRIBUTIONS TO ADHESION<br />
S. M. Jung* (JP), M. Moroi<br />
Platelets physiology and pharmacology<br />
P-T-287<br />
INHIBITION OF AMINOPHOSPHOLIPID TRANSLOCASE ACTIVITY IN<br />
PHOSPHATIDYLSERINE-EXPOSING HUMAN PLATELETS IS INDEPENDENT OF<br />
CALPAIN ACTIVITY<br />
A. M. Gwozdz (CA), R. Leung, H. Wang, K. W. A. Bang, M. A. Packham, J. Freedman,<br />
M. L. Rand*<br />
258
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-288<br />
P-T-289<br />
P-T-290<br />
P-T-291<br />
P-T-292<br />
P-T-293<br />
P-T-294<br />
THE DIFFERENCES OF PLATELET RESPONSE TO SNAKE VENOMS: COMPARATIVE<br />
STUDY OF CHILDREN AND ADULTS<br />
L. Kern (AU), V. Ignjatovic, K. Winkel, R. Summerhayes*, P. Monagle<br />
PLATELET VOLUME IN CORD BLOOD<br />
A. Ihara* (JP), T. Nishiura, Y. Uchida, K. Abe, F. Tanaka, K. Matsui, S. Shouno<br />
PLATELET DELAY TIME AS MEASURED IN THE ARTERIOLES OF RATS USING LASER<br />
INDUCED THROMBOSIS<br />
M. A. A. Kratzer* (DE), T. Yamashita, J. Yamamoto<br />
PLATELET ACTIVATION RESPONSE IS MORE SENSITIVE TO THROMBIN STIMULATION<br />
THAN IS PLATELET APOPTOSIS<br />
V. Leytin* (CA), D. J. All<strong>en</strong>, E. Lyubimov, J. Freedman<br />
INITIAL INTRAVENOUS EXPERIENCE WITH PRT060128 (PRT128), AN ORALLY-<br />
AVAILABLE, DIRECT-ACTING, AND REVERSIBLE P2Y12 INHIBITOR<br />
H. D. Lieu* (US), P. B. Conley, P. Andre, P. T. Leese, K. Romanko, D. R. Phillips,<br />
M. Jurek, A. Meloni, A. Hutchaleelaha, D. D. Gretler<br />
SIRTINOL INHIBITS HUMAN PLATELETS AGGREGATION AND CA++ RELEASE<br />
F. C. Liu* (TW), C. H. Liao, Y. W. Chang, J. T. Liou, Y. J. Day<br />
2-AG PLAY A ROLE ON ASPIRIN RESISTANCE IN TYPE 2 DIABETES<br />
H. Matsuno* (JP), S. Araki, Y. Kannno, A. Kuroki, A. Kashiwagi<br />
P-T-295<br />
P-T-296<br />
ANOMALOUS BEHAVIOR OF PLATELETS IN RESPONSE TO TEMPERATURE<br />
E. Maurer-Spurej* (CA)<br />
VARIATIONS OF PLATELET GLYCOPROTEIN IIB-IIIA QUANTITY AFFECTS PLATELET<br />
AGGREGATION AND SENSITIVITY TO GLYCOPROTEIN IIB-IIIA ANTAGONISTS<br />
A. V. Mazurov* (RU), S. G. Khaspekova, A. M. Zabotina, Y. V. Shimanova,<br />
O. V. Sirotkina<br />
Tuesday Posters<br />
P-T-297<br />
P-T-298<br />
P-T-299<br />
P-T-300<br />
P-T-301<br />
A ROLE FOR ADIPONENCTIN IN HUMAN PLATELET FUNCTION?<br />
N. Moran* (IE), S. Sim, S. Chanchlani, A. Kiernan<br />
FLAVONOIDS INHIBIT PLATELET ADHESION AND AGGREGATION UNDER FLOW:<br />
BLOCKADE OF TXA2 RECEPTORS IN PLATELET RICH PLASMA<br />
L. Navarro-Núñez* (ES), M. Palomo, M. Lozano, C. Martínez, E. Pérez-Ceballos,<br />
V. Vic<strong>en</strong>te, J. Castillo, G. Escolar, M. Díaz-Ricart, J. Rivera<br />
PLASMA S/R RATIO OF WARFARIN CO-VARIES WITH VKORC1 HAPLOTYPE<br />
M. Osman* (SE), C. Enström, T. Lindahl<br />
EFFECT OF CLOPIDOGREL TREATMENT ON STRESS-INDUCED PLATELET<br />
ACTIVATION AND MYOCARDIAL ISCHEMIA IN ASPIRIN-TREATED PATIENTS WITH<br />
STABLE CORONARY ARTERY DISEASE<br />
C. Perneby (SE), H. N. Wallén, C. Hofman-Bang, P. Tornvall, T. Ivert, N. Li, P. Hjemdahl*<br />
EFFECT OF PRESENCE OR ABSENCE OF RED CELLS ON EARLY GROWTH RATES OF<br />
PLATELET MURAL THROMBI<br />
I. V. Pivkin* (US), P. D. Richardson, G. E. Karniadakis<br />
259
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
TTP/HUS and ADAMTS 13<br />
P-T-302<br />
P-T-303<br />
P-T-304<br />
P-T-305<br />
P-T-306<br />
ADAMTS13 AND VON WILLEBRAND FACTOR IN THE PATIENTS WITH DIC<br />
T. Ono* (JP), S. Watanabe, F. Furusaki<br />
DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC<br />
TROMBOCITOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT<br />
METHODS<br />
R. Palla* (IT), C. Valsecchi, M. T. Bajetta, M. T. Canciani, S. Lavoretano,<br />
P. M. Mannucci, F. Peyvandi<br />
ATS-13 ACTIVITY AS A COMMON MARKER OF THE ENDOTHELIAL DYSFUNCTION<br />
DEVELOPING IN THROMBOTIC MICROANGIOPATHIES OF DIFFERENT ORIGIN<br />
M. Palomo* (ES), M. Diaz Ricart, C. Carbo, M. Pino, A. Pereira, M. Lozano, E. Carreras,<br />
C. Altis<strong>en</strong>t, E. Saperas, J. Aznar, G. Escolar<br />
MILD CONGENITAL ADAMTS13 DEFICIENCY DUE TO ONE MISSENSE MUTATION<br />
TOGETHER WITH FOUR AMINO ACID POLYMORPHISMS IN A PATIENT WITH FAMILIAL<br />
RECURRENT ISCHEMIC STROKE<br />
B. Plaimauer* (AT), M. Böhm-Weigert, G. Antoine, I. Scharrer, F. Scheiflinger<br />
EXPRESSION AND CHARACTERISATION OF 4 ADAMTS13 MUTATIONS IDENTIFIED IN<br />
PATIENTS WITH TTP (UPSHAW-SCHULMAN SYNDROME)<br />
A. Ribba* (FR), A. Hommais, J. Rayes, A. Houllier, B. Obert, P. Leg<strong>en</strong>dre, A. Veyradier,<br />
J. Girma<br />
P-T-307 ADAMTS-13 ACTIVITY, ANTIGEN AND INHIBITOR ANTIBODIES IN TTP PATIENTS –<br />
A SINGLE CENTER EXPERIENCE<br />
G. Sarig* (IL), E. J. Dann, G. T<strong>en</strong>n<strong>en</strong>baum, J. M. Rowe, B. Br<strong>en</strong>ner<br />
P-T-308<br />
P-T-309<br />
P-T-310<br />
P-T-311<br />
P-T-312<br />
P-T-313<br />
P-T-314<br />
ADAMTS 13 IN NON-THROMBOTIC THROMBOCYTOPENIC PURPURA CONDITIONS<br />
M. Scully* (UK), R. Liesner, C. Burgess, A. Lawrie, S. J. Machin<br />
SOUTH EAST ENGLAND THROMBOTIC THROMBOCYTOPENIC PURPURA REGISTRY<br />
M. Scully* (UK), H. Yarranton, R. Liesner, J. Cav<strong>en</strong>agh, B. Hunt, S. B<strong>en</strong>jamin, S. Machin<br />
TREATMENT OF IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA WITH<br />
MABTHERA (RITUXIMAB)<br />
M. Scully* (UK), R. Liesner, J. Cav<strong>en</strong>agh, B. Hunt, S. B<strong>en</strong>jamin, H. Coh<strong>en</strong>, S. J. Machin<br />
INTENSIVE PLASMA EXCHANGE WAKES UP PATIENT WITH TTP IN COMA<br />
S. G. Stankovic* (MK), L. Cevreska, O. Karanfilski<br />
FXI/ADAMTS13 COMPLEX IN PLASMA<br />
R. D. Starke (UK), A. Lawrie, M. Scully, S. Machin, I. Mackie*<br />
HUMAN VH1-69 GERMLINE GENE ENCODED ANTI-SPACER DOMAIN ANTIBODIES<br />
THAT DEVELOP IN PATIENTS WITH ACQUIRED TTP INTERFERE WITH THE BINDING<br />
OF ADAMTS13 TO VWF<br />
W. Pos* (NL), B. M. Luk<strong>en</strong>, E. A. M. Tur<strong>en</strong>hout, J. A. K. Kremer Hovinga,<br />
K. Aboulfatova, J. Dong, R. Fijnheer, J. Voorberg<br />
ADAMTS13 RELATED MARKERS IN PLASMA FROM PATIENTS WITH TTP<br />
H. Wada* (JP), T. Kobayashi, T. Nobori, T. Matsumoto, Y. Abe<br />
260
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-316<br />
P-T-317<br />
ADAMTS13 ACTIVITY AND AUTOANTIBODIES IN IDIOPATHIC TTP: RESULTS FROM<br />
THE SERF-TTP GROUP<br />
A. Zakarija* (US), H. Kwaan, N. Bandar<strong>en</strong>ko, J. Cursio, D. Pandey, I. Weiss, C. Buffie,<br />
A. Tevar, P. Yarnold, T. Raife, T. Ortel, C. L. B<strong>en</strong>nett<br />
RISK FACTORS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA: RESULTS OF<br />
THE SURVEILLANCE, EPIDEMIOLOGY AND RISK FACTORS FOR TTP (SERF-TTP)<br />
GROUP<br />
A. Zakarija (US), N. Bandar<strong>en</strong>ko, H. Kwaan, D. Pandey, J. Cursio, A. Tevar, C. Buffie,<br />
I. Weiss, T. Ortel, J. Winters, C. L. B<strong>en</strong>nett*<br />
Heparin<br />
P-T-318<br />
P-T-319<br />
INCIDENCE OF THE VARIOUS HEPARIN DEPENDENT ANTIBODY ISOTYPES IN A<br />
GROUP OF PATIENTS WITH HEPARIN INDUCED THROMBOCYTOPENIA<br />
A. M. Vissac* (FR), M. Catala, J. J. Amiral<br />
NEW APPROACH FOR DETECTION OF HEPARIN DEPENDENT ANTIBODIES AND RISK<br />
ASSESSMENT FOR HEPARIN INDUCED THROMBOCYTOPENIA<br />
J. J. Amiral* (FR), M. Peyrafitte, M. Catala, A. M. Vissac<br />
P-T-320<br />
P-T-321<br />
P-T-322<br />
THE USE OF THE WARKENTIN ET AL 4T CLINICAL SCORING SYSTEM TO DETERMINE<br />
PROSPECTIVELY THE APPROPRIATENESS OF HIT ANTIBODY TESTING AT THE<br />
REGIONAL HAEMOSTASIS LABORATORY, BELFAST CITY HOSPITAL, N IRELAND<br />
G. M. B<strong>en</strong>son* (UK), O. McNulty, P. Cooke, P. Murray, D. O'Keeffe<br />
LONG TERM ANTICOAGULATION WITH FONDAPARINUX FOR DIALYSIS DEPENDENT<br />
PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)<br />
N. Bermejo* (ES), M. Martín Mateos, I. Castellano, E. Pardal, C. Cámara<br />
DO PATIENTS WITH HEPARIN INDUCED THROMBOCYTOPENIA HAVE ANTIBODIES TO<br />
ADAMTS-13<br />
S. J. Davidson* (UK), M. Swain<br />
Tuesday Posters<br />
P-T-323<br />
P-T-324<br />
P-T-325<br />
P-T-326<br />
P-T-327<br />
INCIDENCE OF ANTI-HEPARIN/PLATELET FACTOR 4 (AHPF4) ANTIBODIES AND<br />
HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IN MEDICAL PATIENTS<br />
M. Demir* (TR), E. Duran, O. Yigitbasi, O. Vural, T. Kurum, M. Yuksel, B. Turgut,<br />
E. Tekgunduz, J. M. Wal<strong>en</strong>ga, J. Fareed<br />
HEPARIN INDUCED THROMBOCYTOPENIA: COMPLIANCE WITH GUIDELINES IN<br />
A LARGE COMMUNITY HOSPITAL<br />
A. I. Depaulis (US), E. A. Robinson, W. F. Patton*<br />
DEFIBROTIDE AND ITS MOLECULAR FRACTIONS DO NOT CROSS-REACT WITH HIT<br />
ANTIBODIES. IMPLICATIONS IN THE MANAGEMENT OF HIT<br />
J. Fareed* (US), D. Hopp<strong>en</strong>steadt, G. Cella, H. L. Messmore, M. Iacobelli, W. Jeske,<br />
J. M. Wal<strong>en</strong>ga<br />
RECOMBINANT THROMBOMODULIN DOES NOT CROSS REACT WITH ANTI-HEPARIN<br />
PLATELET FACTOR 4 ANTIBODIES. POTENTIAL IMPLICATION FOR<br />
ANTICOAGULATION OF HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS<br />
J. Fareed* (US), D. Fareed, D. Hopp<strong>en</strong>steadt, J. M. Wal<strong>en</strong>ga, W. P. Jeske, R. Bick<br />
HEPARIN-INDUCED THROMBOCYTOPENIA IN CARDIAC SURGERY PATIENTS<br />
M. Neuffer (DE), D. Fischer, U. Geis<strong>en</strong>, M. Berchtold-Herz, F. Beyersdorf, K. G. Fischer*<br />
261
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-328<br />
P-T-329<br />
P-T-330<br />
P-T-331<br />
PROSPECTIVE EVALUATION OF LABORATORY TESTS FOR THE DIAGNOSIS OF<br />
HEPARIN-INDUCED THROMBOCYTOPENIA<br />
J. L. Francis* (US), A. Drexler, M. Duncan, H. Desai, M. Amaya, T. Robson, T. V. Meyer,<br />
E. Reyes, A. Amirkhosravi<br />
EXPLORING ADULT PATIENT POPULATIONS AT RISK FOR DEVELOPING HIT<br />
W. Dager* (US), A. Lee, R. C. Gosselin, J. King, T. Wun, K. Janatpour, J. Owings,<br />
R. White<br />
UPREGULATION OF MICROPARTICLES IN HEPARIN INDUCED THROMBOCYTOPENIA<br />
(HIT) AND IT’S MODULATION BY ARGATROBAN<br />
W. P. Jeske* (US), D. Hopp<strong>en</strong>steadt, J. M. Wal<strong>en</strong>ga, J. Cunanan, K. Nelson,<br />
H. L. Messmore, J. Fareed<br />
HEPARIN-INDUCED THROMBOCYTOPENIA IN A PATIENT WITH POLYCYTEMIA VERA:<br />
A THREATENING ASSOCIATION<br />
M. Kwon* (ES), A. Rodriguez Huerta, C. Pascual, G. Perez Rus, N. Patrignani, C. Muñoz,<br />
J. Diez Martin<br />
Platelet activation markers<br />
P-T-332<br />
P-T-333<br />
P-T-334<br />
P-T-335<br />
P-T-336<br />
P-T-337<br />
P-T-338<br />
P-T-339<br />
CLINICAL SIGNIFICANCE OF MEAN PLATELETS VOLUME IN CORONARY ARTERY<br />
DISEASE<br />
S. Aref* (EG), T. Goda<br />
HIGH NOREPINEPHRINE LEVEL IS ASSOCIATED WITH SIGNIFICANT PLATELET<br />
HYPERREACTIVITY DEMONSTRATED BY INCREASED PLATELET P-SELECTIN<br />
POSITIVITY, ADENOSIN DIPHOSPHATE AND COLLAGEN INDUCED AGGREGATIONS IN<br />
STABLE CORONARY HEART DISEASE PATIENTS ON DUAL ANTIPLATEL<br />
B. J. Béres* (HU), E. Tóth-Zsámboki, K. Vargová, N. Kiss, A. Kovács, Á. Husvéth,<br />
Á. László, T. Masszi, I. Préda, R. G. Kiss<br />
PLATELET AGGREGATION AND SEROTONIN ACTIVITY<br />
J. S. Berger* (US), R. C. Becker, T. L. Ortel, C. M. Kuhn, M. J. Helms, R. B. Williams<br />
PLATELET ACTIVATION AND MYOCARDIAL ISCHEMIC EVENTS IN PATIENTS<br />
UNDERGOING MAJOR VASCULAR SURGERY<br />
S. Rajagopalan* (UK), I. Ford, P. Bachoo, G. Hillis, B. Croal, M. Greaves, J. Britt<strong>en</strong>d<strong>en</strong><br />
CORRELATION BETWEEN SCD40L LEVELS AND METALLOPROTEINASE EXPRESSION<br />
WITH THE PLATELET FUNCTIONAL RESPONSE IN IMMUNOLOGICAL DISEASES<br />
N. V. Butta* (ES), M. Garcia-Rodriguez, E. Arias-Salgado, T. Fontela, S. Larrucea,<br />
I. Marin, L. M<strong>en</strong>ch<strong>en</strong>, P. Hernandez-Sampelayo, R. Parrilla<br />
THE ADDITIVE ANTIPLATELET ACTION OF CLOPIDOGREL IN PATIENTS WITH<br />
CORONARY ARTERY DISEASE TREATED WITH ASPIRIN<br />
J. Dropinski* (PL), B. Jakiela, M. Sanak, W. Wegrzyn, M. Biernat, S. Dziedzina,<br />
H. Plutecka, A. Szczeklik<br />
EFFECT OF ANTIDEPRESSANT DRUG TREATMENT ON INFLAMMATORY AND<br />
PLATELET ACTIVATION BIOMARKERS IN DEPRESSION<br />
J. Fareed (US), A. Halaris*, J. E. Piletz, H. Zhu, O. Iqbal, D. Hopp<strong>en</strong>steadt<br />
ASSOCIATION BETWEEN ENHANCED SOLUBLE CD40 LIGAND AND PLATELET<br />
ACTIVATION IN HYPERTENSIVES WITH MICROALBUMINURIA<br />
P. Ferroni* (IT), M. Guagnano, M. Manigrasso, F. Santilli, C. Pettinella, V. Raparelli,<br />
F. Guadagni, S. Basili, G. Davì<br />
262
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-340<br />
P-T-341<br />
P-T-342<br />
P-T-343<br />
ASSOCIATION BETWEEN ENHANCED VEGF LEVELS AND PLATELET ACTIVATION IN<br />
HYPERTENSIVE PATIENTS<br />
P. Ferroni* (IT), R. Palmirotta, F. Martini, A. Spila, V. Raparelli, A. Mammarella, A. Scarno,<br />
G. Davì, S. Basili, F. Guadagni<br />
COMPARISON OF TWO ASSAYS FOR THE MEASUREMENT OF URINARY 11-DEHYRO<br />
THROMBOXANE B2<br />
G. Gilmore* (AU), J. Thom, J. Rankin, G. Yong, J. W. Eikelboom<br />
LACTADHERIN IS MORE SENSITIVE THAN ANNEXIN-V AT DETECTING<br />
PHOSPHATIDYLSERINE EXPOSURE WITHIN PLATELETS<br />
A. Albanyan* (UK), P. Harrison, J. T. Rasmuss<strong>en</strong>, C. W. Heegard, M. Murphy<br />
MORPHOLOGIC EVIDENCE OF INTRAVASCULAR PLATELET ACTIVATION WITH<br />
GENERATION OF PLATELET MICROPARTICLES & EXOSOMES IN MURINE HEPATIC<br />
SCHISTOSOMIASIS AND ITS MODULATION BY PENTOXIFYLLINE TREATMENT<br />
A. Lotfi* (EG)<br />
Platelet function tests<br />
P-T-344<br />
PLASMAFHERESIS (PA) INFLUENCE ON MORPHOLOGICAL STATUS OF PLATELES<br />
(PLT) AT WOMEN WHITH SPONTANEOS ABORTIONES INFLAMMATORY GENESIS<br />
A. S. Ochan* (RU), E. V. Strelnicova<br />
P-T-345<br />
P-T-346<br />
CLOPIDOGREL PRODUCES DISTINCT DOSE-RESPONSE RELATIONSHIPS FOR<br />
INHIBITION OF PLATELET AGGREGATION (IPA) AND ANTITHROMBOTIC EFFICACY<br />
MEASURED IN RATS AND RABBITS<br />
M. L. Ogletree* (US), P. C. Wong, W. A. Schumacher, R. P. Rehfuss<br />
VARIABILITY IN PERFORMING PLATELET AGGREGOMETRY FOR DIAGNOSIS OF<br />
INBORN DISORDERS OF PLATELET FUNCTION IN GERMANY, AUSTRIA AND<br />
SWITZERLAND<br />
M. Olivieri* (DE), R. Knöfler, S. Weickardt, W. Eberl, W. Streif<br />
Tuesday Posters<br />
P-T-347<br />
P-T-348<br />
P-T-349<br />
P-T-350<br />
P-T-351<br />
MAXIMAL AND LATE ADP INDUCED PLATELET AGGREGATION IN CORONARY<br />
ARTERY DISEASE PATIENTS ON DUAL ANTIPLATELET THERAPY<br />
R. Panicca* (IT), E. Antonucci, A. Gori, R. Marcucci, E. Romano, L. Rossi, S. Claudia,<br />
D. Prisco, R. Abbate, G. G<strong>en</strong>sini<br />
PLATELET FUNCTION EVALUATION BY USING A NEW POINT-OF-CARE SYSTEM AND<br />
PLATELET LIGHT-TRANSMISSION AGGREGATION IN A LARGE COHORT OF<br />
CORONARY ARTERY DISEASE PATIENTS<br />
R. Panicca* (IT), E. Antonucci, E. Romano, A. Gori, R. Marcucci, M. Attanasio, S. Poli,<br />
D. Prisco, R. Abbate, G. G<strong>en</strong>sini<br />
ASPIRIN-RESISTANCE IN CHILDREN<br />
R. Rauch* (DE), G. Wiegand, K. Stellos, M. Girisch, M. Hofbeck, M. Gawaz<br />
SPECIFIC AND SENSITIVE DETECTION OF THE INHIBITION OF THE PLATELET P2Y12-<br />
RECEPTOR WITH THE PFA-100® SYSTEM USING A NEW CARTRIDGE DESIGN<br />
A. R. Rechner (DE), M. Schwarz, C. Oehler, N. Zander*<br />
VARIATIONS IN PLATELET FUNCTION TEST OF NORMAL INDIVIDUALS MAY AFFECT<br />
TEST INTERPRETATIONS<br />
M. Refaai* (US), R. Sarode, A. Kim<br />
263
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-352<br />
P-T-353<br />
P-T-354<br />
P-T-355<br />
P-T-356<br />
P-T-357<br />
P-T-358<br />
P-T-359<br />
P-T-360<br />
P-T-361<br />
P-T-362<br />
P-T-363<br />
CLOPIDOGREL UNRESPONSIVENESS OVERCOME BY RELOADING: ASSESSEMENT<br />
BY PLATELET AGGREGOMETRY AND IMPACT-R [CONE AND PLATE(LET) ANALYZER]<br />
S. Matetzky* (IL), B. Sh<strong>en</strong>kman, H. Hod, P. Fefer, D. Varon, N. Savion<br />
RESPONSIVENESS TO CLOPIDOGREL AND ASPIRIN AMONG PATIENTS WITH ACUTE<br />
CORONARY SYNDROME AS ASSESSED BY THE IMPACT-R [CONE AND PLATE(LET)<br />
ANALYZER]<br />
B. Sh<strong>en</strong>kman* (IL), S. Matetzky, H. Hod, A. Lubetsky, D. Varon, N. Savion<br />
TESTING AGONIST-INDUCED PLATELET AGGREGATION BY THE IMPACT-R<br />
B. Sh<strong>en</strong>kman* (IL), Y. Einav, O. Salomon, D. Varon, N. Savion<br />
SPECIFIC PHENOTYPE OF PLATELETS GPIB, GPIIB, GPIIIA AND GMP-140 IN<br />
PATIENTS WITH LOW LIMB VARICOSE VEIN DISEASE<br />
Y. B. Sivach<strong>en</strong>ko* (RU), A. V. Kurtova, A. P. Ryzhak, Y. E. Zueva, M. I. Kadinskaya,<br />
M. S. H. Vahitov<br />
CLOPIDOGREL NON-RESPONSIVENESS IN PATIENTS UNDERGOING PERCUTANEOUS<br />
CORONARY INTERVENTION: A META-ANALYSIS<br />
J. D. Snoep* (NL), M. M. C. Hov<strong>en</strong>s, J. C. J. Eik<strong>en</strong>boom, J. G. van der Bom,<br />
J. W. Jukema, M. V. Huisman<br />
LABORATORY-DEFINED ASPIRIN RESISTANCE IS ASSOCIATED WITH A HIGHER RISK<br />
OF RECURRENT CARDIOVASCULAR EVENTS: A META-ANALYSIS<br />
J. D. Snoep* (NL), M. M. C. Hov<strong>en</strong>s, J. C. J. Eik<strong>en</strong>boom, J. G. van der Bom,<br />
M. V. Huisman<br />
EFFICACY OF WHOLE BLOOD PLATELET AGGREGATION IN THE EVALUATION OF<br />
BLEEDING OR THROMBOTIC TENDENCIES<br />
M. D. Spears* (US), A. Y. Kim, J. Yassine, R. Sarode<br />
ASSESSMENT OF PLATELET FUNCTION IN NORMAL ADULTS: RISTOCETIN-INDUCED<br />
PLATELET AGGREGATION (RIPA)<br />
S. F. Stein* (US), A. Rice, K. Lindstrom, C. H. Miller<br />
THE EFFECT OF ADP RECEPTOR ANTAGONISTS AND ASPIRIN ON WHOLE BLOOD<br />
PLATELET AGGREGATION MEASURED BY MULTIPLE ELECTRODE AGGREGOMETRY<br />
O. Toth* (HU), S. P<strong>en</strong>z, A. Calatzis, H. Losonczy, W. Siess<br />
COMPARISON OF IMPEDANCE WHOLE BLOOD AGGREGATION AND OPTICAL<br />
PLATELET-RICH PLASMA AGGREGATION TO MEASURE THE ANTIPLATELET EFFECT<br />
OF ASPIRIN IN HEALTHY CONTROLS AND IN PATIENTS WITH PERIPHERAL ARTERY<br />
DISEASE (PAD)<br />
H. A. Tran* (AU), S. S. Anand, J. S. Ginsberg, J. I. Weitz, M. Johnston,<br />
J. W. Eikelboom<br />
COMPARISON OF A NEW CARTRIDGE* FOR THE PFA-100® WITH OTHER PLATELET<br />
FUNCTION ASSAYS FOR MEASURING THE EFFECT OF CLOPIDOGREL THERAPY IN<br />
CARDIOVASCULAR PATIENTS<br />
J. W. Van Werkum* (NL), J. M. T<strong>en</strong> Berg, A. R. Rechner, J. De Haan, C. M. Hack<strong>en</strong>g<br />
PLATELET RESPONSIVENESS TOWARDS ANTIPLATELET MEDICATIONS BEFORE<br />
AND AFTER CORONARY ANGIOGRAPHY AND PERCUTENOUS CORONARY<br />
INTERVENTIONS AS DETERMINED BY WHOLE BLOOD AGGREGOMETRY<br />
K. W. Von Pape* (DE), A. Calatzis, T. Bonzel, M. Conze, M. Spannagl, H. Weisser<br />
264
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Fibrinolysis and fibrinog<strong>en</strong><br />
Fibrinog<strong>en</strong> and fibrin<br />
P-T-364<br />
P-T-365<br />
P-T-366<br />
P-T-367<br />
RECOMBINANT BBETA-LYS448 IS ASSOCIATED WITH SIGNIFICANT CHANGES IN<br />
FIBRIN STRUCTURE AND CLOT RIGIDITY<br />
R. Ajjan* (UK), K. F. Standev<strong>en</strong>, R. Harrand, F. Pho<strong>en</strong>ix, S. Dolling, P. J. Grant,<br />
R. A. S. Ari<strong>en</strong>s<br />
FIBRIN GEL POROSITY RELATES TO GLYCOSYLATED HAEMOGLOBIN IN PATIENTS<br />
WITH TYPE 1 DIABETES<br />
A. M. Antovic* (SE), N. H. Wall<strong>en</strong>, A. C. Salomonsson, P. E. Lins, U. Adamson,<br />
G. Jörneskog<br />
FIBRIN GEL POROSITY: COMPARISON OF TWO LABORATORY ASSAYS<br />
A. M. Antovic* (SE), G. Jörneskog, A. C. Salomonsson, P. E. Lins, U. Adamson, S. He,<br />
N. H. Wall<strong>en</strong><br />
BLEEDING AND THROMBOTIC MANIFESTATION IN 58 PATIENTS WITH CONGENITAL<br />
DYSFIBRINOGENEMIA<br />
A. Batorova* (SK), D. Horvathova, D. Jankovicova, M. Mistrik, P. de Moerloose,<br />
M. Neerman-Arbez<br />
P-T-369<br />
P-T-370<br />
P-T-371<br />
HAPLOTYPES IN THE PROMOTER REGION OF BETA-FIBRINOGEN GENE AND THEIR<br />
RELATIONSHIP TO ISCHEMIC STROKE IN HAINAN HAN POPULATION IN CHINA<br />
W. Cai* (CN), H. H. X. Xing<br />
COMPLEMENT C3 IS A PLASMA CLOT COMPONENT AND INFLUENCES CLOT LYSIS<br />
A. M. Carter* (UK), R. Somani, J. Howes, A. Shore, K. F. Standev<strong>en</strong>, P. J. Grant<br />
CLINICAL STUDY OF MULTI-LOCUS B-FIBRINOGEN GENE POLYMORPHISMS<br />
W. Fang* (CN)<br />
Tuesday Posters<br />
P-T-372<br />
P-T-373<br />
P-T-374<br />
P-T-375<br />
P-T-376<br />
P-T-377<br />
PRONOUNCED B KNOB CAPACITY TO MODULATE FIBRIN ARCHITECTURE,<br />
STIFFNESS, AND PLASMIN LYSIS<br />
D. K. Galanakis* (US), M. M. Neerman-Arbez, T. Sheiner, D. Hubbs-Taan, C. Nagaswami,<br />
A. H<strong>en</strong>sch<strong>en</strong>, J. Weisel<br />
ANALYSIS OF AFFINITY OF KNOB-HOLE INTERACTIONS RESPONSIBLE FOR FIBRIN<br />
POLYMERIZATION<br />
C. B. Geer (US), A. Tripathy, M. H. Scho<strong>en</strong>fisch, S. T. Lord*, O. Gorkun<br />
A NOVEL DYSFIBRINOGENEMIA DETECTED BY ELECTROPHORESIS IN A PATIENT<br />
PRESENTING WITH FAMILIAL VENOUS THROMBOEMBOLISM<br />
M. L. Hanss* (FR), C. Vergnes, C. Chevreaud, P. Ffr<strong>en</strong>ch, P. De Mazancourt<br />
GENETIC ANALYSIS IN HYPOFIBRINOGENEMIA IN ELEVEN FAMILIES<br />
M. Hill* (UK), J. Hanley, R. Maclean, V. Garipidou, R. Tait, G. Dolan<br />
POTENTIAL ROLE OF RAPID MOLECULAR SCREENING OF PATIENTS WITH<br />
DYSFIBRINOGENEMIA<br />
M. Hill* (UK), S. Krishnamurthy, E. Nicholson, R. Tait, G. Dolan<br />
FIBRINOGEN AND FIBRIN INDUCE SYNTHESIS OF PROINFLAMMATORY CYTOKINES<br />
FROM PERIPHERAL BLOOD MONONUCLEAR CELLS<br />
T. J<strong>en</strong>s<strong>en</strong>* (NO), P. Kierulf, P. M. Sandset, O. Kling<strong>en</strong>berg, G. B. Joø, H. C. Godal,<br />
O. H. Skjønsberg<br />
265
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-378<br />
P-T-379<br />
P-T-380<br />
P-T-381<br />
P-T-382<br />
REPLACEMENT THERAPY WITH FIBRINOGEN CONCENTRATE: INDICATIONS AND<br />
ADEQUACY OF USE<br />
C. M. Lambert* (BE), C. R. Hermans<br />
EFFECTS OF FIBRINOGEN LEVELS AND CLOT STRENGTH IN THE PRESENCE OF<br />
THROMBOCYTOPENIA<br />
T. H. Lang* (DE), D. Scheinich<strong>en</strong>, H. Metzler, S. Piep<strong>en</strong>brock, A. Bornscheuer<br />
EFFECT OF FIBRIN MATRICES ON INCREASED PROLIFERATION AND SPREADING OF<br />
EARLY TERM TROPHOBLASTS AND PLACENTAL VILLI. MODULATION OF<br />
COAGULATION AND ANGIOGENESIS FUNCTIONS<br />
N. Lanir* (IL), B. Br<strong>en</strong>ner, B. Paz, O. Gon<strong>en</strong>, A. Snir<br />
PLATELET FACTOR 4 (PF4/CXCL4) SEALS BLOOD CLOTS BY ALTERING THE<br />
STRUCTURE OF FIBRIN<br />
B. F. Le Bonniec* (FR), A. A. Amelot, M. Tagzirt, G. Ducouret, R. Lai Ku<strong>en</strong><br />
DIRECT EVIDENCE OF SPECIFIC INTERACTIONS OF FIBRINOGEN ALPHA C REGIONS<br />
WITH THE CENTRAL E REGION AND WITH EACH OTHER<br />
R. I. Litvinov* (US), G. Tsurupa, S. Yakovlev, L. Medved, J. W. Weisel<br />
Plasminog<strong>en</strong> activators<br />
P-T-383<br />
P-T-384<br />
P-T-385<br />
P-T-386<br />
P-T-387<br />
P-T-388<br />
P-T-389<br />
P-T-390<br />
INHIBITION OF PLASMINOGEN/PLASMINOGEN ACTIVATOR SYSTEM BY<br />
ANGIOSTATIN-LIKE PLASMINOGEN FRAGMENTS IS INVOLVED IN MECHANISM OF<br />
ANTIANGIOGENESIS<br />
R. B. Aisina* (RU), L. I. Mukhametova, D. A. Gulin, S. S. Larin, K. B. Gershkovich,<br />
M. Y. Levashov, S. D. Varfolomeyev<br />
CARDIAC TPA RELEASE DURING SYMPATHETIC NERVE STIMULATION IN PIGS<br />
DECREASES BY REPEATED STIMULATIONS<br />
T. Aspelin* (NO), M. Eriks<strong>en</strong>, J. A. Björkman, T. Lyberg, A. Ilebekk<br />
ENHANCEMENT OF SINGLE-CHAIN UROKINASE ACTIVITY BY PLATELET PROTEINS<br />
K. M. Baet<strong>en</strong>* (UK), N. A. Booth<br />
THROMBOSIS IN PRETERM INFANTS: A REPORT OF FIVE CASES TREATED WITH<br />
HIGH DOSE OF TISSUE PLASMINOGEN ACTIVATOR (R-TPA)<br />
J. D. A. Carneiro* (BR), E. A. D'Amico, L. A. Matsumoto, M. P. Garanito, M. V. Santos,<br />
R. R. Machado, D. A. F. Chamone<br />
THE DYNAMICS OF THE BINDING OF PLASMINOGEN AND TPA TO IMMOBILIZED HIGH<br />
MOLECULAR WEIGHT FIBRIN DEGRADATION PRODUCTS<br />
P. Cook* (CA), M. E. Nesheim, K. A. Munro<br />
EVALUATION OF THROMBOLYTIC THERAPY WITH TISSUE-TYPE PLASMINOGEN<br />
ACTIVATOR (T-PA) FOR PROSTHETIC VALVE THROMBOSIS IN CHILDREN: A SINGLE<br />
INSTITUTION EXPERIENCE<br />
A. V. Damme* (CA), S. Williams, C. A. Caldarone, A. K. Chan, L. R. Brandao<br />
DEFIBROTIDE DIRECTLY ENHANCE THE ACTIVITY OF PLASMIN<br />
C. Echart* (IT), C. Repice, L. Ferro, M. Iacobelli<br />
EFFECTS OF 7 KDA STREPTOKINASE FRAGMENT ON THE RABBIT HAEMOSTASIS<br />
SYSTEM<br />
S. P. Gavrylyuk* (UA), M. E. Kucher<strong>en</strong>ko, O. M. Savchuk<br />
266
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-391<br />
P-T-392<br />
P-T-393<br />
P-T-394<br />
P-T-395<br />
P-T-396<br />
BETA-ADRENERGIC RECEPTORS MODULATION OF T-PA RELEASE VIA NO<br />
SYNTHASE-DEPENDENT PATHWAY IN NORMOTENSIVE SUBJECTS AND<br />
HYPERTENSIVE PATIENTS<br />
C. Giannarelli* (IT), A. Virdis, F. De Negri, L. Ghiadoni, A. Magagna, A. Salvetti, S. Taddei<br />
EPINEPHRINE INDUCES LOCAL T-PA RELEASE VIA A NITRIC OXIDE-DEPENDENT<br />
PATHWAY IN HUMAN FOREARM<br />
C. Giannarelli* (IT), A. Virdis, F. De Negri, L. Ghiadoni, A. Magagna, A. Salvetti, S. Taddei<br />
NEW VASOPRESSIN ANALOG REMESTYPE INCREASES PLASMINOGEN ACTIVATOR<br />
IN RAT BLOOD<br />
M. E. Grigorjeva* (RU), M. G. Golubeva<br />
INFLUENCE OF THE STREPTOKINASE 36 KDA FRAGMENT ON THE PLASMIN<br />
ACTIVITY<br />
T. V. Grin<strong>en</strong>ko* (UA), G. L. Volkov, E. I. Yusova<br />
ISOLATION AND CHARACTERIZATION OF PLASMINOGEN-ACTIVATING PROTEINASE<br />
FROM AGKISTRODON HALYS HALYS VENOM<br />
V. L. Karbovskyy* (UA), A. N. Savchuk<br />
ISOLATION AND CHARACTERIZATION OF PLASMINOGEN-ACTIVATING PROTEINASE<br />
FROM AGKISTRODON HALYS HALYS VENOM<br />
V. L. Karbovskyy* (UA), A. N. Savchuk<br />
P-T-397<br />
Vascular biology<br />
Tissue remodelling<br />
THE NOVEL PROTEIN-PROTEIN INTERACTION IN MAMMALIAN HAEMOSTASIS<br />
SYSTEM INDUCING BY STREPTOKINASE<br />
I. M. Krasnobryzha* (UA), O. M. Savchuk, T. M. Platonova<br />
Tuesday Posters<br />
P-T-398<br />
P-T-399<br />
P-T-400<br />
P-T-401<br />
P-T-402<br />
NEOINTIMAL CELLS IN WIRE-INJURED ARTERIES HAVE A MIXED ENDOTHELIAL<br />
CELL (EC) / VASCULAR SMOOTH MUSCLE CELL (VSMC) PHENOTYPE WHICH IS<br />
THROMBIN-DEPENDENT<br />
D. Ch<strong>en</strong>* (UK), J. M. Abrahams, R. I. Lechler, J. H. McVey, A. Dorling<br />
GENETIC ABLATION OF JAM-A IMPAIRS SURVIVAL AFTER MYOCARDIAL INFARCT<br />
V. G. Cooke* (US), E. Gao, T. Tsuda, U. P. Naik<br />
EFFECT OF SCLEROSANTS ON ANTITHROMBOTIC MECHANISMS, ENDOTHELIAL<br />
CELLS AND FIBRINOLYSIS<br />
T. Exner* (AU), K. Parsi, A. Herbert, D. D. F. Ma<br />
ROLE OF TISSUE REMODELLING IN HYPERTROPHIC MYOCARDIOPATHY<br />
V. Roldan* (ES), F. Marin, J. Gim<strong>en</strong>o, F. Ruiz-Espejo, R. Gonzalez-Conejero,<br />
A. Garcia-Honrubia, V. Vic<strong>en</strong>te<br />
TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE 1 (TIMP-1) PREDICTS<br />
RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY IN END STAGE SYSTOLIC<br />
HEART FAILURE<br />
V. Roldan* (ES), F. Marin, J. Martinez, A. Hernandez, A. Ibañez, M. Ortego, J. Navarro,<br />
C. Moro, V. Vic<strong>en</strong>te<br />
267
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Statins<br />
P-T-403<br />
P-T-404<br />
P-T-405<br />
P-T-406<br />
P-T-407<br />
P-T-408<br />
P-T-409<br />
P-T-410<br />
ACUTE EFFECT OF STATINS ON THE REGULATION AND EXPRESSION OF<br />
CANDIDATE GENES (CD36, MMP-9 AND IL-8) IN ATHEROSCLEROSIS IN HIV-INFECTED<br />
PATIENTS<br />
F. De Lor<strong>en</strong>zo* (UK), J. Martin, M. Boffito, J. McGregor<br />
IMPROVEMENT OF THIOLACTONASE ACTIVITY OF PARAOXONASE 1 BY<br />
SIMVASTATIN IN PATIENTS WITH CORONARY ARTERY DISEASE<br />
T. B. Domagala* (PL), P. Grzanka, K. Kotula-Horowitz, A. Szczeklik<br />
FLUVASTATIN INHIBITS REGULATED SECRETION OF ENDOTHELIAL CELL VON<br />
WILLEBRAND FACTOR IN RESPONSE TO DIVERSE SECRETAGOGUES<br />
R. J. Fish* (CH), H. Yang, C. Viglino, R. Schorer, S. Dunoyer-Geindre, E. K. O. Kruithof<br />
EFFECT OF ATORVASTATIN ON MARKERS OF INFLAMMATION AND PLATELET<br />
AGGREGATION IN PATIENTS WITH CHRONIC HEART FAILURE<br />
O. Korzh* (UA), G. Kotchuev, S. Krasnokutskiy<br />
NO EFFECT OF LIPID LOWERING BY SIMVASTATIN OR SIMVASTATIN AND EZETIMIBE<br />
ON PLATELET FUNCTION IN PATIENTS WITH TYPE 2 DIABETES OR IMPAIRED<br />
GLUCOSE TOLERANCE AND CORONARY ARTERY DISEASE<br />
R. E. Malmström* (SE), M. Settergr<strong>en</strong>, F. Böhm, L. Rydén, J. Pernow, P. Hjemdahl<br />
ATORVASTATIN NEUTRALIZED THE UP-REGULATION OF THROMBOSPONDIN<br />
INDUCED BY THROMBIN IN ENDOTHELIAL CELLS<br />
V. Martínez-Sales* (ES), V. Vila, M. Ferrando, E. Reganon<br />
INFLUENCE OF LECTIN-LIKE OX-LDL RECEPTOR-1 (LOX-1) AND NITRIC OXIDE<br />
SINTHASE (NOS) POLYMORPHISMS IN ATORVASTATIN ANTITHROMBOTIC ACTION<br />
AND CARDIOVASCULAR EVENTS RATE<br />
L. Puccetti (IT), R. Brandini*, F. Bruni, A. Pasqui, M. Pastorelli, F. Ciani, A. Auteri,<br />
A. Ghezzi<br />
ASSOCIATION BETWEEN ASPIRIN RESISTANCE AND INCREASED THROMBIN<br />
GENERATION AT THE SITE OF MICROVASCULAR INJURY: THE EFFECT OF<br />
SIMVASTATIN<br />
A. Undas* (PL), Z. Siudak, K. Brummel-Ziedins, W. Tracz, E. Stepi<strong>en</strong>, A. Szczeklik,<br />
K. Mann<br />
Extracellular matrix<br />
P-T-411<br />
P-T-412<br />
P-T-413<br />
268<br />
FACTOR VII ACTIVATING PROTEASE INHIBITS THE UROKINASE PLASMINOGEN<br />
ACTIVATION SYSTEM AND STIMULATES GELATINASES (MATRIX<br />
METALLOPROTEINASES-2 AND -9) IN VASCULAR SMOOTH MUSCLE AND<br />
ENDOTHELIAL CELLS<br />
S. M. Kanse* (DE), O. Uslu, K. Hersemeyer, L. Muhl, J. Daniel, K. T. Preissner,<br />
D. Sedding<br />
PRETERM BIRTH AND FETAL GROWTH RESTRICTION HAVE AN IMPACT ON ELASTIC<br />
AND COLLAGENIC STRUCTURES OF HUMAN UMBILICAL ARTERIES<br />
E. Lamy (FR), L. Tauzin, F. Risso, C. Chareyre, P. Charpiot, U. Simeoni, F. Dignat-George*<br />
MUTATION SCREENING ANALYSIS OF TGFBR1 GENE IN PATIENTS WITH MARFAN<br />
SYNDROME<br />
L. Lucarini* (IT), L. Evangelisti, M. Attanasio, C. Fatini, E. Sticchi, E. Romano, A. Cellai,<br />
G. Pepe, R. Abbate, G. G<strong>en</strong>sini
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-414<br />
P-T-415<br />
P-T-416<br />
STUDY OF THE STRUCTURAL DETERMINANTS OF ARTERIAL VESSEL WALL<br />
THROMBOGENICITY<br />
N. Wohner* (HU), E. Komorowicz, K. Kolev<br />
TGFBETA1 IS RESPONSIBLE FOR HIGH-GLUCOSE-INDUCED ENRICHMENT OF<br />
PERICELLULAR MATRIX WITH HYALURONIC ACID. DIFFERENT MECHANISMS FOR<br />
ENDOTHELIAL AND MESANGIAL CELLS<br />
N. Yevdokimova* (UA), S. Komisar<strong>en</strong>ko<br />
FUNCTIONAL STRUCTURE OF THE SOMATOMEDIN B DOMAIN OF VITRONECTIN<br />
A. Zhou* (UK)<br />
Adhesion receptors<br />
P-T-417 EVIDENCE FOR AN ALTERNATIVE REGULATION OF THE ACTIVITY OF THE BETA 3<br />
INTEGRIN ALPHA v BETA 3 IN THE ABSENCE OF THE HIGHLY CONSERVED ALPHA-<br />
SUBUNIT GFFKR MOTIF<br />
I. Ahr<strong>en</strong>s* (DE), J. Heesk<strong>en</strong>s, N. Bassler, I. Neudorfer, C. Bode, K. Peter<br />
P-T-418<br />
INTERACTION AND FUNCTIONAL ASSOCIATION OF PROTEIN-DISULFIDE ISOMERASE<br />
WITH αVβ3 INTEGRIN ON ENDOTHELIAL CELLS<br />
C. S. Cierniewski* (PL), J. Szymanski, M. Swiatkowska, G. Padula<br />
P-T-419<br />
P-T-420<br />
P-T-421<br />
CONSTITUTIVELY ACTIVE OR INACTIVE I DOMAINS AS PROBES FOR INTEGRIN<br />
BINDING TO COLLAGEN<br />
R. W. Farndale (UK), S. W. Hamaia*, N. Allcott, A. R. Peachey, R. Fernandez, N. Raynal<br />
FACTOR VII ACTIVATING PROTEASE (FSAP) REGULATES CELL ADHESION AND<br />
MOTILITY BY MULTIPLE MECHANISMS<br />
S. M. Kanse* (DE), M. Soto-Ribeiro, K. T. Preissner, B. Wehrle-Haller<br />
DETERMINATION OF THE INTEGRIN BINDING PROPERTIES OF THE PUTATIVE<br />
INTEGRIN-BINDING MOTIFS OF ADAM PROTEINS USING MUTANTS BASED UPON A<br />
DENDROASPIN SCAFFOLD<br />
X. Lu* (UK), M. Xia, D. Lu, M. Scully, V. Kakkar<br />
Tuesday Posters<br />
P-T-422<br />
P-T-423<br />
P-T-424<br />
P-T-425<br />
SELECTIVE BINDING TO INTEGRIN ALPHA-9-INTEGRIN EXPRESSING CELLS OF<br />
MUTANTS OF DISINTEGRIN-LIKE DOMAIN OF ADAM-15 CONTAINING THE PUTATIVE<br />
INTEGRIN BINDING MOTIF OF ADAM-2, -12 AND -19, RESPECTIVELY<br />
D. Lu* (UK), M. Xia, M. Scully, X. Lu, V. Kakkar<br />
THE ROLES OF TUMOR NECROSIS FACTOR- AND CELL ADHESION MOLECULES IN<br />
PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND HEART FAILURE<br />
T. Ma* (TW), G. Jong<br />
CIRCULATING ANTIBODIES TO HEAT SHOCK PROTEINS AND THEIR ASSOCIATION<br />
WITH ATHEROTHROMBOTIC PHENOTYPES<br />
V. S. Rao* (IN), R. S. Pratima, B. K. Natesha, J. Shanker, S. Kanjilal, M. Mukherjee,<br />
V. V. Kakkar<br />
LIGAND-RECEPTOR AFFINITY AND RHO-FAMILIY GTPASES IN INTEGRIN<br />
ALPHA2BETA1-MEDIATED PROCESSES<br />
C. Smerling* (UK), R. W. Farndale<br />
P-T-426<br />
MURINE GPVI ANTIBODY DOES NOT INDUCE GPVI-DEPLETION BUT REDUCES IN<br />
VIVO THROMBOSIS WITH MINIMAL BLEEDING RISK IN RATS<br />
N. N. Tandon (US), S. Lockyer*, H. Li, A. Concepcion, X. Gong, Y. Matsumoto,<br />
H. Takizawa, J. Kambayashi, Y. Liu<br />
269
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Thrombotic disorders and antithrombotic therapy<br />
Antiphospholipid antibodies and syndrome<br />
P-T-427<br />
P-T-428<br />
P-T-429<br />
P-T-430<br />
P-T-431<br />
P-T-432<br />
P-T-433<br />
P-T-434<br />
P-T-435<br />
P-T-436<br />
P-T-437<br />
EFFECTS OF A TOLL-LIKE RECEPTOR ANTAGONIST AND ANTI-ANNEXIN A2<br />
ANTIBODIES ON BINDING AND ACTIVATION OF DECIDUAL CELLS BY ANTI--<br />
BETA2GLYCOPROTEIN I ANTIBODIES<br />
M. Borghi* (IT), E. Raschi, S. Scurati, C. Grossi, P. Ch<strong>en</strong>, S. S. Pierangeli, P. Meroni<br />
ROLE OF P38 MITOGEN ACTIVATED PROTEIN KINASE IN ANTIPHOSPHOLIPID<br />
ANTIBODY-MEDIATED THROMBOSIS AND ENDOTHELIAL CELL ACTIVATION<br />
M. Vega-Ostertag* (US), Z. Romay-P<strong>en</strong>abad, D. Ferrara, M. Cold<strong>en</strong>-Stanfield, X. Lui,<br />
S. S. Pierangeli<br />
PLATELET ACTIVATION REINFORCES THE PROCOAGULANT PHENOTYPE INDUCED<br />
BY MURINE MONOCLONAL ANTI-PHOSPHOLIPID ANTIBODIES<br />
A. Membre* (FR), D. Wahl, J. P. Max, P. Lacolley, T. Lecompte, V. Regnault<br />
LONG-TERM OBSERVATION OF 280 PATIENTS WITH SYSTEMIC LUPUS<br />
ERYTHEMATOSUS AND 74 PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID<br />
SYNDROME: 10-YEAR FOLLOW-UP<br />
T. M. Reshetnyak* (RU), E. N. Alexandrova, I. B. Stivelband, A. A. Novikov,<br />
E. L. Nasonov<br />
ELEVATED PLASMA LEVELS OF FACTOR VIIA-ANTITHROMBIN COMPLEXES IN<br />
PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES<br />
R. A. S. Roubey* (US), T. Lovell, J. H. Morrissey<br />
THE MANAGEMENT OF HIGH RISK PREGNANT PATIENTS WITH PRIMARY<br />
ANTIPHOSPHOLIPID SYNDROME<br />
A. Ruffatti* (IT), G. De Silvestro, P. Marson, V. P<strong>en</strong>go, M. Bortolati, M. Favaro, M. Tonello,<br />
D. Minucci<br />
THROMBOPATH KIT HAS INCREASED SENSITIVITY TO PROTHROMBOTIC LUPUS<br />
ANTICOAGULANTS<br />
M. Smirnov* (US), D. Diaz, M. Triscott, R. Marlar<br />
ENDOTHELIAL FUNCTION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND<br />
HISTORY OF VENOUS THROMBOSIS<br />
M. Stalc* (SI), P. Poredos, P. Peternel, M. Tomsic, T. Kveder<br />
ASSOCIATION OF IGG ANTI-OXLDL/B2GPI AND B2GPI-DEPENDENT ANTI-<br />
CARDIOLIPIN (ACL) ANTIBODIES WITH VASCULAR THROMBOSIS IN PATIENTS WITH<br />
ANTIPHOSPHOLIPID SYNDROME (APS)<br />
G. Svanas* (US), M. Bois<strong>en</strong>, D. Oottamasathein, E. Matsuura, L. R. Lopez<br />
THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) DIAGNOSED<br />
USING UPDATED CLASSIFICATION CRITERIA<br />
J. Swadzba* (PL), J. Musial, T. Iwaniec, A. Szczeklik<br />
ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN<br />
PATIENTS WITH SYSTEMIC LUPUS ÉRYTHÉMATOSUS<br />
K. Taouli* (DZ), R. A. Reghis, S. J. F. Schved, B. O. Boudgh<strong>en</strong>e Stambouli,<br />
S. R. Hamidou<br />
270
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-438<br />
P-T-439<br />
P-T-440<br />
P-T-441<br />
P-T-442<br />
ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS): THE ANNEXIN V COMPETITION<br />
ASSAY AS A DIAGNOSTIC TOOL<br />
A. Tomer* (IL)<br />
THE CLINICAL RELEVANCE OF PLATELET HETEROGENEITY AND ACTIVATION IN<br />
PATIENT WITH ANTIPHOSPHOLIPID SYNDROME<br />
I. Vasil<strong>en</strong>ko* (RU), A. Savushkin, T. Reshetnyak, I. Bichkova, I. Nester<strong>en</strong>ko, A. Zaguzin<br />
EFFECTS OF ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES FROM APL PATIENTS WITH<br />
APS OR WITH LEPROSY IN AN IN VIVO MODEL OF APS<br />
M. E. Vega-Ostertag* (AR), R. R. Forastiero, M. Martinuzzo, G. De Larrañaga,<br />
S. S. Pierangeli<br />
SIGNIFICANCE OF PLASMA SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR AND<br />
TISSUE FACTOR PATHWAY INHIBITOR IN PATIENTS WITH ANTIPHOSPHOLIPID<br />
ANTIBODIES<br />
D. G. Wahl* (FR), C. Perret-Guillaume, P. Kaminsky, P. Lacolley, V. Regnault,<br />
T. Lecompte<br />
ANTI CD20 MONOCLONAL ANTIBODIES THERAPY FOR RESISTANT<br />
ANTIPHOSPHOLIPID SYNDROME<br />
A. Winder* (IL), A. Arad, E. Rachmilewitz<br />
P-T-443<br />
P-T-444<br />
CLINICAL SIGNIFICANCE OF PLATELET-DERIVED MICROPARTICLE (PDMP) IN APS:<br />
PLASMA LEVELS OF PDMP WERE SIGNIFICANTLY ELEVATED IN APS PATIENTS WITH<br />
ARTERIAL THROMBOSES<br />
M. Yamazaki* (JP), Y. Kadohira, M. Maekawa, Y. Ontachi, H. Asakura, E. Morishira,<br />
S. Nakao<br />
ANTIPHOSPHOLIPID ANTIBODIES ASSOCIATED WITH MULTIPLE COAGULATION<br />
FACTOR DEFICIENCY IN SEVEN CHINESE PATIENTS<br />
F. Yang* (CN), X. Wang, P. Jin, Q. Ding, H. Wang<br />
Thrombophilia and familial thrombosis<br />
Tuesday Posters<br />
P-T-445<br />
P-T-446<br />
P-T-447<br />
P-T-448<br />
P-T-449<br />
ONE-THIRD OF JAPANESE PATIENTS WITH DEEP VEIN THROMBOSIS CARRIED THE<br />
GENETIC MUTATIONS IN PROTEINS S, C AND ANTITHROMBIN GENES:<br />
THE SUB-GROUP STUDY OF BLOOD COAGULATION ABNORMALITY, THE STUDY<br />
GROUP OF RESEARCH ON MEASURES FOR INTRACTABLE DISEASES IN JAPAN<br />
J. Ishikawa (JP), Y. Sato, S. Takeshita, K. Kokame, R. Kimura, S. Honda, T. Kawasaki,<br />
E. Suehisa, H. Tsuji, S. Madoiwa, Y. Sakata, T. Kojima, M. Murata, Y. Ikeda, T. Miyata*<br />
GIESSEN THROMBOPHILIA STUDY: MANIFESTATION AGE OF THROMBOEMBOLISM<br />
IN THROMBOPHILIA<br />
B. Kemkes-Matthes* (DE), M. Nees, R. Fischer<br />
PERINATAL ISCHEMIC STROKE AND THE INCIDENCE OF MATERNAL AND NEONATAL<br />
THROMBOPHILIA<br />
G. K<strong>en</strong>et (IL), M. J. Simch<strong>en</strong>*, G. Goldstein, A. Lubetsky, I. Tamarin, M. Dulitzki, E. Schiff<br />
INFLUENCE OF THROMBOPHILIA ON VASCULAR ACCESS SURVIVAL IN CHRONIC<br />
HEMODIALYSIS PATIENTS<br />
M. Orlovic* (DE), I. Fritsche, H. Landgraf, F. Seibt, H. Pommer, R. Klamroth<br />
THE USE OF HAEMOSTASIS TESTS IN THE FOLOW UP OF A PATIENT WITH<br />
ANTITHROMBIN DEFICIENCY DURING THE PREGNANCY AND AFTER DELIVERY<br />
M. Kovac* (RS), D. Mikovic, L. Rakic, A. Maslac, Z. Mikovic, V. Mandic<br />
271
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-450<br />
P-T-451<br />
P-T-452<br />
P-T-453<br />
P-T-454<br />
P-T-455<br />
P-T-456<br />
P-T-457<br />
P-T-458<br />
P-T-459<br />
P-T-460<br />
P-T-461<br />
P-T-462<br />
P-T-463<br />
ROLE OF THROMBOPHILIC RISK FACTORS IN PATIENTS WITH RETINAL VEIN<br />
OCCLUSION<br />
V. Krcova* (CZ), L. Slavik, M. Rehak, S. Faude, S. Faude, P. Wiedemann, E. Fric,<br />
J. Rehak, A. Siegemund<br />
STICKY PLATELET SYNDROME (SPS) AND PLATELET GLYCOPROTEIN<br />
POLYMORPHISMS<br />
P. Kubisz (SK), J. Musial, J. Stasko*, J. Ivankova, M. Dobrotova, I. Plam<strong>en</strong>ova,<br />
L. Bartosova, P. Chudy<br />
DNR ANALYSIS RESULTS IN THROMBOSES PATIENTS: THE FIRST DATA IN LATVIA<br />
S. Lejniece* (LV), A. Lejnieks, J. Steinbergs, I. Vasiljeva, V. Boka, I. Udre<br />
ARE PATIENTS WITH THROMBOPHILIA AND A HISTORY OF VENOUS<br />
THROMBOEMBOLISM AT HIGHER RISK TO ARTERIAL THROMBOTIC EVENTS?<br />
B. Linnemann* (DE), M. Schindewolf, D. Zgouras, M. Erbe, M. Jarosch-Preusche,<br />
B. Luxembourg, E. Lindhoff-Last<br />
COINHERITANCE OF FV-LEIDEN MUTATION AND FV-HR2<br />
P. E. Makris* (GR), M. P. Makris, S. I. Papamichos, A. Kanidis<br />
EVALUATION OF PRO-TIME MICROCOAGULLATION SUSTEM<br />
P. E. Makris* (GR), S. I. Papamichos, M. P. Makris<br />
MOLECULAR MARKERS OF BLOOD HYPERCOAGULABILITY IN HETEROZYGOUS<br />
CARRIERS OF FACTOR V LEIDEN MUTATION<br />
P. S. Miljic* (RS), I. Elezovic, V. Djordjevic, M. Colovic<br />
COMMON THROMBOPHILIAS IN 85 INDIAN PATIENTS WITH ARTERIAL THROMBOSIS<br />
M. N. Mishra* (IN), R. Kalra, S. Rohatgi<br />
A LARGE DELETION OF THE PROS1 GENE IN A DEEP VEIN THROMBOSIS PATIENT<br />
WITH PROTEIN S DEFICIENCY<br />
T. Yin (JP), S. Takeshita, Y. Sato, T. Sakata, Y. Shin, S. Honda, T. Kawasaki, H. Tsuji,<br />
T. Kojima, S. Madoiwa, Y. Sakata, M. Murata, Y. Ikeda, T. Miyata*<br />
HEPARIN EYE DROPS ARE EFFECTIVE AS LONG TERM THERAPY FOR LIGNEOUS<br />
CONJUNCTIVITIS<br />
P. Monagle* (AU), J. Elder, D. McConville, S. Mitchell<br />
INTRACELLULAR DEGRADATION OF NATURALLY OCCURRING PROTEIN C (PC)<br />
MUTANTS<br />
M. Nishio* (JP), T. Koyama, M. Nakahara, N. Egawa, S. Hirosawa<br />
D-DIMER MEASUREMENT AND THROMBOPHILIA SCREENING IN THE FOLLOW-UP OF<br />
PATIENTS WITH A HISTORY OF VENOUS THROMBOEMBOLISM<br />
E. Ombandza (FR), M. Samama*, J. Conard, M. Horellou, I. Elalamy<br />
CLINICAL, GENETIC, FUNCTIONAL AND CONFORMATIONAL HETEROGENEITY OF<br />
CONGENITAL ANTITHROMBIN DEFICIENCY. RESULTS FROM 27 UNRELATED CASES<br />
A. Ordóñez* (ES), I. Sánchez, A. Miñano, R. González-Conejero, D. Hernández-Espinosa,<br />
J. Aznar, I. Alberca, N. Gómez, F. López, C. De Cos, H. Cano, M. Navarro,<br />
J. Gutierrez-Pim<strong>en</strong>tel, P. Marcos, D. García-Malo, P. Llamas, D. Marín, R. Lecumberri,<br />
J. J. Sánchez-Blanco, I. Zuazu, V. Vic<strong>en</strong>te, J. Corral<br />
NO INCREASED SIGNS OF ATHEROSCLEROTIC ALTERATIONS IN CARRIERS OF<br />
INHERITED THROMBOPHILIA WITH OR WITHOUT PREVIOUS VENOUS THROMBOSIS<br />
G. Palareti (IT), L. Valdre*, E. Favaretto, V. Bovina, C. Legnani<br />
272
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-464<br />
PREVALENCE OF FACTOR V LEIDEN, PROTHROMBIN G20210A, AND<br />
5,10-METHYLENETETRAHYDROFOLATE REDUCTASE C677T GENE MUTATIONS IN<br />
A HEALTHY RUSSIAN POPULATION<br />
E. A. Kalashnikova (RU), S. N. Kokarovtseva, O. V. Sirotkina, A. M. Sheydina,<br />
T. F. Koval<strong>en</strong>ko, L. I. Patrushev*<br />
G<strong>en</strong>etic determinants and epidemiology<br />
P-T-465<br />
P-T-466<br />
P-T-467<br />
THE ABCB1 (MDR1) C3435T POLYMORPHISM DOES NOT INFLUENCE<br />
PHARMACODYNAMIC RESPONSE TO CLOPIDOGREL IN HEALTHY SUBJECTS<br />
J. S. Hulot* (FR), E. Villard, M. Azizi, C. Vrignaud, V. Remones, M. Aiach, P. Lechat,<br />
P. Gaussem<br />
THE OCCURRENCE OF FACTOR V LEIDEN MUTATION IN HUNGARIAN HELLP<br />
SYNDROME PATIENTS<br />
P. Hupuczi* (HU), B. Nagy, G. Szabo, E. Berkes, B. Rigo, I. Sziller, Z. Papp<br />
ASSOCIATION OF C-REACTIVE PROTEIN AND WHITE BLOOD CELL COUNT WITH<br />
PHYSICAL ACTIVITY IN HEALTHY SUBJECTS<br />
F. Zito* (IT), E. Plescia, S. Costanzo, A. Di Castelnuovo, A. Arcari, F. C<strong>en</strong>tritto, A. De<br />
Curtis, R. Di Giuseppe, I. Di Stefano, S. Magnacca, A. Pampuch, L. Rago, C. Silvestri,<br />
B. Vohnout, M. B. Donati, G. De Gaetano, L. Iacoviello, F. De Lucia, M. Persichillo<br />
P-T-468<br />
P-T-469<br />
ASSOCIATION OF C-REACTIVE PROTEIN AND ALCOHOL INTAKE IN HEALTHY MEN<br />
AND WOMEN FROM THE MOLI-SANI POPULATION<br />
A. Arcari* (IT), A. Di Castelnuovo, S. Costanzo, F. C<strong>en</strong>tritto, A. De Curtis, R. Di Giuseppe,<br />
S. Magnacca, I. Di Stefano, A. Pampuck, E. Plescia, L. Rago, C. Silvestri, B. Vohnout,<br />
F. Zito, M. B. Donati, G. De Gaetano, L. Iacoviello, F. De Lucia, M. Persichillo<br />
INTERLEUKINS GENES TAG-SNP HAPLOTYPES AND RISK OF MYOCARDIAL<br />
INFARCTION: A POPULATION BASED CASE-CONTROL STUDY<br />
L. Iacoviello* (IT), B. Tayo, A. Di Castelnuovo, G. Quaquaruccio, Y. Liang, J. Dorn,<br />
N. Novak, M. B. Donati, M. Trevisan<br />
Tuesday Posters<br />
P-T-470<br />
P-T-471<br />
P-T-472<br />
P-T-474<br />
P-T-475<br />
VENOUS THROMBOSIS IN UNUSUAL SITES: A SINGLE INSTITUTION EXPERIENCE<br />
P. Iannaccaro* (IT), R. Santoro, G. Muleo<br />
APOE GENE POLYMORPHISM CAN MODIFY THE RISK OF VENOUS<br />
THROMBOEMBOLISM<br />
S. I. Kapustin* (RU), Y. S. Drizhun, V. M. Shmeleva, N. B. Saltykova, L. P. Papayan,<br />
M. N. Blinov<br />
GENETIC POLYMORPHISM OF THE PLATELET ADP-RECEPTOR P2Y12 MODIFIES THE<br />
RISK OF PULMONARY EMBOLISM IN PATIENTS WITH DEEP-VEIN THROMBOSIS<br />
S. I. Kapustin* (RU), N. A. Kl<strong>en</strong>kova, V. A. Kobilyanskaya, N. B. Saltykova, V. D. Kargin,<br />
L. P. Papayan, M. N. Blinov<br />
THE ROLE OF DNA POLYMORPHISMS IN GENES CODING THE HOMOCYSTEINE AND<br />
FOLATE METABOLIZING ENZYMES IN ISCHAEMIC HEART DISEASE<br />
N. A. Kl<strong>en</strong>kova* (RU), S. I. Kapustin, O. A. Smirnova, V. M. Shmeleva, L. P. Papayan,<br />
M. N. Blinov<br />
POLYMORPHISMS IN THE IL6 GENE IN FAMILIES WITH EARLY-ONSET CORONARY<br />
ARTERY DISEASE (CAD) -INDIAN ATHEROSCLEROSIS RESEARCH STUDY<br />
A. Maitra* (IN), P. Ganapathy, D. Debabratha, V. S. Rao, B. K. Natesha, M. Mukherjee,<br />
V. V. Kakkar<br />
273
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-476<br />
P-T-477<br />
P-T-478<br />
P-T-479<br />
P-T-480<br />
P-T-481<br />
P-T-482<br />
P-T-483<br />
P-T-484<br />
P-T-485<br />
P-T-486<br />
COAGULATION FACTOR XI LEVELS AND THE LDL RECEPTOR-RELATED PROTEIN<br />
(LRP) GENOTYPE<br />
G. Marchetti* (IT), B. Lunghi, C. Legnani, M. Cini, M. Pinotti, G. Palareti, F. Bernardi<br />
COMMON GENE MUTATIONS AND VENOUS THROMBOEMBOLISM: DISTINCT ROLES<br />
IN DIFFERENT CLINICAL SETTINGS<br />
M. Margaglione* (IT), D. Colaizzo, P. Vergura, M. A. Guardascione, F. Cappucci,<br />
G. L. Tiscia, L. Iannaccone, E. Grandone, N. Cocomazzi, L. Amitrano<br />
THE RELATIVE EFFECTS OF VKORC1 AND CYP2C9 VARIANTS ON CLINICAL<br />
OUTCOMES IN WARFARIN PATIENTS<br />
L. M. Meckley* (US), A. K. Wittkowsky, M. J. Rieder, A. E. Rettie, D. L. Ve<strong>en</strong>stra<br />
PLASMA LEVELS OF CLOTTING FACTORS ARE POSITIVELY CORRELATED IN<br />
HEALTHY POPULATION: A COMPREHENSIVE PERSPECTIVE TO ASSESS<br />
THROMBOTIC RISK?<br />
D. Mezzano* (CL), O. Panes, V. Matus, B. Muñoz, M. Goycoolea, J. Pereira, T. Quiroga<br />
P2RY12 RECEPTOR POLYMORPHISMS (SNPS) IN PATIENTS WITH A HISTORY OF<br />
MYOCARDIAL INFARCTION<br />
G. Murugesan* (US), L. Zhang, S. Jang, T. Kaldus, J. Barnard, Q. Wang, P. Gaussem,<br />
E. J. Topol, K. Kottke-Marchant<br />
STUDY OF THE METHYLENETETRAHYDROFOLATE REDUCTASE C677T<br />
POLYMORPHISM IN HELLP SYNDROME PATIENTS<br />
B. Nagy* (HU), P. Hupuczi, B. Rigo, G. Szabo, E. Berkes, I. Sziller, Z. Papp<br />
AQUAPORIN 2 GENE VARIATIONS, LEVELS OF VON WILLEBRAND FACTOR AND<br />
FACTOR VIII AND THE RISK OF VENOUS THROMBOSIS<br />
A. Y. Noss<strong>en</strong>t* (NL), J. C. J. Eik<strong>en</strong>boom, H. L. Vos, R. M. Bertina, F. R. Ros<strong>en</strong>daal<br />
INFLUENCE OF HERITABILITY AND HOUSEHOLD COMPONENTS ON LIPID<br />
CONCENTRATIONS AND CLOTTING FACTOR LEVELS IN 282 PEDIATRIC STROKE<br />
FAMILIES<br />
U. Nowak-Gottl* (DE), C. Langer, S. Bergs, S. Thedieck, R. D. Strater, M. Stoll<br />
THE RELATIONSHIP OF P2Y1 ADP RECEPTOR POLYMORPHISMS AND ISCHEMIC<br />
VASCULAR DISEASE<br />
E. Park* (KR), S. Park, I. Kim, S. Yoon, S. Park, J. Park, H. Yun-Choi, J. Kim, S. Park,<br />
Y. Hong, S. Lee<br />
FREQUENCIES OF CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5, MDR1 ALLELIC<br />
VARIANTS IN PATIENTS WITH DIFFERENT ACENOCOUMAROL DOSE REQUIREMENTS<br />
I. Paskaleva* (BG), R. Saraeva, E. Doncheva, C. Eap, V. Ganev<br />
PSEUDO-HOMOZYGOUS APC RESISTANCE DUE TO COINHERITANCE OF<br />
HETEROZYGOUS FACTOR V-R506Q AND FV TYPE I DEFICIENCY<br />
A. Pavlova* (DE), R. Loreth, D. Delev, J. Old<strong>en</strong>burg<br />
274
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Cancer and thrombosis<br />
P-T-487<br />
P-T-488<br />
P-T-489<br />
P-T-490<br />
P-T-491<br />
VENOUS THROMBOSIS (VTE) HAS AN ADVERSE IMPACT ON THE SURVIVAL IN<br />
PATIENTS WITH MALIGNANCY<br />
S. Paneesha* (UK), A. Lokare, Z. Lester, T. Nokes, R. Arya, T. Farr<strong>en</strong>, A. McManus,<br />
D. O'Shaughnessy, F. Pressley, N. Scriv<strong>en</strong>, P. Rose<br />
PROSPECTIVE, RANDOMIZED OPEN TRIAL OF ENOXAPARIN IN PATIENTS WITH<br />
ADVANCED PANCREATIC CANCER UNDERGOING FIRST-LINE CHEMOTHERAPY<br />
U. Pelzer* (DE), H. Oettle, H. Riess, M. Stauch, B. Opitz, T. Scholt<strong>en</strong>, J. Stieler<br />
VENOUS THROMBOEMBOLISM AND CANCER: THE PERCEIVE REGISTRY<br />
G. A. Petralia* (UK), M. Rickard, M. Baginski, N. Saba, J. Wong, I. Pabinger,<br />
A. Young on behalf of the Perceive Investigators, A. K. Kakkar<br />
HYPERCOAGULABLE STATE IN MULTIPLE MYELOMA PATIENTS TREATED OR NOT<br />
WITH THALIDOMIDE<br />
A. D. Petropoulou* (FR), G. T. Gerotziafas, F. R<strong>en</strong>du, M. M. Samama, I. Elalamy<br />
HEPARIN TREATMENT INCREASES TYROSINE PHOSPHORYLATION OF PROTEINS IN<br />
BREAST CANCER CELLS: DIFFERENCES IN THE EFFECT OF LMWH AND UFH<br />
T. M. Razzaq* (UK), M. F. Scully, R. Wait, A. K. Kakkar<br />
P-T-492<br />
P-T-493<br />
THIOSULFINATES MODULATE PLATELET ACTIVATION AND MONOCYTE FUNCTION<br />
BY REACTION WITH SURFACE FREE SULFHYDRYLS AND INTERNAL<br />
THIOL-CONTAINING PROTEINS<br />
F. Merhi (FR), P. Badol, M. David-Dufilho, B. Bauvois, F. R<strong>en</strong>du*<br />
ISRAELI PEDIATRIC ONCOLOGY REGISTRY ON CENTRAL VENOUS LINE RELATED<br />
COMPLICATIONS<br />
S. Revel-Vilk* (IL), G. K<strong>en</strong>et, H. Tamary, Y. Levy-Shraga, J. Yacobovich, P. Step<strong>en</strong>ski,<br />
S. Shick, S. Fischer, A. Tor<strong>en</strong>, I. Yaniv, M. Weintraub<br />
Tuesday Posters<br />
P-T-494<br />
P-T-495<br />
P-T-496<br />
P-T-497<br />
CANCER AND VENOUS THROMBOEMBOLISM: ROLE OF GENETIC POLYMORPHISMS<br />
IN SELECTINS AND TISSUE FACTOR<br />
J. C. Reverter* (ES), C. Font, J. Monteagudo, M. Corbella, C. Freire, J. Pijoan,<br />
P. Gascon, D. Tassies<br />
LACK OF ASSOCIATION OF ANTIPHOSPHOLIPID ANTIBODIES WITH CORONARY<br />
ATHEROSCLEROSIS IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY<br />
R. A. S. Roubey* (US), B. Hertzberg, C. Patterson, R. Stouffer, S. Wu, P. C. Charles,<br />
S. Mapara, E. Hilliard, R. Lineberger<br />
A SURVEY ON POST-SURGERY OUTCOMES IN PATIENTS WITH ESSENTIAL<br />
THROMBOCYTHEMIA AND POLYCYTHEMIA VERA IN A RETROSPECTIVE COHORT<br />
M. Ruggeri* (IT), F. Rodeghiero, A. Tosetto, G. Castaman, F. Scognamiglio, G. Finazzi,<br />
F. Delaini, C. Micò, A. Vannucchi, E. Antonioli, V. De Stefano, T. Zà, L. Gugliotta,<br />
A. Tieghi, M. G. Mazzucconi, T. Barbui<br />
A HIGH PLATELET COUNT INDEPENDENTLY PREDICTS VENOUS<br />
THROMBOEMBOLISM IN CANCER PATIENTS<br />
R. Simanek* (AT), R. Vormittag, G. Alguel, C. Ay, D. Dunkler, P. Queh<strong>en</strong>berger,<br />
C. Zielinski, U. Jaeger, I. Pabinger<br />
275
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-498<br />
P-T-499<br />
P-T-500<br />
P-T-501<br />
P-T-502<br />
P-T-503<br />
P-T-504<br />
P-T-505<br />
THE PERSISTANCE OF RESIDUAL VEIN THROMBOSIS, AFTER AN EPISODE OF DEEP<br />
VEIN THROMBOSIS, AND THE RISK OF NEW OVERT CANCER AND<br />
CARDIOVASCULAR DISEASE<br />
S. Siragusa* (IT), V. Cigna, A. Malato, F. Fulfaro, L. Lo Coco, R. Anastasio, I. Abb<strong>en</strong>e,<br />
G. Saccullo, A. Casuccio<br />
THE EFFECT OF ANTICOAGULANTS ON CANCER RISK AND SURVIVAL:<br />
SYSTEMATIC REVIEW<br />
V. Tagalakis* (CA), C. Robinson-Coh<strong>en</strong>, M. Blostein, S. R. Kahn<br />
THE RGD-CONTAINING PEPTIDE DERIVED FROM PLATELET DISABLED-2 INHIBITS<br />
DU145 PROSTATE CANCER CELL-INDUCED PLATELET AGGREGATION<br />
C. Ts<strong>en</strong>g* (TW), L. Ch<strong>en</strong>, C. Huang, J. Ch<strong>en</strong>g, C. Liao<br />
SCREENING FOR OCCULT MALIGNANCY IN PATIENTS WITH IDIOPATHIC VENOUS<br />
THROMBOEMBOLISM. THE TROUSSEAU INVESTIGATORS<br />
F. F. Van Doormaal* (NL), H. Ott<strong>en</strong>, H. R. Buller<br />
DETECTION OF HYPERCOAGULABILITY IN PATIENTS WITH THYROID CANCER<br />
P. Van Dred<strong>en</strong> (FR), A. Rousseau, S. Fontaine, T. Exner, B. J. Woodhams*<br />
LOW MOLECULAR WEIGHT HEPARIN (LMWH) DALTEPARIN REDUCES THE<br />
PROTHROMBOTIC AND PROANGIOGENIC POTENTIAL OF MICROVASCULAR<br />
ENDOTHELIAL CELLS ELICITED BY TUMOR CELLS<br />
A. Vignoli* (IT), M. Marchetti, L. Russo, D. Balducci, A. Falanga<br />
LYMPHOCYTE PLATELET ADHESION IN THROMBOPHILIC PATIENTS WITH LUNG<br />
SURGERY<br />
Y. A. Vitkovsky* (RU), I. G. Bogdanov, A. S. Bogdanova, S. N. Dimova,<br />
A. M. Ryabch<strong>en</strong>ko<br />
APPLICATION OF LOW MOLECULAR-WEIGHT HEPARIN (NARDROPARINE) IN<br />
PATIENTS WITH LUNG CANCER<br />
E. Vorobiova* (GE), M. Akhvlediani, N. Pargalava, R. Gagua, M. Aloeva<br />
P-T-506 EXPRESSION OF TISSUE FACTOR (TF), FACTOR X, PROTHROMBIN FRAGMENT 1+2<br />
(F 1+2) AND FIBRIN IN BREAST CANCER: COMPARISON BETWEEN PRIMARY TUMOR<br />
AND METASTATIC LESIONS IN REGIONAL LYMPH NODES<br />
M. Z. Wojtukiewicz* (PL), E. Sierko, Z. Sawicki, L. Zimnoch, W. Kisiel<br />
P-T-507<br />
P-T-508<br />
P-T-509<br />
A SYSTEMATIC REVIEW OF THE INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE)<br />
AND EFFECTIVENESS OF PROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA<br />
(MM) RECEIVING THALIDOMIDE<br />
C. M. Wu* (CA), A. Y. Lee<br />
CAUSE OF DEATH AMONG PATIENTS WITH LOCAL OR REGIONAL STAGE CANCER<br />
OF THE BREAST AND LUNG WHO DEVELOP VENOUS THROMBOEMBOLISM (VTE)<br />
T. Wun* (US), H. Chew, H. Zhou, D. Harvey, R. White<br />
RNAPC2, A NOVEL INHIBITOR OF TISSUE FACTOR/FACTOR VIIA COMPLEX,<br />
SUPPRESSES LIVER AND LUNG METASTASES IN MOUSE MODELS OF COLORECTAL<br />
CANCER<br />
J. Zhao* (US), G. Aguilar, S. R. Deitcher, M. D. Levy, W. D. Funk, A. Abo<br />
276
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Deep vein thrombosis and pulmonary embolism<br />
P-T-510<br />
P-T-511<br />
P-T-512<br />
P-T-513<br />
CYTOMEGALOVIRUS AND HIGH RISK OF (RECURRENT) VENOUS THROMBOSIS<br />
AFTER RENAL TRANSPLANTATION<br />
W. M. Lijfering* (NL), A. P. J. De Vries, N. J. G. M. Veeger, W. J. Van Son,<br />
S. J. L. Bakker, J. Van Der Meer<br />
LOW MOLECULAR WEIGHT HEPARIN IN PATIENTS WITH RENAL INSUFFICIENCY:<br />
ANALYSIS OF ANTI-XA LEVELS AND CREATININE CLEARANCE<br />
W. Lim* (CA), L. Wang, M. Sridhara, M. Wang, J. Douketis, M. Rodger, M. Crowther<br />
ETIOLOGY, CLINICAL COURSE AND TREATMENT OUTCOME OF PATIENTS WITH<br />
INFERIOR VENA CAVA THROMBOSIS<br />
B. Linnemann* (DE), H. Schmidt, M. Schindewolf, D. Zgouras, M. Erbe, R. Grossmann,<br />
E. Lindhoff-Last<br />
MALE GENDER INCREASES RISK OF VTE RECURRENCE AFTER SPONTANEOUS AND<br />
RISK-ASSOCIATED FIRST VENOUS THROMBOEMBOLISM<br />
B. Linnemann* (DE), M. Schindewolf, D. Zgouras, M. Erbe, M. Jarosch-Preusche,<br />
E. Lindhoff-Last<br />
P-T-514<br />
P-T-515<br />
P-T-516<br />
EFFECT OF THE IMPLEMENTATION OF A VENOUS THROMBOEMBOLISM<br />
PROPHYLAXIS GUIDELINE IN THE MANAGEMENT OF SURGICAL AND ORTHOPEDIC<br />
PATIENTS IN A PRIVATE TERTIARY HOSPITAL<br />
F. H. A. Maffei* (BR), A. C. Sato, F. Torggler Filho, A. Atallah<br />
HCAN CHANGES IN HEMOSTATIC PARAMETERS EXPLAIN THE INCREASED<br />
INCIDENCE OF DVT IN ELDERLY?<br />
I. Mahé* (FR), C. Boulanger, C. Bal Dit Sollier, G. Simoneau, J. Bergmann, A. Tedgui,<br />
L. Drouet<br />
HIGH ABSOLUTE RISKS AND PREDICTORS OF VENOUS AND ARTERIAL<br />
THROMBOEMBOLIC EVENTS IN PATIENTS WITH NEPHROTIC SYNDROME<br />
B. K. Mahmoodi* (NL), M. K. T<strong>en</strong> Kate, F. Waanders, N. J. G. M. Veeger, G. J. Navis,<br />
J. Van Der Meer<br />
Tuesday Posters<br />
P-T-517<br />
P-T-518<br />
P-T-519<br />
P-T-520<br />
P-T-521<br />
ASSOCIATION OF VENOUS THROMBOEMBOLISM AND OLANZAPINE<br />
R. Maly* (CZ), J. Masopust, L. Hosak, A. Urban<br />
CONFIRMATION OF EFFICACY, SAFETY AND COST EFFECTIVENESS OF<br />
FRAXIPARINE® FORTE IN THE OUTPATIENT TREATMENT OF DEEP VENOUS<br />
THROMBOSIS<br />
J. Maly* (CZ), P. Dulicek, M. Pecka, L. Vodickova, R. Maly<br />
POST-THROMBOTIC SYNDROME (PTS) AFTER TOTAL HIP REPLACEMENT (THR):<br />
INCIDENCE AND CORRELATES<br />
M. J. Mant* (CA), D. T. Eurich, D. B. Russell, S. R. Majumdar<br />
THROMBOPHILIA IS FREQUENT IN SUPERFICIAL VEIN THROMBOSIS AND IS<br />
ASSOCIATED WITH RECURRENCE<br />
R. Marcucci (IT), G. Ciuti, D. Poli, M. L<strong>en</strong>ti, E. Blagojevic, M. Falciani, A. Abdullahi,<br />
G. G<strong>en</strong>sini, R. Abbate, D. Prisco*<br />
MASSIVE VENOUS THROMBOEMBOLISM IN A PEDIATRIC PATIENT: A CASE REPORT<br />
M. Mariz* (PT), S. Morais, L. Corbillón, M. Pereira, M. Guedes, M. Medina, R. Matos,<br />
M. Campos<br />
277
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-522<br />
P-T-523<br />
P-T-524<br />
P-T-525<br />
P-T-526<br />
P-T-527<br />
P-T-528<br />
P-T-529<br />
P-T-530<br />
P-T-531<br />
P-T-532<br />
P-T-533<br />
P-T-534<br />
APPLICABILITY OF D-DIMER IN RULING OUT VENOUS THROMBOEMBOLISM (VTE) IN<br />
ELDERLY MEDICAL PATIENTS: COMPARISON BETWEEN IMMUNOTURBIDIMETRIC<br />
AND ELISA (ELFA) METHODS<br />
L. Masotti* (IT), G. Landini, L. Villani, F. Antonelli<br />
ELEVATED D-DIMER LEVELS IN PATIENTS WITH DEEP VEIN THROMBOSIS<br />
T. Matsumoto* (JP), H. Wada, Y. Abe, T. Kobayashi, T. Nobori, N. Yamada<br />
AN ASSESSMENT OF THE EFFECTIVENESS OF INFERIOR VENA CAVA FILTERS IN<br />
PREVENTION OF PULMONARY EMBOLISM BASED UPON DEMONSTRATION OF<br />
TRAPPED EMBOLUS AT THE TIME OF FILTER RETRIEVAL<br />
S. C. McK<strong>en</strong>zie* (AU), D. Leggett, M. Neels, J. Harper, H. Gibbs<br />
AN AUSTRALIAN EXPERIENCE OF RETRIEVABLE INFERIOR VENA CAVA FILTERS IN<br />
PATIENTS WITH INCREASED RISK OF THROMBOEMBOLIC DISEASE<br />
S. C. McK<strong>en</strong>zie* (AU), D. Leggett, M. Neels, J. Harper, H. Gibbs<br />
QUANTIFICATION OF THE MEASUREMENT UNCERTAINTY FOR D-DIMER ASSAY<br />
RESULTS AROUND THE CUT-OFF LEVEL: IMPROVED DECISION RULES REQUIRED?<br />
P. Meijer* (NL), F. Haas, C. Kluft<br />
DELAY IN STARTING ORAL ANTICOAGULATION IN PATIENTS WITH ACUTE VENOUS<br />
THROMBOEMBOLISM (VTE): ANALYSIS FROM THE MASTER REGISTRY<br />
M. Moia* (IT), G. Agnelli, W. Ag<strong>en</strong>o, G. Palareti, D. Imberti, R. Pistelli, R. Rossi,<br />
M. Verso<br />
ACTIVATED PROTEIN C INHIBITION BY PROTEIN C INHIBITOR IS NOT ACCELERATED<br />
BY THE SYNTHETIC PENTASACCHARIDE FONDAPARINUX<br />
J. Müller* (DE), B. Pötzsch, S. Page, K. Madl<strong>en</strong>er<br />
CLINICALLY SUSPECTED ACUTE RECURRENT PULMONARY EMBOLISM:<br />
A DIAGNOSTIC CHALLENGE<br />
M. Nijkeuter* (NL), H. M. Kwakkel-Van Erp, M. Sohne, L. W. Tick, M. J. H. M. Kruip,<br />
E. F. Ullmann, M. H. H. Kramer, H. R. Buller, M. H. Prins, F. W. G. Leebeek,<br />
M. V. Huisman<br />
DECLINING RATE OF VENOUS THROMBOEMBOLISM IN PATIENTS EVALUATED FOR<br />
PULMONARY EMBOLISM IN TWO UNITED STATES EMERGENCY DEPARTMENTS AND<br />
LOW RATE OF EMPIRIC ANTICOAGULATION<br />
K. E. Nord<strong>en</strong>holz* (US), A. M. Mitchell, J. A. Kline<br />
EVALUATION OF 50 POTENTIAL MARKERS OF PULMONARY EMBOLISM FOR USE IN<br />
THE EMERGENCY DEPARTMENT<br />
K. E. Nord<strong>en</strong>holz* (US), A. M. Mitchell, J. A. Kline<br />
TANDEM MEASUREMENT OF D –DIMER AND MYELOPEROXIDASE DECREASES<br />
UNNECESSARY PULMONARY VASCULAR IMAGING IN EMERGENCY DEPARTMENT<br />
PATIENTS EVALUATED FOR PULMONARY EMBOLISM<br />
K. E. Nord<strong>en</strong>holz* (US), A. M. Mitchell, J. A. Kline<br />
PREVALENCE AND DISTRIBUTION OF DEEP VEIN THROMBOSIS IN PATIENTS WITH<br />
SYMPTOMATIC PULMONARY EMBOLISM<br />
M. Ochi* (JP), T. Yamaki, M. Nozaki, H. Sakurai, M. Takeuchi, K. Soejima, T. Kono<br />
BODY MASS INDEX, MILD HYPERHOMOCYSTEINEMIA AND VENOUS<br />
THROMBOEMBOLISM RISK<br />
E. J. Oger (FR), G. Le Gal*, A. Delluc, K. Lacut, F. Couturaud, D. Mottier<br />
278
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-535<br />
P-T-536<br />
P-T-537<br />
P-T-538<br />
P-T-539<br />
P-T-540<br />
EARLY HOME THERAPY AND OUTCOME AMONG 675 PATIENTS WITH PULMONARY<br />
EMBOLISM<br />
C. Olsson* (SE), R. Linné, J. Elf, B. Jonson, M. Bajc<br />
ISOLATED DISTAL DEEP VEIN THROMBOSIS (ID-DVT) IN THE MASTER MULTICENTER<br />
ITALIAN REGISTRY<br />
G. Palareti* (IT), G. Agnelli, W. Ag<strong>en</strong>o, M. Moia, D. Imberti, R. Pistelli, R. Rossi,<br />
M. Verso<br />
SECONDARY THROMBOPHYLAXIS USING ANTIPLATELET AGENTS AND LONG TERM<br />
MONITORING AFTER 1ST UNPROVOKED EPISODE OF VENOUS THROMBOEMBOLISM<br />
E. S. Papadakis* (GR), G. Papaioannou, M. Topalidou, M. Braimi, I. Korantzis<br />
RECURRENT VENOUS THROMBOEMBOLISM LINKED TO LOW PLASMA HDL<br />
N. M. Pech<strong>en</strong>iuk (US), H. Deguchi, J. H. Griffin, P. A. Kyrle, S. Eichinger*<br />
UNEXPLAINED HIGH D-DIMER<br />
C. Pechlaner* (AT), P. Eller, C. Heingärtner, F. Hartig, G. Falk<strong>en</strong>sammer, A. Griesmacher<br />
USEFULNESS OF PERFUSION LUNG SCAN COMBINED WITH CLINICAL ASSESSMENT<br />
TO RULE OUT PULMONARY EMBOLISM<br />
A. P<strong>en</strong>aloza* (BE), D. Blocklet, B. N. T. Tang, C. Melot, S. Motte<br />
P-T-541<br />
P-T-542<br />
P-T-543<br />
D-DIMER TESTING AND RECURRENT VENOUS THROMBOEMBOLISM AFTER<br />
UNPROVOKED PULMONARY EMBOLISM<br />
V. P<strong>en</strong>go* (IT), B. Cosmi, C. Legnani, F. Marzot, A. Tosetto, S. Testa, A. Ghirarduzzi,<br />
G. Palareti<br />
ANTITHROMBOTIC PROPHYLAXIS AND THERAPY. THE HUNGARIAN CONSENSUS<br />
AND EXPERIENCE, 2007<br />
G. P. Pfliegler On Behalf Of The Hungarian Cons<strong>en</strong>sus Confer<strong>en</strong>ce* (HU)<br />
LONG TERM OUTCOMES OF DEEP-VEIN THROMBOSIS IN ASIA AFTER MAJOR<br />
ORTHOPEDIC SURGERY: THE AIDA EXTENSION STUDY<br />
F. Piovella* (IT), M. Barone, C. Beltrametti, C. J. Wang, L. H. Lee, W. C. Lee,<br />
A. G. Turpie, A. S. Gallus, A. Planes, R. Passera<br />
Tuesday Posters<br />
P-T-544<br />
P-T-545<br />
P-T-546<br />
P-T-547<br />
QUALITY OF OAT AND VTE RECURRENCE<br />
D. Poli* (IT), E. Antonucci, R. Marcucci, A. Cellai, A. Rogolino, M. Attanasio, A. Corsi,<br />
R. Abbate, G. G<strong>en</strong>sini, D. Prisco<br />
ROLE OF D-DIMER IN COMBINATION WITH F1+2, RVO AND THROMBOPHILIA IN THE<br />
RISK OF RECURRENCE OF PATIENTS WITH A FIRST VTE EPISODE AFTER OAT<br />
WITHDRAWA<br />
D. Poli* (IT), E. Antonucci, M. Falciani, L. Lucarini, L. Evangelisti, N. Pucci, S. Poli,<br />
R. Abbate, G. G<strong>en</strong>sini, D. Prisco<br />
SMOKING INCREASES THE RISK OF VENOUS THROMBOSIS<br />
E. R. Pomp* (NL), F. R. Ros<strong>en</strong>daal, C. J. M. Dogg<strong>en</strong><br />
TRENDS IN THE DIAGNOSTIC WORK-UP OF DEEP VENOUS THROMBOSIS OF THE<br />
LEG BETWEEN 1999 AND 2004<br />
E. R. Pomp* (NL), K. J. Van Stral<strong>en</strong>, I. D. Bezemer, C. J. M. Dogg<strong>en</strong>, H. R. Büller,<br />
F. R. Ros<strong>en</strong>daal<br />
279
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-548<br />
P-T-549<br />
P-T-550<br />
P-T-551<br />
P-T-552<br />
P-T-553<br />
P-T-554<br />
P-T-555<br />
P-T-556<br />
P-T-557<br />
P-T-558<br />
COMPARISON OF FOUR CLINICAL PREDICTION MODELS IN PATIENTS WITH<br />
SUSPECTED PULMONARY EMBOLISM<br />
M. P<strong>en</strong>go (IT), V. P<strong>en</strong>go, E. Bernardi, P. Prandoni*<br />
QUALITY OF ORAL ANTICOAGULANT TREATMENT AND RISK OF SUBSEQUENT<br />
RECURRENT THROMBOEMBOLISM IN PATIENTS WITH DEEP VENOUS THROMBOSIS.<br />
A PROSPECTIVE COHORT STUDY<br />
P. Prandoni* (IT), B. A. Hutt<strong>en</strong>, C. J. J. Van Dong<strong>en</strong>, R. Pesav<strong>en</strong>to, M. H. Prins<br />
THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM AFTER DISCONTINUING<br />
ANTICOAGULATION IN PATIENTS WITH ACUTE PROXIMAL DEEP VEIN THROMBOSIS<br />
OR PULMONARY EMBOLISM. A PROSPECTIVE COHORT STUDY<br />
P. Prandoni* (IT), F. Nov<strong>en</strong>ta, A. Ghirarduzzi, V. P<strong>en</strong>go, E. Bernardi, R. Pesav<strong>en</strong>to,<br />
M. Iotti, D. Torm<strong>en</strong>e, P. Simioni, A. Pagnan<br />
THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM AMONG HETEROZYGOUS<br />
CARRIERS OF FACTOR V LEIDEN OR PROTHROMBIN G20210A MUTATION.<br />
A SYSTEMATIC REVIEW OF PROSPECTIVE STUDIES<br />
A. Marchiori (IT), L. Mos<strong>en</strong>a, M. H. Prins, P. Prandoni*<br />
CONVENIENCE OF THE NEW LONG-ACTING ANTICOAGULANT IDRAPARINUX (IDRA)<br />
VERSUS VITAMIN K ANTAGONIST (VKA) IN PATIENTS WITH DEEP VENOUS<br />
THROMBOSIS (DVT)<br />
M. H. Prins (NL), P. Leguet*, H. Gilet, A. Roborel De Clim<strong>en</strong>s<br />
MULTINATIONAL DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT<br />
SATISFACTION WITH ANTI-COAGULANT TREATMENT<br />
M. H. Prins (NL), B. Arnould, P. Leguet*, P. Caire, G. Raskob, A. Marrel<br />
ASSOCIATION BETWEEN ASYMPTOMATIC DEEP-VEIN THROMBOSIS DETECTED BY<br />
SCREENING VENOGRAPHY AND SYMPTOMATIC VENOUS THROMBOEMBOLISM IN<br />
PATIENTS UNDERGOING ELECTIVE HIP OR KNEE SURGERY – A SYSTEMATIC<br />
REVIEW<br />
D. J. Quinlan (UK), J. W. Eikelboom, O. E. Dahl*, B. I. Eriksson, P. S. Sidhu, J. Hirsh<br />
D-DIMER REPORTING: WHAT’S THE PROBLEM FOR THE ELECTRONIC HEALTH<br />
RECORD? AN ONTARIO PERSPECTIVE<br />
A. Raby* (CA), M. Crowther, G. Flynn<br />
THROMBOPROPHYLAXIS IN HIGH-RISK ADOLESCENT INPATIENTS<br />
L. J. Raffini* (US), D. Davis, T. Trimarchi, M. Martucci, C. Manno<br />
ELEVATED PLASMA GAS6 LEVELS ARE ASSOCIATED WITH CLOT BURDEN AND<br />
UNDERLYING MALIGNANCY IN DEEP-VEIN THROMBOSIS<br />
D. Rao* (CA), C. Holcroft, S. R. Kahn, M. Blostein<br />
DURATION OF SYMPTOMS AND D-DIMER TESTING FOR VENOUS<br />
THROMBOEMBOLISM RULING-OUT<br />
S. M. Rez<strong>en</strong>de (BR), M. De Bastos*, A. B. F. Carneiro-Proietti, T. Bogutchi,<br />
M. R. D. De Bastos<br />
280
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Ischaemic heart disease<br />
P-T-559<br />
P-T-560<br />
P-T-561<br />
P-T-562<br />
DOWN REGULATION OF THROMBOTIC AND INFLAMMATORY MEDIATORS IN<br />
PATIENTS WITH ACUTE CORONARY SYNDROME TREATED WITH CLOPIDOGREL.<br />
RELEVANCE TO THE OBSERVED CLINICAL EFFECTS<br />
J. Fareed* (US), D. Fareed, R. Bick, D. Hopp<strong>en</strong>steadt, W. P. Jeske, B. E. Lewis,<br />
J. M. Wal<strong>en</strong>ga<br />
CARDIOVASCULAR DISEASE, HYPERHOMOCYSTEINEMIA AND ATHEROTHROMBOTIC<br />
RISK FACTORS IN PSORIATIC PATIENTS<br />
G. Gamba* (IT), R. Longoni, L. Fornara, L. Bocchi, N. Montani, V. Brazzelli<br />
CONTRAINDICATIONS TO ANTICOAGULANTS ARE COMMON IN PATIENTS<br />
REQUIRING VENOUS THROMBOEMBOLISM PROPHYLAXIS<br />
H. Gibbs* (AU), R. Collins, J. Gibbs<br />
POST - CORONARY INTERVENTION RECURRENT ISCHEMIA IN THE PRESENCE OF<br />
ADEQUATE PLATELET INHIBITION BY DUAL ANTIPLATELET THERAPY: WHAT ARE<br />
WE OVERLOOKING?<br />
P. A. Gurbel* (US), K. P. Blid<strong>en</strong>, I. Navickas, E. Coh<strong>en</strong>, U. S. Tantry<br />
P-T-563<br />
P-T-564<br />
P-T-565<br />
TRANSITION TO AN UNSTABLE CORONARY SYNDROME IS MARKED BY<br />
HYPERCOAGUABILITY, PLATELET ACTIVATION, HEIGHTENED PLATELET<br />
REACTIVITY, AND INFLAMMATION: RESULTS OF THE THROMBOTIC RISK<br />
PROGRESSION (TRIP) STUDY<br />
U. S. Tantry (US), K. P. Blid<strong>en</strong>, R. P. Kreutz, J. Dichiara, P. A. Gurbel*<br />
MECHANISMS ASSOCIATED WITH FAILURE OF THROMBOLYTIC THERAPY TO<br />
RECANALIZE THE INFARCT ARTERY IN ACUTE MYOCARDIAL INFARCTION<br />
M. G. Huisse* (FR), L. Feldman, M. C. Guillin, P. G. Steg<br />
THE ROLES OF SERUM MATRIX METALLOPROTEINASES IN PATIENTS WITH<br />
CORONARY ARTERY DISEASE AND ATRIAL FIBRILLATION TO HEART FAILURE<br />
G. Jong* (TW), T. Ma<br />
Tuesday Posters<br />
P-T-566<br />
P-T-567<br />
P-T-568<br />
P-T-569<br />
P-T-570<br />
CONSIDERATION OF MODIFIED CUT-OFFS FOR ANTHROPOMETRIC VARIABLES IN<br />
DEFINING METABOLIC SYNDROME AMONG ASIAN INDIANS WITH CORONARY<br />
ARTERY DISEASE (CAD)<br />
S. Kanjilal (IN), J. Shanker*, V. S. Rao, B. K. Natesha, M. Mukherjee, V. V. Kakkar<br />
CORRELATION OF METABOLIC SYNDROME WITH ATHEROGENIC PHENOTYPES IN<br />
INDIAN POPULATION<br />
S. Kanjilal (IN), J. Shanker*, V. Rao, B. K. Natesha, M. Mukherjee, V. V. Kakkar<br />
MEASUREMENT OF THROMBIN GENERATION IN PATIENTS AT RISK FOR<br />
ATHEROTHROMBOSIS<br />
V. Kaufmann* (AT), J. Mager, B. Laemmle, B. R. Binder, M. Redondo<br />
INCREASED LEVELS OF D—DIMER IN PATIENTS WITH MYOCARDIAL INFARCTION<br />
K. Kawasugi* (JP), C. Simazu, M. Noguchi, H. Tashiro, M. Gotoh, N. Shirafuji,<br />
J. Matsuda, Y. Miyazawa<br />
DECREASE OF SOLUBLE P-SELECTIN AND INHIBITION BOTH, ACTIVATED FACTOR<br />
XA AND THROMBIN AFTER I.V.ENOXAPARIN DURING PCI<br />
J. Kvasnicka* (CZ), J. Horak, I. Malikova, T. Kvasnicka, Z. Necasova<br />
281
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-571<br />
P-T-572<br />
P-T-573<br />
P-T-574<br />
P-T-575<br />
ASPIRIN PREVENTS PLATELET ACTIVATION AFTER CORONARY ARTERY BYPASS<br />
SURGERY DESPITE AN INCREASE IN THROMBOXANE A2 SYNTHESIS<br />
L. Macchi (FR), F. Favreau*, C. Jayle, L. Bosc, L. Christia<strong>en</strong>s<br />
INCIDENCE OF ANTITHROMBIN LEVEL ON “HEMOFILTER CIRCUIT” THROMBOSIS<br />
DURING EARLY CONTINUOUS VENOVENOUS HEMOFILTRATION IN POST<br />
CARDIOPULMONARY BYPASS PATIENTS<br />
H. Lanquetot (FR), T. Leprince, C. Boinot, S. Ragot, C. Jayle, L. Macchi*<br />
ACETYLSALICYLIC ACID (ASA) RESISTANCE IN PATIENTS WITH ISCHEMIC HEART<br />
DISEASE (IHD) AS BIOINDICATOR OF THE TREATMENT STRATEGY<br />
J. Maly* (CZ), M. Pecka, R. Pudil, R. Maly, P. Dulicek, J. Gregor, D. Vokurkova<br />
POST-TREATMENT PLATELET FUNCTION PREDICTS MYOCARDIAL INJURY IN ACUTE<br />
MYOCARDIAL INFARCTION PATIENTS UNDERGOING PRIMARY PCI<br />
R. Marcucci (IT), R. Paniccia, A. Gori, E. Antonucci, E. Romano, S. Poli, C. Giglioli,<br />
D. Prisco, G. G<strong>en</strong>sini, R. Abbate*<br />
PLATELET P-SELECTIN IS ASSOCIATED WITH CIRCULATING NEUTROPHIL<br />
ACTIVATION AT THE VERY ONSET OF MYOCARDIAL INFARCTION<br />
N. Maugeri* (IT), C. Godino, V. Evangelista, M. Mussardo, F. Figini, A. Colombo,<br />
D. Cianflone, A. Manfredi, A. Maseri<br />
Cerebrovascular disease<br />
P-T-576<br />
P-T-577<br />
P-T-578<br />
P-T-579<br />
P-T-580<br />
P-T-581<br />
P-T-582<br />
P-T-583<br />
HEREDITARY THROMBOPHILIC DEFECTS IN IRANIAN PATIENTS WITH CEREBRO<br />
VASCULAR ACCIDENT<br />
M. Ahmadinejad* (IR), D. Bashash, S. Zolfaghari, A. Talebian, J. Dadgar, M. Tabatabaii<br />
A ROLE FOR PLATELET ACTIVATION IN LACUNAR STROKE?<br />
N. Ajz<strong>en</strong>berg* (FR), P. Lavallée, J. Labreuche, M. Guillin, P. Amar<strong>en</strong>co, T. Dupré,<br />
P. Nicaise<br />
SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR AND CYTOKINE LEVELS IN<br />
TURKISH PEDIATRIC STROKE PATIENTS<br />
N. Akar* (TR), G. Deda, Y. Egin, D. Yürürer<br />
TPA IN CHILDREN WITH ARTERIAL ISCHEMIC STROKE: CASES FROM THE IPSS<br />
COMPARED WITH LITERATURE-BASED CASES<br />
C. Amlie-Lefond* (US), A. Chan, R. Ichord, G. Deveber and members of the IPSS<br />
PROTHROMBOTIC FACTORS IN INFANTS WITH NEONATAL CEREBRAL INFARCTION<br />
G. Barillari* (IT), E. Bigotto, A. Janes, G. De Stasio, R. Giacomello, F. Maccagno<br />
BENIGN OUTCOME OF OBJECTIVELY PROVEN SPONTANEOUS RECANALIZATION OF<br />
INTERNAL CAROTID ARTERY OCCLUSION: LONG-TERM FOLLOW UP<br />
G. Camporese* (IT), N. Labropoulos, F. Verlato, E. Bernardi, G. Salmistraro,<br />
D. Kontothanassis, R. Ragazzi, M. Barban, A. Dalla Pozza, G. M. Andreozzi<br />
REAL EFFECT OF WARFARIN THERAPY PREVENTING STROKE IN PATIENTS WITH<br />
ATRIAL FIBRILLATION<br />
R. Y. Cotrina* (PE)<br />
SOCIAL COSTS OF ANTICOAGULANT TREATMENT FOR ATRIAL FIBRILLATION<br />
E. Filippucci* (IT), A. Blass, P. Parise, S. Grasselli, A. Ascani, F. Brunetti, M. Verducci,<br />
G. Fattore, G. Aguzzi, I. Colangelo, G. Agnelli<br />
282
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-584<br />
P-T-585<br />
P-T-586<br />
P-T-587<br />
P-T-588<br />
P-T-589<br />
THE SAFETY OF ANTICOAGULANTS IN PEDIATRIC ARTERIAL ISCHEMIC STROKE:<br />
PRELIMINARY RESULTS<br />
T. S. Finkelstein (CA), L. R. Brandao*, A. Kirton, A. K. Chan, S. Williams, D. Macgregor,<br />
Y. Finkelstein, A. Pontigon, M. Adams, G. Deveber<br />
ARTERIAL STIFFNESS, ENDOTHELIAL FUNCTION AND THE RISK OF ISCHAEMIC<br />
STROKE<br />
I. Ford* (UK), K. K. Kalal, I. MacKay, M. Greaves, J. Britt<strong>en</strong>d<strong>en</strong><br />
THROMBOTIC MARKERS AND MITRAL VALVE PROLAPSE IN MIGRAINE WITH AND<br />
WITHOUT AURA AT CHILDHOOD ONSET<br />
R. Longoni (IT), P. Ondei, N. Montani, L. Bocchi, G. Gamba*, A. Gamba<br />
RISK FACTOR PROFILE ASSOCIATED WITH ICD IN SPANISH POPULATION<br />
A. García-Raso (ES), V. P. Mor<strong>en</strong>o, A. Drozdowskyj, M. J. García-Bu<strong>en</strong>o, C. Sánchez,<br />
A. García-Torres, P. Llamas*, R. Mata<br />
COMPARISON OF EFFICACY AND SAFETY OF INTRAVENOUS AND INTRA-ARTERIAL<br />
THROMBOLYSIS IN ACUTE ISCHEMIC STROKE<br />
Y. He* (CN), Z. Fu, M. Yin, L. Qiu, L. Ma<br />
FIBRINOGEN HAPLOTYPES AND PLASMA LEVELS SHOW INDEPENDENT<br />
ASSOCIATION TO ISCHEMIC STROKE<br />
K. Jood* (SE), J. Danielson, C. Lad<strong>en</strong>vall, C. Blomstrand, C. Jern<br />
P-T-590<br />
P-T-591<br />
C936T MUTATION IN THE VEGF GENE AS AN INDEPENDENT RISK FACTOR FOR<br />
PATIENTS WITH SILENT BRAIN INFARCTION<br />
N. Kim* (KR), S. Hong, O. Kim, H. Kim, H. Park, S. Bae, D. Oh<br />
GENDER-SPECIFIC ASSOCIATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR<br />
POLYMORPHISMS (VEGF -2578C>A AND -634G>C) AND THE RISK OF ISCHEMIC<br />
STROKE<br />
N. Kim* (KR), H. Park, O. Kim, S. Bae, S. Hong, D. Oh, H. Yoon, S. Park<br />
Tuesday Posters<br />
P-T-592<br />
HEMORRHAGIC TRANSFORMATION OF ARTERIAL ISCHEMIC STROKE IN CHILDREN<br />
A. Kirton (CA), T. Schechter, L. Brandao, S. Laughlin, A. Chan*, S. Williams,<br />
D. MacGregor, A. Pontigon, G. Deveber<br />
Hormones, pregnancy, wom<strong>en</strong>'s issues<br />
P-T-593<br />
P-T-594<br />
P-T-595<br />
P-T-596<br />
LOW MOLECULAR WEIGHT HEPARIN IN PREGNANCY - INFLUENCE ON BIRTH<br />
WEIGHT AND DURATION OF PREGNANCY IN WOMEN WITH THROMBOPHILIA<br />
R. Klamroth* (DE), S. Gottstein, E. Essers, J. Fischer, K. Joschko, H. Landgraf<br />
SAFETY AND EFFICACY OF TINZAPARIN ADMINISTRATION DURING PREGNANCY<br />
P. Kotsi* (GR), C. Tsoucala, I. Anastasopoulou, A. Sarantopoulos, G. Kanellopoulou,<br />
T. Adraktas, A. Karafoulidou<br />
MONITORING AND DOSAGE MODULATION OF ENOXAPARIN DURING PREGNANCY<br />
C. Lambert* (BE), B. Dessomme, V. D<strong>en</strong>eys, C. Hermans<br />
PATHOGENETIC PROPHYLAXIS OF RECCURENT FETAL LOSS SYNDROME IN<br />
PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND GENETIC THROMBOPHILIA<br />
A. D. Makatsariya* (RU), S. M. Baimuradova, V. O. Bitsadze, E. V. Donina,<br />
S. V. Akinshina<br />
283
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-597<br />
P-T-598<br />
P-T-599<br />
P-T-600<br />
P-T-601<br />
P-T-602<br />
P-T-603<br />
P-T-604<br />
P-T-605<br />
P-T-606<br />
P-T-607<br />
SCREENING FOR THROMBOPHILIA: RETROSPECTIVE STUDY IN WOMEN WITH<br />
GESTACIONAL VASCULAR COMPLICATIONS<br />
M. Mariz* (PT), L. Corbillón, J. Abreu Lima, M. Pereira, R. Matos, J. Braga, S. Morais,<br />
M. Campos<br />
A RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF LMWH ON<br />
PREGNANCY OUTCOME OF WOMEN WITH PREVIOUS PREGNANCY COMPLICATIONS.<br />
H.A.P.P.Y. STUDY<br />
I. Martinelli* (IT), T. Battaglioli, P. M. Mannucci<br />
CORRELATION BETWEEN DIFFERENT FIBRINOLYTIC TESTS IN PATIENTS WITH<br />
OBSTETRIC COMPLICATIONS<br />
M. E. Martinuzzo* (AR), Y. P. Adamczuk, M. L. Iglesias Varela, G. S. Cerrato,<br />
R. R. Forastiero<br />
CUTANEOUS REACTION TO LOW MOLECULAR WEIGHT HEPARIN AND<br />
HOMOZYGOUSIS FOR FACTOR V LEIDEN MUTATION DURING PREGNANCY: A CASE<br />
REPORT<br />
F. T. Mathonnet* (FR), M. Uzan, C. Fischer, J. Nizard, E. Jaou<strong>en</strong>, P. Roz<strong>en</strong>berg,<br />
N. Tabary, Y. Ville, Y. Giudicelli<br />
PROPHYLACTIC APPROACH TO WOMEN WITH THROMBOPHILIA AND REPEATED<br />
SPONTANEOUS ABORTIONS<br />
G. Mitic* (RS), P. Filipov, L. Povazan, V. Canak, M. Maticki, A. M. Lucic, A. Novakov<br />
Mikic<br />
FV LEIDEN, FII G20210A AND MTHFR T677T GENOTYPES: IS THEIR EVALUATION A<br />
USEFUL TOOL IN THE ETIOLOGICAL APPROACH OF THE EARLY RECURRENT<br />
PREGNANCY LOSSES IN THE GREEK POPULATION?<br />
A. Mougiou* (GR), M. Karakantza, G. Androutsopoulos, G. Decavalas, N. Zoumbos<br />
PLASMA COAGULATION TESTS AND GENETIC THROMBOPHILIC MUTATION STUDIES<br />
ARE MANDATORY FOR PREVENTING THE IDIOPATHIC RECURRENT ABORTIONS OR<br />
REPEATED FETAL LOSS IN HEALTHY WOMEN<br />
R. Musso* (IT), F. Nardo, D. Cultrera, G. Sortino, M. Azzaro, A. Cipolla, E. Di Francesco,<br />
M. Musso, A. Musso<br />
THE THERAPEUTICAL STRATEGIES ARE EFFECTIVE TO PREVENT THE RECURRENT<br />
ABORTIONS, REPEATED FETAL LOSS OR THE INTRAUTERINE FETAL GROWTH<br />
RETARDATION IN WOMEN WITH COAGULATION ABNORMALITIES AND/OR GENETIC<br />
THROMBOPHILIC MUTATIONS<br />
R. Musso* (IT), F. Nardo, D. Cultrera, G. Sortino, M. Azzaro, A. Cipolla, E. Di Francesco,<br />
M. Musso, A. Musso<br />
THE GENETIC ANALYSIS OF DEEP VEIN THROMBOSIS DURING PREGNANCY AND<br />
PERINATAL ASSOCIATED DISORDERS IN JAPANESE<br />
R. Neki* (JP), T. Ikeda, T. Fujita, J. Ishikawa, Y. Sato, T. Miyata<br />
ONCE DAILY TINZAPARIN SODIUM (175 INTERNATIONAL UNITS PER KG) IS SAFE<br />
AND EFFECTIVE FOR ANTENATAL THROMBOPROPHYLAXIS IN HIGH RISK<br />
PREGNANCIES AND FOR TREATMENT OF ANTENATAL VENOUS THROMBOEMBOLIC<br />
EVENTS<br />
F. B. Ni Ainle* (IE), N. Appleby, A. Wong, B. Byrne, C. Regan, M. Milner, T. Hassan,<br />
B. Nolan, B. White, J. O'Donnell<br />
TREATMENT OF VTE DURING PREGANCY WITH A ONCE-DAILY REGIMEN OF LMWH<br />
F. Par<strong>en</strong>t* (FR), X. Jaïs, M. Wolf, C. Boyer-Neuman, G. Simonneau<br />
284
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-608<br />
P-T-609<br />
P-T-610<br />
P-T-611<br />
INHERITED AND ACQUIRED THROMBOPHILIA IN PATIENTS WITH METABOLIC<br />
SYNDROME IN OBSTETRIC-GYNECOLOGIC PRACTICE<br />
E. B. Perederyaeva* (RU), T. B. Psh<strong>en</strong>ichnikova, A. D. Makatsaria<br />
FACTOR V LEIDEN AND PLACENTAL PATHOLOGY<br />
M. Procházka* (CZ), R. Laurini, K. Marsál, J. Procházková, P. G. Lindqvist<br />
ESTROGEN TREATMENT OF CONSTITUTIONAL TALL STATURE IN GIRLS:<br />
RISK OF THROMBOSIS OR BLEEDING?<br />
O. Rask* (SE), K. Nilsson, E. Berntorp<br />
IS THE RISK OF VENOUS THROMBOEMBOLISM HIGHER WITH CYPROTERONE<br />
CONTRACEPTIVES?<br />
S. Regina* (FR), D. Leroux, C. Pouplard, B. Fimbel, B. Delahousse, Y. Gruel<br />
Homocysteine<br />
P-T-613<br />
P-T-614<br />
EVALUATION OF MILD HHCY IN THE DEVELOPMENT OF ATHEROSCLEROSIS IN<br />
APOE-DEFICIENT AND NORMAL MICE<br />
A. C. M. Aléssio* (BR), N. F. Höehr, R. Haddad, L. C. Oliveira,<br />
J. M. Annichino-Bizzacchi<br />
ASSOCIATION OF HYPERHOMOCYSTEINEMIA WITH RESTENOSIS<br />
S. Ammar* (TN), N. B<strong>en</strong> Romdhane, S. Chabrak, R. Mechmeche<br />
P-T-615<br />
P-T-616<br />
HOMOCYSTEINE INDUCES VCAM-1 GENE EXPRESSION THROUGH NF-KB AND<br />
NAD(P)H OXIDASE ACTIVATION: PROTECTIVE ROLE OF MEDITERRANEAN DIET<br />
POLYPHENOLIC ANTIOXIDANTS<br />
M. A. Carluccio (IT), M. Massaro, M. Carluccio, E. Scoditti, A. Distante, C. Storelli,<br />
R. De Caterina*<br />
ASSOCIATION BETWEEN PLASMA LEVELS OF HOMOCYSTEINE (HCY) AND SMOKING<br />
IN PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD)<br />
A. P. L. Mota (BR), M. E. R. C. Santos, A. P. S. M. Fernandes, F. C. L. Silva,<br />
M. G. Carvalho*<br />
Tuesday Posters<br />
P-T-617<br />
P-T-618<br />
P-T-619<br />
P-T-620<br />
P-T-621<br />
PLASMA LEVELS OF HOMOCYSTEINE (HCY) AND OTHER PARAMETERS<br />
INTERRELATED IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE<br />
(PAOD)<br />
A. P. L. Mota (BR), M. E. R. C. Santos, A. P. S. M. Fernandes, F. C. L. Silva,<br />
M. G. Carvalho*<br />
HYPERHOMOCYSTEINEMIA IS ASSOCIATED WITH APC RESISTANCE<br />
B. M. Binetti (IT), I. Martinelli, M. Cattaneo, N. Semeraro, M. Colucci*<br />
MODERATE HYPERHOMOCYSTEINEMIA IS ASSOCIATED WITH REDUCED PLASMA<br />
FIBRINOLYTIC CAPACITY AND INCREASED TAFI LEVELS<br />
M. Colucci* (IT), F. Semeraro, M. Cattaneo, I. Martinelli, N. Semeraro<br />
EVALUATION OF A NEW LATEX-BASED HOMOCYSTEINE ASSAY<br />
P. C. Cooper* (UK), K. P. Hickey, S. M. Cooper, S. Kitch<strong>en</strong>, M. Makris<br />
HOMOCYSTEINE AS INDICATOR OF OSTEOPOROSIS. THE INCHIANTI STUDY<br />
A. Corsi (IT), F. Lauretani, S. Bandinelli, A. Gori*, S. Fedi, L. Ferrucci, R. Abbate<br />
285
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-622<br />
P-T-623<br />
P-T-624<br />
P-T-625<br />
P-T-626<br />
ANALYSIS OF FOLATE-RELATED GENES FOR ASSOCIATION WITH PLASMA<br />
HOMOCYSTEINE LEVEL IN A SNP-MICROARRAY APPROACH<br />
M. D<strong>en</strong> Heijer* (NL), S. H. H. M. Vemeul<strong>en</strong>, B. Franke, M. J. Co<strong>en</strong><strong>en</strong>, M. Schijv<strong>en</strong>aars,<br />
H. Scheffer, H. J. Blom<br />
CATECHOL-O-METHYLTRANSFERASE GENOTYPE IS ASSOCIATED WITH PLASMA<br />
TOTAL HOMOCYSTEINE LEVELS AND MAY INCREASE RECURRENT VENOUS<br />
THROMBOSIS RISK<br />
M. D<strong>en</strong> Heijer* (NL), H. Gellekink, J. Muntjewerff, S. Vermeul<strong>en</strong>, A. R. Hermus,<br />
H. J. Blom<br />
THE NIJMEGEN HAEMOSTASIS ASSAY (NHA) IN THE VITRO-STUDY: RELATION WITH<br />
HOMOCYSTEINE, B-VITAMIN TREATMENT AND RECURRENCE RISK<br />
M. D<strong>en</strong> Heijer* (NL), P. Lap, A. Loof, W. L. Van Heerde<br />
METABOLIC SYNDROME AND HYPERHOMOCYSTEINEMIA IN PATIENTS WITH DEEP<br />
VEIN THROMBOSIS: A CASE-CONTROL STUDY<br />
F. D<strong>en</strong>tali* (IT), W. Ag<strong>en</strong>o, E. Romualdi, P. Prandoni, R. Pesav<strong>en</strong>to, A. Ghirarduzzi,<br />
A. V<strong>en</strong>co<br />
HYPERHOMOCYSTEINEMIA AND THROMBOSIS: THE DIAGNOSTIC ROLE OF POST<br />
METHIONINE-LOAD TEST<br />
C. Durante (IT), R. Boschian B., F. Pivetta, O. Poles, S. Zanolin, L. De Marco, A. Steffan*<br />
New antithrombotic ag<strong>en</strong>ts and approaches<br />
P-T-627<br />
P-T-628<br />
P-T-629<br />
P-T-630<br />
P-T-631<br />
P-T-632<br />
CORRECTION HAEMOSTASIOLOGIC AND RHEOLOGIC DISTURBANCES AT THE<br />
PATIENTS WITH ISCHEMIC HEART AND BRAIN DESIASES BY MEANS OF<br />
COMBINATION OF PHARMACOLOGICAL DRUGS AND EXTRACORPOREAL<br />
AUTOBLOOD-MAGNET-THERAPY<br />
N. G. Kruchinsky* (BY), A. I. Teplyakov, D. K. Zubovsky<br />
THE EFFECT OF AGE AND GENDER ON THE PHARMACOLOGY AND SAFETY OF THE<br />
ORAL, DIRECT FACTOR XA INHIBITOR RIVAROXABAN<br />
D. Kubitza* (DE), M. Becka, W. Mueck, M. Zuehlsdorf<br />
ANTIPLATELET AND ANTITHROMBOTIC ACTIVITY OF NP-313, 2-ACETYLAMINO-3-<br />
CHLORO-1,4-NAPHTHOQUINONE, A NOVEL CPLA2 AND CYTOSOLIC CA 2 +<br />
MOBILIZATION INHIBITOR<br />
H. L. Kuo* (TW), J. C. Li<strong>en</strong>, S. C. Kuo, C. H. Chung, C. H. Chang, T. F. Huang<br />
ANTIPLATELET ACTIVITY OF FENOFIBRATE, A PPARALPHA AGONIST, WAS<br />
MEDIATED BY BLOCKING OF CYTOSOLIC CALCIUM MOBILIZATION AND<br />
THROMBOXANE A2 RECEPTOR<br />
J. Lee* (KR), Y. Jin, Y. Lim, J. Yu, J. Lee, M. Tudev, J. Im, E. Park, T. Kim, M. Lee,<br />
Y. Yun<br />
EFFECTS AND MECHANISMS OF BUYANG HUANWU DECOCTION ON THE CELL<br />
VIABILITY AND TF EXPRESSION INDUCED BY ANGII IN ENDOTHELIAL CELLS<br />
J. L. Li* (CN), S. L. Xiong, W. H. Zhu<br />
SEROTONERGIC MECHANISMS IN HAEMOSTASIS: A CONNECTION BETWEEN MAJOR<br />
DEPRESSION AND THROMBOTIC RISK<br />
I. Lopez-Vilchez* (ES), M. Serra, A. Alonso, F. Navalon, R. Hernandez, E. Gomez,<br />
C. Gasto, G. Escolar, A. M. Galan<br />
286
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-633<br />
P-T-634<br />
P-T-635<br />
P-T-636<br />
P-T-637<br />
P-T-638<br />
INHIBITION OF MEASURED THROMBIN GENERATION IN HUMAN PLASMA BY<br />
APIXABAN: A PREDICTIVE MATHEMATICAL MODEL BASED ON EXPERIMENTALLY<br />
DETERMINED RATE CONSTANTS<br />
J. M. Luettg<strong>en</strong>* (US), Z. Wang, D. A. Seiffert, A. R. R<strong>en</strong>dina, R. M. Knabb,<br />
M. L. Ogletree<br />
THE PREVENTION OF THROMBFORMATION UNDER INFLUENCE OF A COMPLEX<br />
PREPARATION OF PLANT ANTICOAGULANT<br />
G. Y. Lyapin* (RU), T. Y. Obergan<br />
THE PREVENTION OF THROMBFORMATION UNDER INFLUENCE OF A COMPLEX<br />
PREPARATION OF PLANT ANTICOAGULANT<br />
G. Y. Lyapin* (RU), T. Y. Obergan<br />
CHARACTERISATION OF THE ACTIVE FORM OF THE NOVEL ORAL DIRECT<br />
THROMBIN INHIBITOR AZD0837 IN COAGULATION ASSAYS<br />
C. Mattsson* (SE), A. Lundin, J. Ulvinge<br />
ANTITHROMBOTIC ACTIVITIES IN PHARMACOLOGICAL MODELS OF A LONG-ACTING<br />
REVERSIBLE SYNTHETIC OLIGOSACCHARIDE<br />
L. Millet* (FR), P. Savi, J. Herault, P. Duchaussoy, M. Petitou, P. Schaeffer, F. Bono,<br />
J. Herbert<br />
N-METHYLNICOTINAMIDE INHIBITS ARTERIAL THROMBOSIS IN HYPERTENSIVE RATS<br />
A. Mogielnicki* (PL), K. Kramkowski, W. Buczko<br />
P-T-639<br />
P-T-640<br />
ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE, RECOMBINANT FACTOR VIII<br />
AND FACTOR IX REVERSE PROLONGED CLOTTING TIME INDUCED BY DU-176B,<br />
A DIRECT FACTOR XA INHIBITOR, IN HUMAN PLASMA<br />
Y. Morishima* (JP), T. Fukuda, Y. Honda, T. Shibano<br />
COMPARISON OF ANTITHROMBOTIC PROPERTIES OF A DIRECT FXA INHIBITOR,<br />
DU-176B, WITH AN ANTITHROMBIN DEPENDENT FXA INHIBITOR, FONDAPARINUX, IN<br />
A CAPILLARY PERFUSION CHAMBER THROMBOSIS MODEL<br />
Y. Morishima (JP), T. Shibano*, N. Tsuji, T. Fukuda<br />
Tuesday Posters<br />
P-T-641<br />
P-T-642<br />
P-T-643<br />
P-T-644<br />
EFFECT OF A FACTOR XA INHIBITOR DU-176B ON INTRACEREBRAL HEMORRHAGE<br />
IN RATS: A WIDER SAFETY MARGIN COMPARED WITH A THROMBIN INHIBITOR<br />
Y. Morishima* (JP), Y. Shirasaki, F. Kito, Y. Honda, T. Shibano<br />
EFFECTS OF DU-176B, A NOVEL DIRECT FACTOR XA INHIBITOR, ON<br />
PROTHROMBINASE ACTIVITY AND PLATELET AGGREGATION IN VITRO<br />
T. Shibano* (JP), N. Tsuji, F. Kito, T. Fukuda, T. Furugohri, Y. Morishima<br />
PHARMACOLOGICAL CHARACTERIZATION OF AN ORAL DIRECT THROMBIN<br />
INHIBITOR, MCC-977: HIGH THROMBIN SPECIFICITY AND LOW HEMORRHAGIC<br />
PROFILE<br />
M. Nakajima* (JP), M. Suga, K. Sugawara, M. Katsu, S. Yuki, J. Anabuki, T. Yamamoto,<br />
Y. Abe, Y. Kitada<br />
THE ANTI-COAGULANT AND THE ANTI-THROMBOTIC EFFECT OF MCC-977, A NOVEL<br />
ORALLY-ACTIVE THROMBIN INHIBITOR<br />
M. Nakajima* (JP), M. Suga, K. Sugawara, K. Yamada, J. Anabuki, T. Yamamoto,<br />
Y. Kitada<br />
287
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-645<br />
P-T-646<br />
P-T-647<br />
COMPARISON OF ANTIPLATELET AND ANTITHROMBOTIC EFFECTS OF PRASUGREL<br />
AND AZD6140<br />
T. Ogawa* (JP), C. Isobe, M. Kakusaka, Y. Yokouchi, Y. Niitsu, A. Sugidachi, F. Asai,<br />
J. A. Jakubowski<br />
DEVELOPING ANTIDOTE CONTROLLED ANTIPLATELET THERAPIES BY TARGETING<br />
THE VWF - GP IB-IX-V INTERACTION<br />
S. Oney* (US), J. Layzer, S. M. Nimjee, N. S. Que, D. Ginsburg, J. A. Lopez,<br />
G. M. Arepally, R. C. Becker, B. A. Sull<strong>en</strong>ger<br />
WARFARIN ANTICOAGULATION INTENSITY IN SPECIALIST-BASED AND IN<br />
COMPUTER -ASSISTED DOSING PRACTICE<br />
P. T. Onundarson* (IS), K. A. Einarsdottir, B. R. Gudmundsdottir<br />
Clinical trials: oral anticoagulants incl. New compounds<br />
P-T-648<br />
P-T-649<br />
P-T-650<br />
P-T-651<br />
P-T-652<br />
P-T-653<br />
P-T-654<br />
P-T-655<br />
PHARMACOGENETICS OF ORAL ANTICOAGULATION - VKORC1-HAPLOTYPES<br />
DETERMINE THE INTER-INDIVIDUAL VARIABILITY<br />
C. Geis<strong>en</strong>* (DE), B. Luxembourg, K. Sittinger, S. W. To<strong>en</strong>nes, M. Watzka,<br />
E. Lindhoff-Last, E. Seifried, J. Old<strong>en</strong>burg<br />
BRIDGING THERAPY IN PATIENTS TREATED WITH LMWH AND COUMARIN INDUCES<br />
DEEP INHIBITION OF THROMBIN GENERATION<br />
G. T. Gerotziafas* (FR), C. Dupont, I. Elalamy, E. Verdy<br />
OVER-ANTICOAGULATION ASSOCIATED WITH COMBINED USE OF COUMARIN<br />
ANTICOAGULANTS AND TOPICAL ECONAZOLE OR BIFONAZOLE IN ELDERLY<br />
PATIENTS<br />
I. Gouin-Thibault (FR), J. Alexandra, E. Pautas, A. Gouronnec, N. Le Strat, V. Siguret*<br />
SPECIFIC MULTI-RULE EXPERT SYSTEM FOR ELDERLY INPATIENT ANTICOAGULANT<br />
CONTROL<br />
I. Gouin-Thibault* (FR), V. Siguret, V. Vieillefond, C. Visseaux, C. Levy, C. Boccara,<br />
C. Bal Dit Sollier, J. Cambus, L. Drouet, I. Mahé, M. Horellou, E. Pautas<br />
EVALUATION OF THE FACTOR XA (FXA) INHIBITOR, PRT054021 (PRT021), AGAINST<br />
ENOXAPARIN IN A RANDOMIZED TRIAL FOR THE PREVENTION OF VENOUS<br />
THROMBOEMBOLIC EVENTS AFTER TOTAL KNEE REPLACEMENT (EXPERT)<br />
A. G. Turpie* (CA), M. G<strong>en</strong>t, K. Bauer, B. L. Davidson, W. Fisher, M. Huo, K. Borow,<br />
V. B. Frame, C. Michalsky, D. D. Gretler, K. Romanko, U. Sinha<br />
RESULTS OF A ONE-YEAR REGISTRY OF BLEEDING COMPLICATIONS OF VITAMIN K<br />
ANTAGONIST THERAPY OUTSIDE A CONTROLLED POPULATION<br />
K. M. Halbritter* (DE), J. Beyer, W. Oettler, B. Kleinstück, S. M. Schellong<br />
LONG LASTING ANTICOAGULANT EFFECTS OF ONCE WEEKLY SUBCUTANEOUS<br />
INJECTIONS OF IDRAPARINUX TO TREAT PATIENTS FOR PROPHYLAXIS OF<br />
RECURRENT VENOUS THROMBOEMBOLISM<br />
J. Har<strong>en</strong>berg* (DE), C. Weiss<br />
ANTICOAGULANT MANAGEMENT USING AN INTERNET BASED MONITORING<br />
SYSTEM<br />
P. L. Harper* (NZ), S. Stott, C. Ford, P. Ngata<br />
288
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-656<br />
P-T-657<br />
P-T-658<br />
P-T-659<br />
P-T-660<br />
D-DIMER VALUE AND ECHOCARDIOGRAPHIC CHANGES AS PREDICTORS OF<br />
THROMBOEMBOLIC COMPLICATIONS AFTER THE FONTAN OPERATION<br />
M. F. H<strong>en</strong>dler* (AR), F. Alberto, S. S. Mesch<strong>en</strong>gieser, W. M. Conejeros, M. I. Roman,<br />
A. Sanchez-Luceros, P. Casais, A. Schlichter, G. O. Kreutzer, M. A. Lazzari<br />
BETAINE (TRIMETHYLGLYCINE), A NOVEL ORAL ANTICOAGULANT WITH COMBINED<br />
NITRIC OXIDE AND TISSUE FACTOR PATHWAY INHIBITOR RELEASE POTENTIAL.<br />
IMPLICATIONS IN THE MANAGEMENT OF VASCULAR DISEASES<br />
O. M. Iqbal* (US), J. Messadek, R. Ennamany, D. Fareed, D. Hopp<strong>en</strong>steadt, J. Fareed<br />
MATRIX METALLOPROTEINASE-3, TISSUE INHIBITOR OF METALLOPROTEINASES-1<br />
AND WARFARIN TREATMENT<br />
M. Kozak* (SI), M. Bozic, M. Stegnar<br />
RIVAROXABAN – AN ORAL, DIRECT FACTOR XA INHIBITOR – HAS NO CLINICALLY<br />
RELEVANT INTERACTION WITH ACETYLSALICYLIC ACID OR NAPROXEN<br />
D. Kubitza* (DE), M. Becka, W. Mueck, M. Zuehlsdorf<br />
DETERMINATION OF VKORC1 AND CYP2C9 GENOTYPES IS OF LIMITED VALUE<br />
DURING CHRONIC ANTICOAGULATION WITH ACENOCOUMAROL<br />
C. Lambert* (BE), J. Gala, B. Dessomme, V. D<strong>en</strong>eys, C. Hermans<br />
P-T-661<br />
P-T-662<br />
P-T-663<br />
RISK FACTOR FOR ORAL ANTICOAGULANT TREATMENT OVERDOSE: A CASE<br />
CONTROL STUDY IN AN EMERGENCY UNIT<br />
V. Le Cam-Duchez* (FR), G. Cadiou, Y. B<strong>en</strong>hamou, R. Varin, I. Tiret, J. M. Kerleau,<br />
B. Veber, B. Dieu, J. Y. Borg, H. Lévesque<br />
ACCEPTABILITY AND EFFICACY OF PATIENT SELF-TESTING IN PATIENTS NEW TO<br />
THE ANTICOAGULATION CLINIC<br />
I. Longair (UK), C. Gardiner, M. A. Pescott, H. Erwin, S. J. Machin, H. Coh<strong>en</strong>*<br />
LACK OF EFFECT OF INFLUENZA IMMUNISATION ON ANTICOAGULANT CONTROL IN<br />
PATIENTS ON LONG-TERM WARFARIN<br />
P. K. MacCallum* (UK), M. Madhani, S. Mt-Isa, D. Ashby<br />
Tuesday Posters<br />
P-T-664<br />
P-T-665<br />
QUALITY OF ANTICOAGULANT MANAGEMENT: A 4-YEAR ANALYSIS OF TREATMENT<br />
AND COMPLICATIONS IN ANTICOAGULATION SERVICE IN LJUBLJANA<br />
A. Mavri* (SI), A. Kramaric<br />
A NATIONAL FIELD STUDY OF QUALITY ASSESSMENT (QA) OF COAGUCHEK<br />
MONITORS<br />
P. Meijer* (NL), C. Kluft, L. Poller, F. J. M. Van Der Meer, M. Keown, S. Ibrahim,<br />
A. M. H. P. Van D<strong>en</strong> Besselaar, A. Tripodi, J. Jespers<strong>en</strong><br />
Clinical trials: par<strong>en</strong>teral drugs (e.g.heparins/LMWH/fondaparinux)<br />
P-T-666<br />
P-T-667<br />
ANTITHROMBIN III IN COMPARISON WITH FRESH FROZEN PLASMA IN PATIENTS<br />
WITH DISSEMINATED INTRAVASCULAR COAGULATION ACCOMPANIED BY<br />
ANTITHROMBIN III DEFICIENCY<br />
E. L. Neporada (RU), N. A. Vorobyeva*, O. V. Turundaevskaya, G. N. Melnikova<br />
IMMUNE RESPONSE AFTER FIRST AND SECOND IV INJECTION OF AVIDIN USED AS<br />
THE NEUTRALIZING AGENT FOR BIOTINYLATED IDRAPARINUX<br />
I. Paty* (FR), N. Paquet, M. Sibille, P. Cortez, F. Berard, J. F. Nicolas<br />
289
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-668<br />
P-T-669<br />
P-T-670<br />
P-T-671<br />
P-T-672<br />
P-T-673<br />
P-T-674<br />
P-T-675<br />
P-T-676<br />
P-T-677<br />
P-T-678<br />
P-T-679<br />
ENOXAPARIN VERSUS HEPARIN PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM<br />
AFTER ABDOMINAL ONCOLOGIC SURGERY: A RANDOMIZED DOUBLE-BLIND<br />
CONTROLLED TRIAL<br />
M. Petrov* (RU), A. Anosov, N. Piskunova<br />
ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN FOR VENOUS<br />
THROMBOEMBOLISM (VTE) PROPHYLAXIS IN ACUTE ISCHEMIC STROKE PATIENTS<br />
G. F. Pineo* (CA), G. W. Albers, C. Bladin, C. Fieschi, A. A. Gabbai, C. S. Kase,<br />
W. O’Riordan, D. G. Sherman<br />
CERTIFY, A PHASE III STUDY COMPARING CERTOPARIN WITH UNFRACTIONATED<br />
HEPARIN IN ELDERLY, ACUTELY ILL MEDICAL PATIENTS<br />
H. B. Riess* (DE), C. Sieder, S. Schellong, S. Haas, U. Tebbe, H. Gerlach, J. Adams<br />
BEMIPARIN THROMBOPROPHYLAXIS IN ELDERLY MEDICAL PATIENTS:<br />
THE "ANCIANOS" STUDY<br />
L. Rodríguez-Mañas (ES), R. Gómez-Huelgas, G. Monteagudo, R. Maeso,<br />
A. Gómez-Outes*, J. Martínez-González<br />
A RANDOMIZED, CONTROLLED, DOUBLE BLIND STUDY OF BEMIPARIN VS<br />
UNFRACTIONATED HEPARIN AS BRIDGING THERAPY OF ORAL ANTICOAGULATION<br />
THERAPY IN INVASIVE PROCEDURES OR AMBULATORY SURGERY. DESIGN OF THE<br />
BERTA STUDY<br />
A. Santamaría (ES), J. Fontcuberta*<br />
USE OF FONDAPARINUX IN PATIENTS WITH HEPARIN-INDUCED<br />
THROMBOCYTOPENIA TYPE II<br />
M. Schindewolf* (DE), E. Lindhoff-Last, B. Luxembourg<br />
PHARMACOKINETICS OF DALTEPARIN IN PROPHYLACTIC DOSAGE IN PATIENTS<br />
WITH IMPAIRED RENAL FUNCTION<br />
P. Schmid* (CH), D. Brodmann, A. G. Fischer, W. A. Wuillemin<br />
EVALUATION OF A NEW FUNCTIONAL CLOTTING ASSAY FOR THE MONITORING OF<br />
HEPARIN AND HEPARINOID ANTICOAGULANTS BASED ON THROMBIN AND/OR<br />
FACTOR XA INHIBITION WITH CLINICAL PATIENT PLASMAS AT THREE UNIVERSITY<br />
MEDICAL CENTERS<br />
R. Schöni* (CH), J. Wal<strong>en</strong>ga, M. Samama, J. Har<strong>en</strong>berg, A. F. Dr<strong>en</strong>th, C. Le Courvoisier-<br />
Flaujac, C. Giese, K. Rudin, B. Bühler, M. Wilmer<br />
ENOXAPARIN 40 MG VERSUS NADROPARIN 0.3 ML IN THE PREVENTION OF VENOUS<br />
THROMBOEMBOLISM (VTE) IN COLORECTAL CANCER SURGERY ACCORDING TO<br />
AGE AND CREATININE CLEARANCE (CRCL)<br />
G. Simonneau* (FR), P. Mismetti<br />
COADMINISTRATION OF THE ORAL DIRECT THROMBIN INHIBITOR DABIGATRAN<br />
ETEXILATE AND DICLOFENAC HAS LITTLE IMPACT ON THE PHARMACOKINETICS OF<br />
EITHER DRUG<br />
J. Stangier* (DE), K. Rathg<strong>en</strong>, H. Stähle, K. Reseski, T. Körnicke<br />
BIOEQUIPOTENCY OF IDRAPARINUX AND BIOTINYLATED IDRAPARINUX AFTER<br />
SINGLE DOSE IN HEALTHY SUBJECTS<br />
M. Trellu* (FR), Y. Perez, J. Ortiz, S. Ch<strong>en</strong>g, I. Paty<br />
FONDAPARINUX 1.5 MG ONCE DAILY IN THE PROPHYLAXIS OF VENOUS<br />
THROMBOEMBOLISM (VTE): EFFICACY AND SAFETY IN RENALLY-IMPAIRED<br />
PATIENTS FROM A DOSE-RANGING STUDY IN MAJOR ORTHOPEDIC SURGERY<br />
A. G. Turpie* (CA)<br />
290
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
P-T-680<br />
P-T-681<br />
P-T-682<br />
PHARMACOKINETICS (PK) OF SUBCUTANEOUS FONDAPARINUX 1.5 MG IN PATIENTS<br />
WITH MODERATE RENAL IMPAIRMENT (MRI)<br />
D. Boyle* (US), A. G. Turpie<br />
REPLACING ORAL ANTICOAGULANTS WITH TINZAPARIN SODIUM IN PATIENTS<br />
UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY: SAFETY AND COST<br />
CONSIDERATIONS<br />
S. K. Volteas* (GR), A. Babos<br />
ANTI XA ASSAYS FOR DANAPAROID: ASSESSMENT OF PRE ANALYTICAL AND<br />
ANALYTICAL VARIABLES<br />
A. Wemyss* (UK), J. M. Smith, A. Woolley, J. Storr, E. Hampton, R. MacLean, S. Kitch<strong>en</strong><br />
Clinical trials: antiplatelet ag<strong>en</strong>ts<br />
P-T-683<br />
PR-15 A NOVEL INTRAVENOUS INHIBITOR OF PLATELET ADHESION: A PHASE I<br />
DOSE ASCENDING PHARMACOKINETIC, PHARMACODYNAMIC, AND TOLERANCE<br />
STUDY<br />
S. Combe* (UK), K. Rosport, A. K<strong>en</strong>nedy<br />
P-T-684<br />
P-T-685<br />
P-T-686<br />
EFFECT OF BIVALIRUDIN VS. BIVALIRUDIN WITH EPTIFIBATIDE ON PLATELET<br />
ACTIVATION AND AGGREGATION IN PATIENTS RECEIVING CHRONIC CLOPIDOGREL<br />
THERAPY UNDERGOING ELECTIVE PCI<br />
P. A. Gurbel* (US), K. P. Blid<strong>en</strong>, J. Dichiara, M. Antonino, T. B. Gesheff, U. S. Tantry,<br />
O. V. Bailon<br />
EFFECTS OF A FLAVANOL-RICH COCOA BEVERAGE ON PLATELET AND LEUCOCYTE<br />
FUNCTION IN MAN<br />
J. A. May* (UK), S. C. Fox, S. Heptinstall, C. Kwik-Uribe<br />
NON-RESPONSE TO ASPIRIN (ASA) IN PATIENTS WITH PERIPHERAL ARTERIAL<br />
OCCLUSIVE DISEASE (PAOD); A PROSPECTIVE STUDY<br />
S. Prochnow* (DE), B. Linnemann, J. Schwonberg, H. Mani, E. Lindhoff-Last<br />
Tuesday Posters<br />
P-T-687<br />
P-T-688<br />
P-T-689<br />
P-T-690<br />
P-T-691<br />
HIGH INCIDENCE OF CLOPIDOGREL NON-RESPONSIVENESS IN PATIENTS WITH<br />
CORONARY ARTERY DISEASE – A REAL WORLD SITUATION<br />
A. Schaefer* (DE), S. Weinberger, M. Eig<strong>en</strong>thaler, G. Ertl, J. Bauersachs<br />
NON-RESPONSE TO CLOPIDOGREL IN PATIENTS WITH PERIPHERAL ARTERIAL<br />
OCCLUSIVE DISEASE (PAOD); A PROSPECTIVE STUDY<br />
J. Schwonberg* (DE), B. Linnemann, S. Prochnow, H. Mani, E. Lindhoff-Last<br />
PLATELET RESPONSE DOES NOT CHANGE DURING LONG-TERM-TREATMENT<br />
(8YEARS) WITH 50 OR 100 MG ACETYLSALICYLIC ACID (ASA) FOR SECONDARY<br />
PREVENTION<br />
H. Sinzinger* (AT), H. Kritz, R. Ber<strong>en</strong>t, P. Schmid, D. Steinbr<strong>en</strong>ner<br />
NO DECREASE IN THROMBIN FORMATION AT THE SITE OF MICROVASCULAR<br />
INJURY IN PATIENTS TREATED WITH CLOPIDOGREL<br />
A. Undas* (PL), E. Stepi<strong>en</strong>, A. Branicka, K. Zmudka, W. Tracz<br />
PREVALENCE OF “ASPIRIN RESISTANCE” IN CHILDREN<br />
D. L. Yee* (US), B. Dinu, C. Sun,<br />
291
POSTER PRESENTATIONS<br />
TUESDAY, 10 JULY 2007<br />
Pati<strong>en</strong>t education<br />
P-T-692<br />
P-T-693<br />
P-T-694<br />
P-T-695<br />
P-T-696<br />
P-T-697<br />
P-T-698<br />
KNOWLEDGE RETENTION IMPROVES OUTCOMES FOR CHILDREN REQUIRING<br />
VITAMIN K ANTAGONISTS<br />
M. E. Bauman* (CA), K. Black, M. Massicotte<br />
THROMBOPHILIA TESTING IN A DEVELOPING COUNTRY REFERRAL CENTER:<br />
A 3-YEAR OBSERVATIONAL STUDY<br />
P. Casais* (AR), S. S. Mesch<strong>en</strong>gieser, M. A. Lazzari<br />
EVALUATION OF THE HYPERLIPIDEMIA AND HYPERGLYCEMIA IN PROGESTERONE<br />
ONLY PILL USERS<br />
M. Kashanian* (IR), M. Fekrat<br />
IMPACTS OF GENETIC TESTING FOR THROMBOPHILIA ON FIRST DEGREE<br />
RELATIVES OF PATIENTS WITH VENOUS THROMBOEMBOLISM AND A<br />
THROMBOPHILIA - A CROSS-SECTIONAL SURVEY<br />
M. L. Louzada* (CA), P. S. Wells, M. A. Rodger, C. R. Dunn, B. Wilson<br />
PSYCHOLOGICAL IMPACTS OF GENETIC TESTING FOR THROMBOPHILIA ON FIRST<br />
DEGREE RELATIVES OF PATIENTS WITH VENOUS THROMBOEMBOLISM AND A<br />
THROMBOPHILIA – A PILOT STUDY<br />
M. L. Louzada* (CA), P. S. Wells, C. R. Dunn, N. Langlois, B. Wilson, S. R. Kahn,<br />
M. A. Rodger, D. R. Anderson, M. J. Kovacs<br />
DO POINT OF CARE DEVICES IMPROVE OUTCOMES IN PATIENTS ON ORAL<br />
ANTICOAGULANT THERAPY<br />
P. S. Wells* (CA), A. Brown, J. Jaffey, M. Poon<br />
REDUCTION IN EMERGENCY DEPARTMENT VISITS BY PATIENTS ATTENDING<br />
AN ANTICOAGULATION CLINIC<br />
P. Whittaker* (US), J. L. Donovan<br />
Innovation and technology<br />
Structural biology and drug design<br />
P-T-699<br />
P-T-700<br />
BIOCHEMICAL AND MECHANICAL PROPERTIES OF INTRALUMINAL THROMBUS<br />
FROM HUMAN ABDOMINAL AORTIC ANEURYSM<br />
M. Camera* (IT), R. Ballerio, R. Spirito, E. Di Martino, F. Boschetti, E. Tremoli<br />
DIFFERENTIATION OF LOW MOLECULAR WEIGHT HEPARINS AS STUDIED BY<br />
MOLECULAR WEIGHT PROFILE AND HEPARINASE-I DEPOLYMERIZATION:<br />
PHARMACOLOGIC IMPLICATIONS<br />
A. Brubaker (US), W. P. Jeske, D. Hopp<strong>en</strong>steadt, J. Maddin<strong>en</strong>i, M. Kujawski, J. Fareed*<br />
292